

0001493152-24-04305810-Q Processa Pharmaceuticals, Inc. 2021103020241030160542160542160542 0 0001493152-24-043058 10-Q 51 20240930 20241030 20241030 Processa Pharmaceuticals, Inc. 0001533743 2834 4451539785 DE 1231 10-Q 34 001-395131 24110274 7380 COCA COLA DRIVE SUITE 106 HANOVER MD 21076 Heatwux, Inc. 20111028 10-Q 1 form10-q.htm false Q13 -12-31 0001533743 0001533743 2024-01-01 2024-09-30 0001533743 2024-10-15 0001533743 2024-09-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2024-09-30 0001533743 2023-07-01 2023-09-30 0001533743 us-gaap:CommonStockMember 2022-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2022-12-31 0001533743 us-gaap:RetainedEarningsMember 2022-12-31 0001533743 2022-12-31 0001533743 us-gaap:CommonStockMember 2023-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-03-31 0001533743 us-gaap:RetainedEarningsMember 2023-03-31 0001533743 us-gaap:CommonStockMember 2023-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-06-30 0001533743 us-gaap:RetainedEarningsMember 2023-06-30 0001533743 2023-06-30 0001533743 us-gaap:CommonStockMember 2023-12-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-12-31 0001533743 us-gaap:RetainedEarningsMember 2023-12-31 0001533743 us-gaap:CommonStockMember 2024-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2024-03-31 0001533743 us-gaap:RetainedEarningsMember 2024-03-31 0001533743 us-gaap:CommonStockMember 2024-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-06-30 0001533743 us-gaap:RetainedEarningsMember 2024-06-30 0001533743 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0001533743 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001533743 2023-01-01 2023-03-31 0001533743 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-04-01 2023-06-30 0001533743 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001533743 2023-04-01 2023-06-30 0001533743 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-07-01 2023-09-30 0001533743 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001533743 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001533743 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001533743 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001533743 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001533743 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001533743 2024-04-01 2024-06-30 0001533743 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001533743 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001533743 us-gaap:CommonStockMember 2023-09-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001533743 us-gaap:TreasuryStockCommonMember 2023-09-30 0001533743 us-gaap:RetainedEarningsMember 2023-09-30 0001533743 us-gaap:CommonStockMember 2024-09-30 0001533743 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001533743 us-gaap:TreasuryStockCommonMember 2024-09-30 0001533743 us-gaap:RetainedEarningsMember 2024-09-30 0001533743 PCSA:ConsultingAgreementMember PCSA:SpartanCapitalSecuritiesLLCMember 2023-09-30 0001533743 2024-01-22 2024-01-22 0001533743 2024-01-22 0001533743 2024-01-21 0001533743 PCSA:PurchaseAgreementMember 2024-01-29 2024-01-30 0001533743 PCSA:PreFundedWarrantMember PCSA:PurchaseAgreementMember 2024-01-30 0001533743 us-gaap:WarrantMember PCSA:PurchaseAgreementMember 2024-01-30 0001533743 2024-01-29 2024-01-30 0001533743 PCSA:RegistrationStatementMember srt:MaximumMember 2024-05-31 2024-05-31 0001533743 PCSA:SalesAgreementMember PCSA:AllianceGlobalPartnersMember srt:MaximumMember PCSA:ATMOfferingMember 2024-05-21 2024-05-21 0001533743 PCSA:ATMOfferingMember 2024-07-31 2024-07-31 0001533743 PCSA:PurchaseAgreementMember 2024-01-01 2024-09-30 0001533743 PCSA:PreFundedWarrantMember PCSA:PurchaseAgreementMember 2024-09-30 0001533743 us-gaap:WarrantMember PCSA:PurchaseAgreementMember 2024-09-30 0001533743 PCSA:PurchaseAgreementMember PCSA:PlacementAgentMember 2024-09-30 0001533743 PCSA:ATMOfferingMember 2024-01-01 2024-09-30 0001533743 PCSA:ElionOncologyIncMember PCSA:LicenseAgreementMember 2024-01-01 2024-09-30 0001533743 PCSA:ConsultantMember PCSA:ConsultingAgreementMember 2024-01-01 2024-09-30 0001533743 PCSA:EmployeesAndConsultantsMember 2024-01-01 2024-09-30 0001533743 PCSA:TwoThousandAndNineteenPlanMember 2024-06-28 2001533743 PCSA:TwoThousandAndNineteenPlanMember 2024-09-30 0001533743 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-09-30 0001533743 us-gaap:EmployeeStockOptionMember 2024-09-30 0001533743 us-gaap:RestrictedStockMember 2024-01-01 2024-09-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0001533743 us-gaap:RestrictedStockUnitsRSUMember PCSA:EmployeesMember 2024-06-28 2001533743 PCSA:ServiceBasedRestrictedStockUnitsMember PCSA:JanuaryOneTwoThousandTwentyFiveVestingMember PCSA:EmployeesMember 2024-06-28 2001533743 PCSA:ServiceBasedRestrictedStockUnitsMember PCSA:EmployeesMember PCSA:ThreeYearVestingMember 2024-06-28 2001533743 PCSA:FirstPerformanceBasedRSUMember PCSA:EmployeesMember 2024-06-28 2001533743 PCSA:SecondPerformanceBasedRSUMember PCSA:NextGenerationCapcibitabineCAPMember PCSA:EmployeesMember 2024-06-28 2001533743 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefFinancialOfficerMember 2024-07-16 2024-07-16 0001533743 us-gaap:RestrictedStockUnitsRSUMember PCSA:JulySixteenTwoThousandTwentyFiveVestingMember srt:ChiefFinancialOfficerMember 2024-07-16 2024-07-16 0001533743 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefFinancialOfficerMember PCSA:FirstPerformanceBasedRSUMember 2024-07-16 0001533743 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefFinancialOfficerMember PCSA:SecondPerformanceBasedRSUMember 2024-07-16 0001533743 us-gaap:RestrictedStockUnitsRSUMember srt:ChiefFinancialOfficerMember PCSA:SecondPerformanceBasedRSUMember 2024-07-16 0001533743 us-gaap:RestrictedStockUnitsRSUMember srt:DirectorMember 2024-09-03 2024-09-03 0001533743 us-gaap:RestrictedStockUnitsRS

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Stocklink:presentationLinklink:calculationLinklink:definitionLink 995617 – Disclosure – Leaseslink:presentationLinklink:calculationLinklink:definitionLink 995618 – Disclosure – Related Party Transactionslink:presentationLinklink:calculationLinklink:definitionLink 995619 – Disclosure – Commitments and Contingencieslink:presentationLinklink:calculationLinklink:definitionLink 995620 – Disclosure – Organization and Summary of Significant Accounting Policies (Policies)link:presentationLinklink:calculationLinklink:definitionLink 995621 – Disclosure – Stock based Compensation (Tables)link:presentationLinklink:calculationLinklink:definitionLink 995622 – Disclosure – Net Loss per Share of Common Stock (Tables)link:presentationLinklink:calculationLinklink:definitionLink 995623 – Disclosure – Leases (Tables)link:presentationLinklink:calculationLinklink:definitionLink 995624 – Disclosure – Organization and Summary of Significant Accounting Policies (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 995625 – Disclosure – Stockholders’ Equity (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 995626 – Disclosure – Schedule of Stock based Compensation Expense (Details)link:presentationLinklink:calculationLinklink:definitionLink 995627 – Disclosure – Schedule of Restricted Stock Units (“RSUs”) Activity (Details)link:presentationLinklink:calculationLinklink:definitionLink 995628 – Disclosure – Stock based Compensation (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 995629 – Disclosure – Schedule of Net Loss Per Share Basic and Diluted (Details)link:presentationLinklink:calculationLinklink:definitionLink 995630 – Disclosure – Net Loss per Share of Common Stock (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 995631 – Disclosure – Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)link:presentationLinklink:calculationLinklink:definitionLink 995632 – Disclosure – Schedule of Annual Lease Liabilities for all Operating Leases (Details)link:presentationLinklink:calculationLinklink:definitionLink 995633 – Disclosure – Schedule of Annual Lease Liabilities for all Financing Leases (Details)link:presentationLinklink:calculationLinklink:definitionLink 995634 – Disclosure – Leases (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 995635 – Disclosure – Related Party Transactions (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink 995636 – Disclosure – Commitments and Contingencies (Details Narrative)link:presentationLinklink:calculationLinklink:definitionLink EX 101.CAL 7 pgsa 20240930 cal.xml XBRL CALCULATION FILE EX 101.DEF 8 pgsa 20240930 def.xml XBRL DEFINITION FILE EX 101.LAB 9 pgsa 20240930 lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid in Capital [Member] Treasury Stock, Common [Member] Retained Earnings [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Consulting Agreement [Member] Legal Entity [Axis] Spartan Capital Securities LLC [Member] Purchase Agreement [Member] Class of Warrant or Right [Axis] Pre-Funded Warrants [Member] Warrant [Member] Scenario [Axis] Registration Statement [Member] Statistical Measurement [Axis] Maximum [Member] Sales Agreement [Member] Related and Nonrelated Parties [Axis] Alliance Global Partners [Member] Sale of Stock [Axis] ATM Offering [Member] Placement Agent [Member] Elion Oncology, Inc. [Member] License Agreement [Member] Consultant [Member] Employees and Consultants [Member] Plan Name [Axis] 2019 Plan [Member] Award Type [Axis] Share Based Payment Arrangement, Option [Member] Restricted Stock [Member] Restricted Stock Units (RSUs) [Member] Title and Position [Axis] Employees [Member] Service Based RSUs [Member] Vesting [Axis] January 1, 2025 Vesting [Member] 3-Year Vesting [Member] First Performance Based RSUs [Member] Second Performance Based RSUs [Member] Next Generation Capcetine – Cap [Member] Chief Financial Officer [Member] July 16, 2025 Vesting [Member] Director [Member] Offering [Member] Statement of Income Location, Balance [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Antidilutive Securities [Axis] Long-Lived Tangible Asset [Axis] Facility Lease [Member] Equipment [Member] Related Party Transaction [Axis] CorLyst, LLC [Member] CROs [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] ASSETS Current Assets Cash and cash equivalents Prepaid expenses and other Total Current Assets Property and Equipment, net Other Assets Lease right of use assets, net of accumulated amortization Security deposit Total Other Assets Total Assets LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Current maturities of lease liabilities Accounts payable Due to licensor Due to related parties Accrued expenses Total Current Liabilities Non-current Liabilities Non-current lease liabilities Total Liabilities Commitments and Contingencies Stockholders’ Equity Common stock, par value \$0.0001, 100,000,000 shares authorized, 3,271,944 issued and 3,266,944 outstanding at September 30, 2024, and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023 Additional paid-in capital Treasury stock at cost – 5,000 shares at September 30, 2024 and December 31, 2023 Accumulated deficit Total Stockholders’ Equity Total Liabilities and Stockholders’ Equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury stock shares Income Statement [Abstract] Operating Expenses Research and development General and administrative Operating Loss Other Income (Expense) Interest income, net Net Loss Net Loss per Common Share – Basic Net Loss per Common Share – Diluted Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares – Basic Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares – Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Stock based compensation Stock based compensation, shares Shares issued in connection with capital raise, net of transaction costs Shares issued in connection with capital raise, net of transaction costs, shares Net Loss Warrant granted in connection with a consulting agreement Stock based compensation, net of forfeitures Stock based compensation, net of forfeitures, shares Settlement of stock award Shares issued in connection with license agreement Shares issued in connection with license agreement, shares Shares withheld to pay income taxes on stock based compensation Shares withheld to pay income taxes on stock based compensation, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Non-cash lease expense for right-of-use assets Stock based compensation Warrants issued to purchase 158,007 shares of common stock in connection with a consulting agreement Net changes in operating assets and liabilities: Prepaid expenses and other Operating lease liability Accounts payable Due (from) to related parties Accrued expenses Net cash used in operating activities Cash Flows From Investing Activities Purchase of property and equipment Net cash used in investing activities Cash Flows From Financing Activities Net proceeds from common stock issued Shares withheld to pay taxes on stock based compensation Settlement of stock award Payment of finance lease obligation Net cash provided by (used in) financing activities Net Increase (Decrease) in Cash Cash and Cash Equivalents – Beginning of Period Cash and Cash Equivalents – End of Period Non-Cash Financing Activities Issuance of common stock in satisfaction of a due to licensor in connection with a licensing agreement Right-of-use asset obtained in exchange for financing lease liability Financing lease liability Net Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Warrants to purchase shares Pay vs Performance Disclosure [Table] Executive Category [Axis] Individual [Axis] Adjustment to Compensation [Axis] Measure [Axis] Pay vs Performance Disclosure, Table Company Selected Measure Name Named Executive Officers, Footnote Peer Group Issuers, Footnote Changed Peer Group, Footnote PEO Total Compensation Amount PEO Actually Paid Compensation Amount Adjustment To PEO Compensation, Footnote Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Compensation Actually Paid Amount Adjustment to Non-PEO NEO Compensation Footnote Equity Valuation Assumption Difference, Footnote Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Company Selected Measure Total Shareholder Return Vs Peer Group Compensation Actually Paid vs. Other Measure Tabular List, Table Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Net Income (Loss) Company Selected Measure Amount Other Performance Measure, Amount Adjustment to Compensation, Amount PEO Name Name Non-GAAP Measure Description Additional 402(v) Disclosure Pension Benefits Adjustments, Footnote Erroneously Awarded Compensation Recovery [Table] Restatement Determination Date [Axis] Restatement Determination Date Aggregate Erroneous Compensation Amount Erroneous Compensation Analysis Stock Price or TSR Estimation Method Outstanding Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Not Yet Determined Name Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery, Explanation of Impracticability Name Compensation Amount Restatement does not require Recovery Awards Close in Time to MNPI Disclosures [Table] Award Timing MNPI Disclosure Award Timing Method Award Timing Predetermined Award Timing MNPI Considered Award Timing, How MNPI Considered MNPI Disclosure Timed for Compensation Value Awards Close in Time to MNPI Disclosures, Table Name Underlying Securities Exercise Price Fair Value as of Grant Date Underlying Security Market Price Change Insider Trading Arrangements [Line Items] Material Terms of Trading Arrangement Name Title Rule 10b5-1 Arrangement Adopted Non Rule 10b5-1 Arrangement Adopted Adoption Date Rule 10b5-1 Arrangement Terminated Non Rule 10b5-1 Arrangement Terminated Termination Date Expiration Date Arrangement Duration Insider Trading Policies and Procedures [Line Items] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Not Adopted Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies Equity [Abstract] Stockholders’ Equity Share-Based Payment Arrangement [Abstract] Stock based Compensation Earnings Per Share [Abstract] Net Loss per Share of Common Stock Leases Leases Related Party Transactions [Abstract] Related Party Transactions Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Organization Basis of Presentation Liquidity Use of Estimates Income Taxes Concentration of Credit Risk Recent Accounting Pronouncements Schedule of Stock based Compensation Expense Schedule of Restricted Stock Units (“RSUs”) Activity Schedule of Net Loss Per Share Basic and Diluted Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases Schedule of Annual Lease Liabilities for all Operating Leases Schedule of Annual Lease Liabilities for all Financing Leases Organization Table [Table] Organization Line Items [Line Items] Scenario Axis [Axis] Reverse stock split Common stock shares issued Common stock shares outstanding Common stock shares authorized Accumulated deficit Net loss Net cash for operating activities from continuing operations Shares issued Net proceeds from sale of common stock Warrant exercised Maximum value to be sold Maximum value to be sold at the market offering Stock, Class of Stock [Table] Class of Stock [Line Items] Preferred stock, shares issued Preferred stock, shares outstanding Class of warrant or right, number of securities called by warrants or rights Class of warrant or right, exercise price of warrants or rights Warrant expiration date Shares issued, price per share Gross proceeds from issuance of common stock Proceeds from Issuance of Common Stock Class of warrant or right, outstanding Stock withheld for income taxes Share Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Total Schedule of Share Based Compensation Arrangements by Share Based Payment Award [Table] Share Based Compensation Arrangement by Share Based Payment Award [Line Items] Number of shares, Beginning balance Weighted average grant date fair value per share, Beginning balance Number of shares, granted Weighted average grant date fair value per share, granted Number of shares, forfeited Weighted average grant date fair value per share, forfeited Number of shares, issued Weighted average grant date fair value per share, shares issued Number of shares, ending balance Weighted average grant date fair value per share, ending balance Number of shares, vested and unissued Weighted average grant date fair value per share, vested and unissued Number of shares, unvested Weighted average grant date fair value per share, unvested Maximum equity available for issuance Shares available for future grants Options, forfeited Options, forfeited weighted average exercise price Options exercisable, shares Options exercisable weighted average exercise price Exercisable weighted average remaining contractual term Number of shares, vested Weighted average grant date fair value per share, shares vested Number of shares, outstanding Market capitalization Performance vesting criteria Unrecognized share based compensation expense Weighted average period for recognition Unrecognized share based compensation expense Warrants, expired Share based compensation arrangement by share based payment award, non-option equity instruments, forfeitures Payments for settlement of stock awards Weighted average exercise price Weighted average remaining contractual life Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Line Items] Net loss available to common stockholders Weighted average number of common shares basic Weighted average number of common shares diluted Basic net loss per share Diluted net loss per share Antidilutive securities excluded from computation of earnings per share, amount Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Remaining lease term (years) Remaining lease term (years) Weighted average discount rate for our facility and equipment leases Schedule Of Annual Lease Liabilities For All Operating Leases 2024 2025 Total lease payments Less: Interest Present value of lease liabilities Less: current maturities Non-current lease liability Schedule Of Annual Lease Liabilities For All Financing Leases 2024 2025 2026 Total lease payments Less: Interest Present value of lease liabilities Less: current maturities Non-current lease liability Operating and financing lease borrowing rate Lease cost Related Party Transaction [Table] Related Party Transaction [Line Items] Rent and other costs reimbursements received Due from related parties Purchase obligation Amount of lessee’s right of use underlying asset under operating and finance leases, Operating and finance lease liability current, Due to licensor, Operating and finance lease liability noncurrent, Purchase agreement [Member] Pre-Funded Warrant [Member] Warrants exercisable and maturity date, Stock issued during period shares exercised, Gross proceeds from issuance of common stock, Placement Agent [Member] Elion Oncology, Inc. [Member] License Agreement [Member] ATM Offering [Member] Consultant [Member] Consulting Agreement [Member] Employees and Consultants [Member] Stock issued during period shares stock withheld for income taxes, 2019 Plan [Member] Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding, Share based compensation arrangement by share based payment award equity instruments other than options issued in period, Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued, Per share or unit weighted average fair value of vested and nonvested award under share based payment arrangement, Excludes share and unit options, Share based compensation arrangement by share based payment award equity instruments other than options issued in period weighted average grant date fair value, Share based compensation arrangement by share based payment award equity instruments other than options vested and unissued weighted average grant date fair value, Adjustments to additional paid in capital settlement of stock awards, Value of shares issued in connection with license agreement, Number of shares issued in connection with license agreement, Employees [Member] Service Based RSUs [Member] January 1, 2025 Vesting [Member] 3-Year Vesting [Member] First Performance Based RSUs [Member] Second Performance Based RSUs [Member] Next Generation Capcetine – Cap [Member] Spartan Capital Securities LLC [Member] Payments for settlement of stock awards, Financing lease liability, Non-cash lease liability net, Stock issued in satisfaction of due to licensor in connection with licensing agreement, Business Activities And Organization [Policy Text Block] Liquidity [Policy Text Block] Maximum value to be sold at the market offering, Sales Agreement [Member] Alliance Global Partners [Member] July 16, 2025 Vesting [Member] Market capitalization, Performance vesting criteria value Unrecognized share based compensation expense, Offering [Member] Lessee Operating And Financing Leases [Text Block] Operating and financing lease weighted average discount rate, Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating And Financing Leases [Table Text Block] Facility Lease [Member] Rent and other costs reimbursements received, CorLyst, LLC [Member] CROs [Member] Due (from) to related parties, Assets, Current Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment Assets Liabilities, Current Liabilities Treasury Stock, Value Equity, Attributable to Parent Liabilities and Equity Operating Income (Loss) Shares, Outstanding Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Share Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Accounts Payable Increase Decrease in Due From Related Parties Increase (Decrease) in Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Payment, Tax Withholding, Share-Based Payment Arrangement Finance Lease, Principal Payments Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Forgone Recovery, Individual Name Outstanding Recovery, Individual Name Awards

Close in Time to MNPI Disclosures, Individual Name Trading Arrangement, Individual Name Equity [Text Block] Lessee Operating And Financing Leases [Text Block] Commitments and Contingencies Disclosure [Text Block] ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unrecognized share based compensation expense, Lessee, Finance Lease, Remaining Lease Term Lessee, Operating Lease, Liability, to be Paid Lessee, Operating Lease, Liability, Undiscounted Excess Amount Operating Lease, Liability, Current Finance Lease, Liability, to be Paid, Remainder of Fiscal Year Finance Lease, Liability, to be Paid, Year One Finance Lease, Liability, to be Paid Finance Lease, Liability, Undiscounted Excess Amount Finance Lease, Liability, Current Finance Lease, Liability, Current Finance Lease, Liability, Noncurrent EX-101.PRE-10.pcsa-20240930_pre.xml XBRL PRESENTATION FILE XML-12-R1.htm IDEA: XBRL DOCUMENT

Cover - shares 9 Months Ended

Sep-30-2024
Oct-15-2024
Cover [Abstract] Document Type 10-Q Amendment Flag false Document Quarterly Report true Document Transition Report false Document Period End Date Sep-30-2024 Document Fiscal Period Focus Q3 Document Fiscal Year Focus 2024 Current Fiscal Year End Date 12-31 Entity File Number 001-39531 Entity Registrant Name Processa Pharmaceuticals, Inc. Entity Central Index Key 0001533743 Entity Tax Identification Number 45-1539785 Entity Incorporation, State or Country Code DE Entity Address, Address Line One 7380 Coca Cola Drive Entity Address, Address Line Two Suite 106 Entity Address, City or Town Hanover Entity Address, State or Province MD Entity Address, Postal Zip Code 21076 City Area Code 443 Local Phone Number 776-3133 Title of 12(b) Security Common Stock, \$0.0001 par value per share Trading Symbol PCSA Security Exchange Name NASDAQ Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company false Entity Shell Company false Entity Common Stock, Shares Outstanding 3,266,944

-Definition
Boolean flag that is true when the XBRL content amends previously filed or accepted submission.

+ References

No definition available.

+ Details
Name: dei-AmendmentFlag Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration

-Definition

Area code of city

+ References

No definition available.

+ Details
Name: dei-CityAreaCode Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration

-Definition

Cover page.

+ References

No definition available.

+ Details
Name: dei-CoverAbstract Namespace Prefix: dei Data Type: xbrli:stringItemType Balance Type: na Period Type: duration

-Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details
Name: dei-CurrentFiscalYearEndDate Namespace Prefix: dei Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration

-Definition

Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.

+ References

No definition available.

+ Details
Name: dei-DocumentsFiscalPeriodFocus Namespace Prefix: dei Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration

-Definition

This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details
Name: dei-DocumentsFiscalYearFocus Namespace Prefix: dei Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration

-Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details
Name: dei-DocumentsPeriodEndDate Namespace Prefix: dei Data Type: xbrli:dateItemType Balance Type: na Period Type: duration

-Definition

Boolean flag that is true only for a form used as an quarterly report.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-10-Q-Number-240-Section-308-Subsection-a>

+ Details
Name: dei-DocumentsQuarterlyReport Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration

-Definition

Boolean flag that is true only for a form used as a transition report.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/presentationRef_Publisher_SEC_Name_Forms 10-K, 10-O, 20-F-Number 240-Section 13-Subsection a-1](http://www.xbrl.org/2003/role/presentationRef_Publisher_SEC_Name_Forms_10-K_10-O_20-F_Number_240_Section_13-Subsection_a-1)

[+ Details](#)

Name:[dei_DocumentTransitionReport](#) **Namespace Prefix:**[dei](#) **Data Type:**[xbrli:booleanItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

The type of document being provided (such as 10-K, 10-O, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

[+ References](#)

No definition available.

[+ Details](#)

Name:[dei_DocumentType](#) **Namespace Prefix:**[dei](#) **Data Type:**[dei:submissionTypeItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

Address Line 1 such as Attn, Building Name, Street Name

[+ References](#)

No definition available.

[+ Details](#)

Name:[dei_EntityAddressAddressLine1](#) **Namespace Prefix:**[dei](#) **Data Type:**[xbrli:normalizedStringItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

Address Line 2 such as Street or Suite number

[+ References](#)

No definition available.

[+ Details](#)

Name:[dei_EntityAddressAddressLine2](#) **Namespace Prefix:**[dei](#) **Data Type:**[xbrli:normalizedStringItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

Name of the City or Town

[+ References](#)

No definition available.

[+ Details](#)

Name:[dei_EntityAddressCityOrTown](#) **Namespace Prefix:**[dei](#) **Data Type:**[xbrli:normalizedStringItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

Code for the postal or zip code

[+ References](#)

No definition available.

[+ Details](#)

Name:[dei_EntityAddressPostalZipCode](#) **Namespace Prefix:**[dei](#) **Data Type:**[xbrli:normalizedStringItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

Name of the state or province.

[+ References](#)

No definition available.

[+ Details](#)

Name:[dei_EntityAddressStateOrProvince](#) **Namespace Prefix:**[dei](#) **Data Type:**[dei:stateOrProvinceItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

A unique 10 digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/presentationRef_Publisher_SEC_Name Exchange Act-Number 240-Section 12-Subsection b-2](http://www.xbrl.org/2003/role/presentationRef_Publisher_SEC_Name_Exchange_Act_Number_240_Section_12-Subsection_b-2)

[+ Details](#)

Name:[dei_EntityCentralIndexKey](#) **Namespace Prefix:**[dei](#) **Data Type:**[dei:centralIndexKeyItemType](#) **Balance Type:**[na](#) **Period Type:**[duration](#)

[-Definition](#)

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument {Domain} of the Entity Listings, Instrument.

[+ References](#)

No definition available.

[+ Details](#)

Name:[dei_EntityCommonStockSharesOutstanding](#) **Namespace Prefix:**[dei](#) **Data Type:**[xbrli:sharesItemType](#) **Balance Type:**[na](#) **Period Type:**[instant](#)

[-Definition](#)

Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityCurrentReportingStatus **Namespace Prefix:**dei **Data Type:**dei:yesNoItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Indicate if registrant meets the emerging growth company criteria.

[+References](#)

Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher SEC Name Exchange Act Number 240 Section 12 Subsection b 2

[+Details](#)

Name:dei_EntityEmergingGrowthCompany **Namespace Prefix:**dei **Data Type:**xbri:booleanItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

[+References](#)

No definition available.

[+Details](#)

Name:dei_EntityFileNumber **Namespace Prefix:**dei **Data Type:**dei:fileNumberItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

[+References](#)

Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher SEC Name Exchange Act Number 240 Section 12 Subsection b 2

[+Details](#)

Name:dei_EntityFilerCategory **Namespace Prefix:**dei **Data Type:**dei:filerCategoryItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Two-character EDGAR code representing the state or country of incorporation.

[+References](#)

No definition available.

[+Details](#)

Name:dei_EntityIncorporationStateCountryCode **Namespace Prefix:**dei **Data Type:**dei:edgarStateCountryItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

[+References](#)

Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher SEC Name Regulation S-T Number 232 Section 405

[+Details](#)

Name:dei_EntityInteractiveDataCurrent **Namespace Prefix:**dei **Data Type:**dei:yesNoItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

[+References](#)

Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher SEC Name Exchange Act Number 240 Section 12 Subsection b 2

[+Details](#)

Name:dei_EntityRegistrantName **Namespace Prefix:**dei **Data Type:**xbri:normalizedStringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

[+References](#)

Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher SEC Name Exchange Act Number 240 Section 12 Subsection b 2

[+Details](#)

Name:dei_EntityShellCompany **Namespace Prefix:**dei **Data Type:**xbri:booleanItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Indicates that the company is a Smaller Reporting Company (SRC).

[+References](#)

Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher SEC Name Exchange Act Number 240 Section 12 Subsection b 2

[+ Details](#)

Name:dei_EntitySmallBusiness **Namespace Prefix:**dei **Data Type:**xbri:booleanItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> Publisher SEC Name Exchange Act Number 240 Section 12 Subsection b 2

[+ Details](#)

Name:dei_EntityTaxIdentificationNumber **Namespace Prefix:**dei **Data Type:**dei:employerIdItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Local phone number for entity.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_LocalPhoneNumber **Namespace Prefix:**dei **Data Type:**xbri:normalizedStringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Title of a 12(b) registered security.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> Publisher SEC Name Exchange Act Number 240 Section 12 Subsection b

[+ Details](#)

Name:dei_Security12bTitle **Namespace Prefix:**dei **Data Type:**dei:securityTitleItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Name of the Exchange on which a security is registered.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef> Publisher SEC Name Exchange Act Number 240 Section 12 Subsection d1-1

[+ Details](#)

Name:dei_SecurityExchangeName **Namespace Prefix:**dei **Data Type:**dei:edgarExchangeCodeItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Trading symbol of an instrument as listed on an exchange.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_TradingSymbol **Namespace Prefix:**dei **Data Type:**dei:tradingSymbolItemType **Balance Type:**na **Period Type:**duration XML 13 R2.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Balance Sheets (Unaudited) - USD (\$) Sep. 30, 2024Dec. 31, 2023**Current Assets** **Cash and cash equivalents**\$ 2,891,464\$ 4,706,197**Prepaid expenses and other**
1,946,675926,300**Total Current Assets**4,838,1395,632,497**Property and Equipment, net**5,3172,554**Other Assets** **Lease right-of-use assets, net of accumulated amortization**93,161146,057
Security deposits5,5355,535**Total Other Assets**98,696151,592**Total Assets**4,942,1525,786,643**Current Liabilities** **Current maturities of lease liabilities**94,67683,649**Accounts payable**711,710
311,617**Due to licensor**189,000**Due to related parties**39**Accrued expenses**412,813146,274**Total Current Liabilities**1,219,199730,579**Non-current Liabilities** **Non-current lease liabilities**2,168
66,905**Total Liabilities**1,221,367797,484**Commitments and Contingencies** **Stockholders' Equity** **Common stock, par value \$0.0001, 100,000,000 shares authorized; 3,271,944 issued and**
3,266,944 outstanding at September 30, 2024; and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023327129**Additional paid-in capital**88,510,94980,658,111**Treasury stock at**
cost— 5,000 shares at September 30, 2024 and December 31, 2023(300,000)(300,000)**Accumulated deficit**(84,490,491)(75,369,081)**Total Stockholders' Equity**3,720,7854,989,159**Total**
Liabilities and Stockholders' Equity\$ 4,942,152\$ 5,786,643

[- Definition](#)

Due to licensor.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_DueToLicensor **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Operating and finance lease liability current.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_OperatingAndFinanceLeaseLiabilityCurrent **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Operating and finance lease liability noncurrent.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_OperatingAndFinanceLeaseLiabilityNoncurrent **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)

Amount of lessee's right of use underlying asset under operating and finance leases.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_OperatingAndFinancingLeaseRightofUseAsset **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[-Definition](#)

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>

[+ Details](#)

Name:us-gaap-AccountsPayableCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap-AccruedLiabilitiesCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\(a\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30)(a)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap-AdditionalPaidInCapitalCommonStock **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)

Amount of asset recognized for present right to economic benefit.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 49-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482064/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482064/270-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 12: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(12\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(12))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)

~~Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21:~~
~~http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher~~
~~FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards~~
~~Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23:~~
~~http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher~~
~~FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards~~
~~Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25:~~
~~http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher~~
~~FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards~~
~~Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27:~~
~~http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB~~
~~-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards~~
~~Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef-~~
~~Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-~~
~~30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(11))-~~
~~Publisher FASB-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1~~

[+ Details](#)

Name:us:gaap:Assets **Namespace Prefix:**us:gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Amount of asset recognized for present right to economic benefit, classified as current.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 810_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph \(bb\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 810_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph (bb)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic 810_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 25_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef_Topic 810_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 25_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.4-08(g)(1)(iii))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: http://www.xbrl.org/2003/role/exampleRef_Topic 852_SubTopic 10_Name Accounting Standards Codification_Section 55_Paragraph 10_Publisher FASB_URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef_Topic 210_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 1_Publisher FASB_URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 210_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.5-02\(9\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 210_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.5-02(9))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(i))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iii))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iii))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iii)(A))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-02(a)(4)(iii)(B))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iv))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(i))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iii)(A))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iii)(B))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iv))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(5\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(5))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 852_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 7_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 852_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 7_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)

[+ Details](#)

Name:us-gaap_AssetsCurrent **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_AssetsCurrentAbstract **Namespace Prefix:**us-gaap **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_AssetsNoncurrentAbstract **Namespace Prefix:**us-gaap **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-4>

[+ Details](#)

Name:us-gaap_CashAndCashEquivalentsAtCarryingValue **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-03\(17\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-03(17))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(25\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(25))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(19))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(15\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(15))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>

[+ Details](#)

Name:us-gaap_CommitmentsAndContingencies **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10> - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(22))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>

[+ Details](#)

Name:us-gaap-CommonStockValue **Namespace Prefix:**us-gaap- **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)

Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.

[+References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(22\)\)-SubTopic10-Topic210-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(22))-SubTopic10-Topic210-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(20\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(20))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(24\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(24))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(19\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(19))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(25\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(25))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(26\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(26))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(23\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(23))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(21\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(21))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph25-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph25-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(bb\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic810-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(bb)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(g\)\(1\)\(iii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(g)(1)(iii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 15: <http://www.xbrl.org/2003/role/exampleRef-Topic946-SubTopic830-NameAccountingStandardsCodification-Section55-Paragraph12-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6-04\(14\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic210-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6-04(14))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(B))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 27: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 28: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic852-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph7-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 29: [http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph\(d\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph(d)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482810/280-10-50-30)

[+ Details](#)

Name:us-gaap-Liabilities **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/exampleRef_Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI
<https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(25\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(25))) Publisher FASB URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef_Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(g)(1)(ii))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(c\)](http://www.xbrl.org/2009/role/commonPracticeRef_Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(c)) Publisher FASB URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)](http://www.xbrl.org/2009/role/commonPracticeRef_Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)) Publisher FASB URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-03\(23\)\)](http://fasb.org/us-gaap/role/ref/legacyRef_Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-03(23))) Publisher FASB URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(32\)\)](http://fasb.org/us-gaap/role/ref/legacyRef_Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(32))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)

Name:us-gaap_LiabilitiesAndStockholdersEquity **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(21))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef_Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef_Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 7-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef_Topic 7-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 8: http://www.xbrl.org/2003/role/exampleRef_Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 21: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)

[+ Details](#)
Name:us-gaap_LiabilitiesCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- References](#)
No definition available.

[+ Details](#)
Name:us-gaap_LiabilitiesCurrentAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- References](#)
No definition available.

[+ Details](#)
Name:us-gaap_LiabilitiesNoncurrentAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)
Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.
[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(20\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(20))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>

[+ Details](#)

Name:us-gaap_OtherLiabilitiesCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

[+ References](#)

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(9\)\)](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(9)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)

Name:us-gaap_PrepaidExpenseAndOtherAssetsCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef_Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef_Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 3: http://www.xbrl.org/2003/role/exampleRef_Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 5: http://www.xbrl.org/2003/role/disclosureRef_Topic 942-SubTopic 360-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147478451/942-360-50-1

[+ Details](#)

Name:us-gaap_PropertyPlantAndEquipmentNet **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Amount of accumulated undistributed earnings (deficit).

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30)(a)(3))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: http://www.xbrl.org/2003/role/exampleRef_Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(23)(a)(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(17\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(17))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap:RetainedEarningsAccumulatedDeficit **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.

[+ References](#)

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(17\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)

Name:us-gaap:SecurityDeposit **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10> - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12> - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2>

[+ Details](#)

Name:us-gaap:StockholdersEquity **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap:StockholdersEquityAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(30\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(30))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-30-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481520/505-30-50-4>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-30-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481549/505-30-45-1>

[+ Details](#)

Name:us-gaap:TreasuryStockValue **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant XML 14 R3.htm IDEA: XBRL DOCUMENT **Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - \$ / shares** Sep. 30, 2024Dec. 31, 2023**Statement of Financial Position [Abstract] - Common stock, par value** \$ 0.0001\$ 0.0001**Common stock, shares authorized**100,000,000100,000,000**Common stock, shares issued**3,271,9441,291,000**Common stock, shares outstanding**3,266,9441,286,000**Treasury stock shares**5,0005,000

[- Definition](#)

Face amount or stated value per share of common stock.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap:CommonStockParOrStatedValuePerShare **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(16\)\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(16)(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1)

[+ Details](#)

Name:us-gaap-CommonStockSharesAuthorized **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap-CommonStockSharesIssued **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.6-05\(4\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.6-05(4))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-09\(4\)\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(4)(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(16\)\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(16)(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-09\(7\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(7))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479134/946-220-S99-3)

[+ Details](#)

Name:us-gaap-CommonStockSharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap-StatementOfFinancialPositionAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

-Definition

Number of previously issued common shares repurchased by the issuing entity and held in treasury.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-30-Section-45-Paragraph-1-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147481549/505-30-45-1>

+ Details

Name:us-gaap-TreasuryStockCommonShares-**Namespace Prefix:**us-gaap-**Data Type:**xbrii:sharesItemType-**Balance Type:**na-**Period Type:**instant XML 15-R4.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Statements of Operations (Unaudited) - USD (\$) 3 Months Ended9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Operating Expenses—**Research and development**\$ 2,287,525\$ 1,151,740\$ 5,556,694\$ 4,478,793**General and administrative**1,137,3281,015,8723,759,7814,508,818**Operating Loss**(3,424,853)
(2,167,612)(9,316,475)(8,987,611)**Other Income (Expense)**—**Interest income, net**40,15085,661195,065271,022**Net Loss**\$(3,384,703)\$(2,081,951)\$(9,121,410)\$(8,716,589)**Net Loss per**
Common Share—Basic\$(1.03)\$(1.54)\$(3.13)\$(6.81)**Net Loss per Common Share—Diluted**\$(1.03)\$(1.54)\$(3.13)\$(6.81)**Weighted Average Common Shares Used to Compute Net Loss**
Applicable to Common Shares—Basic3,275,9981,350,1882,909,9411,279,298**Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares—Diluted**3,275,998
1,350,1882,909,9411,279,298

-Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-52-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(g\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(g)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)\(3\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)(3)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-15-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(e\)\(4\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(e)(4)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-\(d\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(d)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.5-03\(25\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.5-03(25))-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-04\(27\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-04(27))-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-04\(23\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-04(23))-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482689/260-10-45-7>

[+ Details](#)

Name:~~us-gaap_EarningsPerShareBasic~~ **Namespace Prefix:**us-gaap **Data Type:**~~dtr-types:perShareItemType~~ **Balance Type:**na **Period Type:**duration

[- Definition](#)

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 55_Paragraph 52_Publisher FASB_URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(g\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (g)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph \(g\)\(3\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph (g)(3)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 55_Paragraph 15_Publisher FASB_URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(e\)\(4\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (e)(4)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(b\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (b)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 7_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 7_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 2_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph \(d\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph (d)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 4_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph \(SX 210.5-03\(25\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph (SX 210.5-03(25))_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 942_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.9-04\(27\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 942_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.9-04(27))_Publisher FASB_URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.7-04\(23\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.7-04(23))_Publisher FASB_URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 7_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

[+ Details](#)

Name:us-gaap_EarningsPerShareDiluted **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph \(SX 210.5-03\(4\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph (SX 210.5-03(4))_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.6-07\(2\)\(a\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.6-07(2)(a))_Publisher FASB_URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)

[+ Details](#)

Name:us-gaap_GeneralAndAdministrativeExpense_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType_Balance Type:debit_Period Type:duration

[- Definition](#)

Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 280_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 22_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef_Topic 280_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 22_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 2: http://www.xbrl.org/2003/role/exampleRef_Topic 280_SubTopic 10_Name Accounting Standards Codification_Section 55_Paragraph 48_Publisher FASB_URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph \(SX 210.5-03\(7\)\(b\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph (SX 210.5-03(7)(b))_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 270_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(i\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 270_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (i)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef_Topic 280_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 32_Subparagraph \(ee\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef_Topic 280_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 32_Subparagraph (ee)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)

[+ Details](#)

Name:us-gaap_InvestmentIncomeInterest_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType_Balance Type:credit_Period Type:duration

[- Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 9_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(g\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (g)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph \(g\)\(3\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph (g)(3)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph \(SX 210.5-03\(20\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph (SX 210.5-03(20))_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.4-08(g)(1)(ii))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(b\)\(2\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (b)(2)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 8_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(b\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (b)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 4_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

~~https://www.xbrl.org/2003/role/disclosureRef_Topic 259_SubTopic 19_Name Accounting Standards Codification-Section 55-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4~~~~Reference 17: http://www.xbrl.org/2003/role/exampleRef_Topic 946_SubTopic 830_Name Accounting Standards Codification-Section 55-Paragraph 10_Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10~~~~Reference 18: http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification-Section 45-Paragraph 7_Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7~~~~Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 1_Subparagraph \(SX 210.7-04\(18\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 1_Subparagraph (SX 210.7-04(18))_Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)~~~~Reference 20: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 1_Subparagraph \(SX 210.6-07\(9\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 1_Subparagraph (SX 210.6-07(9))_Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)~~~~Reference 21: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 3_Subparagraph \(SX 210.6-09\(1\)\(d\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 3_Subparagraph (SX 210.6-09(1)(d))_Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)~~~~Reference 22: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(i))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~~~Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(ii))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~~~Reference 24: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iii)(A))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~~~Reference 25: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iv))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~~~Reference 26: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(5\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1A_Subparagraph (SX 210.13-01(a)(5))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)~~~~Reference 27: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(i))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)~~~~Reference 28: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iii)(A))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)~~~~Reference 29: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iii)(B))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)~~~~Reference 30: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iv))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)~~~~Reference 31: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(5\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification-Section S99-Paragraph 1B_Subparagraph (SX 210.13-02(a)(5))_Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)~~~~Reference 32: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification-Section 45-Paragraph 60B_Subparagraph \(a\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification-Section 45-Paragraph 60B_Subparagraph (a)_Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)~~~~Reference 33: http://www.xbrl.org/2003/role/disclosureRef_Topic 205_SubTopic 20_Name Accounting Standards Codification-Section 50-Paragraph 7_Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7~~~~Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification-Section 45-Paragraph 28_Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28~~~~Reference 35: [http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification-Section 45-Paragraph 1A_Subparagraph \(a\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification-Section 45-Paragraph 1A_Subparagraph (a)_Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)~~~~Reference 36: [http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification-Section 45-Paragraph 1B_Subparagraph \(a\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification-Section 45-Paragraph 1B_Subparagraph (a)_Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)~~~~Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 942_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 1_Subparagraph \(SX 210.9-04\(22\)\)_Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 942_SubTopic 220_Name Accounting Standards Codification-Section S99-Paragraph 1_Subparagraph (SX 210.9-04(22))_Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)~~

[+ Details](#)

Name:us-gaap_NetIncomeLoss **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_OperatingExpensesAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The net result for the period of deducting operating expenses from operating revenues.

[+ References](#)

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(ee\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(ee)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-31>

[+ Details](#)

Name:us-gaap-OperatingIncomeLoss **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap-OtherIncomeAndExpensesAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

[+ References](#)

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef_Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

[+ Details](#)

Name:us-gaap-ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 16-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16

[+ Details](#)

Name:us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10

[+ Details](#)

Name:us-gaap-WeightedAverageNumberOfSharesOutstandingBasic **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration XML 16-R5.htm

IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Changes in Stockholders' Equity

(Unaudited) - USD (\$)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022\$ 80\$ 72,018,222\$ (300,000)\$ (64,247,561)\$ 7,470,741Balance, shares at Dec. 31, 2022806,774 (5,000)Stock-based compensation\$ 1341,503341,504Stock-based compensation, shares3,195Shares issued in connection with capital raise, net of transaction costs\$ 426,352,0356,352,077Shares issued in connection with capital raise, net of transaction costs, shares421,611Net loss (4,022,073)(4,022,073)Balance at Mar. 31, 2023\$ 12378,711760\$ (300,000)(68,269,634)10,142,249Balance, shares at Mar. 31, 20231,231,580 (5,000)Balance at Dec. 31, 2022\$ 8072,018,222\$ (300,000)(64,247,561)7,470,741Balance, shares at Dec. 31, 2022806,774 (5,000)Net loss (8,716,589)Balance at Sep. 30, 2023\$ 12480,431,905\$ (300,000)(72,964,150)7,167,879Balance, shares at Sep. 30, 20231,236,580 (5,000)Balance at Mar. 31, 2023\$ 12378,711760\$ (300,000)(68,269,634)10,142,249Balance, shares at Mar. 31, 20231,231,580 (5,000)Stock-based compensation319,123319,123Net loss (2,612,565)(2,612,565)Warrant granted in connection with a consulting agreement1,310,8751,310,875Balance at Jun. 30, 2023\$ 12380,341,758\$ (300,000)(70,882,199)9,159,682Balance, shares at Jun. 30, 20231,231,580 (5,000)Net loss (2,081,951)(2,081,951)Stock-based compensation, net of forfeitures\$ 142,893142,894Stock-based compensation, net of forfeitures, shares5,000Settlement of stock award (52,746)(52,746)Balance at Sep. 30, 2023\$ 12480,431,905\$ (300,000)(72,964,150)7,167,879Balance, shares at Sep. 30, 20231,236,580 (5,000)Balance at Dec. 31, 2023\$ 12980,658,111\$ (300,000)(75,369,081)4,989,159Balance, shares at Dec. 31, 20231,291,000 (5,000)Stock-based compensation\$ 1167,642167,643Stock-based compensation, shares13,176Shares issued in connection with capital raise, net of transaction costs\$ 1566,282,2746,282,430Shares issued in connection with capital raise, net of transaction costs, shares1,555,555Net loss (2,726,381)(2,726,381)Settlement of stock award (8,561)(8,561)Shares issued in connection with license agreements\$ 1188,999189,000Shares issued in connection with license agreement, shares5,000Shares withheld to pay income taxes on stock-based compensation\$ (1)(0,923)(0,924)Shares withheld to pay income taxes on stock-based compensation, shares(3,750)Balance at Mar. 31, 2024\$ 28687,278,542\$ (300,000)(78,095,462)8,883,366Balance, shares at Mar. 31, 20242,860,981 (5,000)Balance at Dec. 31, 2023\$ 12980,658,111\$ (300,000)(75,369,081)4,989,159Balance, shares at Dec. 31, 20231,291,000 (5,000)Net loss (9,121,410)Balance at Sep. 30, 2024\$ 32788,510,949\$ (300,000)(84,490,491)3,720,785Balance, shares at Sep. 30, 20243,271,944 (5,000)Balance at Mar. 31, 2024\$ 28687,278,542\$ (300,000)(78,095,462)8,883,366Balance,					

[shares at Mar. 31, 2024](#)2,860,981 (5,000) [Stock-based compensation](#) \$ 1152,631 152,632 [Stock-based compensation, shares](#) 14,167 [Net loss](#) (3,010,326) (3,010,326) [Shares withheld to pay income taxes on stock-based compensation](#) (2,008) (2,008) [Shares withheld to pay income taxes on stock-based compensation, shares](#) (1,265) [Balance at Jun. 30, 2024](#) \$ 28787,429 165 \$ (300,000) (81,105,788) 6,923,664 [Balance, shares at Jun. 30, 2024](#) 2,873,883 (5,000) [Stock-based compensation](#) \$ 3154,188 154,191 [Stock-based compensation, shares](#) 26,010 [Shares issued in connection with capital raise, net of transaction costs](#) \$ 37931,254 931,291 [Shares issued in connection with capital raise, net of transaction costs, shares](#) 374,190 [Net loss](#) (3,384,703) (3,384,703) [Shares withheld to pay income taxes on stock-based compensation](#) (3,658) (3,658) [Shares withheld to pay income taxes on stock-based compensation, shares](#) (2,139) [Balance at Sep. 30, 2024](#) \$ 327\$ 88,510,949\$ (300,000)\$ (84,490,491)\$ 3,720,785 [Balance, shares at Sep. 30, 2024](#) 3,271,944 (5,000) [Definition](#)

[Adjustments to additional paid in capital settlement of stock awards.](#)

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[-Definition](#)

[Number of shares issued in connection with license agreement.](#)

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_SharesIssuedinConnectionwithLicenseAgreementShares **Namespace Prefix:**PCSA **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

[Value of shares issued in connection with license agreement.](#)

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_SharesIssuedinConnectionwithLicenseAgreementValue **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[-Definition](#)

[Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.](#)

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[-Definition](#)

[Amount of increase in additional paid in capital \(APIC\) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.](#)

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic470-SubTopic20-Section25-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481284/470-20-25-2>

[+ Details](#)

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[-Definition](#)

[The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.](#)

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic805-SubTopic60-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph\(g\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic805-SubTopic60-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph(g)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic323-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph\(g\)\(3\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic323-NameAccountingStandardsCodification-Section65-Paragraph2-Subparagraph(g)(3)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph\(SX210.5-03\(20\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic220-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph2-Subparagraph(SX210.5-03(20))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4-08\(g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4-08(g)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic946-SubTopic830-NameAccountingStandardsCodification-Section55->

~~Paragraph 10—Publisher FASB—URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: http://www.xbrl.org/2003/role/disclosureRef_Topic_946-SubTopic_220-Name_Accounting_Standards_Codification-Section_45-Paragraph_7—Publisher FASB—URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic_944-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1-Subparagraph_\(SX_210.7-04\(18\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_944-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1-Subparagraph_(SX_210.7-04(18)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: [http://www.xbrl.org/2003/role/disclosureRef_Topic_946-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1-Subparagraph_\(SX_210.6-07\(9\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_946-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1-Subparagraph_(SX_210.6-07(9)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: [http://www.xbrl.org/2003/role/disclosureRef_Topic_946-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_3-Subparagraph_\(SX_210.6-09\(1\)\(d\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_946-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_3-Subparagraph_(SX_210.6-09(1)(d)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_\(SX_210.13-01\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_(SX_210.13-01(a)(4)(i)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_\(SX_210.13-01\(a\)\(4\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_(SX_210.13-01(a)(4)(ii)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_\(SX_210.13-01\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_(SX_210.13-01(a)(4)(iii)(A)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_\(SX_210.13-01\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_(SX_210.13-01(a)(4)(iv)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 26: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_\(SX_210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1A-Subparagraph_(SX_210.13-01(a)(5)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_\(SX_210.13-02\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_(SX_210.13-02(a)(4)(i)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_\(SX_210.13-02\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_(SX_210.13-02(a)(4)(iii)(A)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_\(SX_210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_(SX_210.13-02(a)(4)(iii)(B)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_\(SX_210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_(SX_210.13-02(a)(4)(iv)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_\(SX_210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_470-SubTopic_10-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1B-Subparagraph_(SX_210.13-02(a)(5)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: [http://www.xbrl.org/2003/role/disclosureRef_Topic_260-SubTopic_10-Name_Accounting_Standards_Codification-Section_45-Paragraph_60B-Subparagraph_\(a\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_260-SubTopic_10-Name_Accounting_Standards_Codification-Section_45-Paragraph_60B-Subparagraph_(a))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: http://www.xbrl.org/2003/role/disclosureRef_Topic_205-SubTopic_20-Name_Accounting_Standards_Codification-Section_50-Paragraph_7—Publisher FASB—URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef_Topic_230-SubTopic_10-Name_Accounting_Standards_Codification-Section_45-Paragraph_28—Publisher FASB—URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef_Topic_220-SubTopic_10-Name_Accounting_Standards_Codification-Section_45-Paragraph_1A-Subparagraph_\(a\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_220-SubTopic_10-Name_Accounting_Standards_Codification-Section_45-Paragraph_1A-Subparagraph_(a))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef_Topic_220-SubTopic_10-Name_Accounting_Standards_Codification-Section_45-Paragraph_1B-Subparagraph_\(a\)](http://www.xbrl.org/2003/role/disclosureRef_Topic_220-SubTopic_10-Name_Accounting_Standards_Codification-Section_45-Paragraph_1B-Subparagraph_(a))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic_942-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1-Subparagraph_\(SX_210.9-04\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef_Topic_942-SubTopic_220-Name_Accounting_Standards_Codification-Section_S99-Paragraph_1-Subparagraph_(SX_210.9-04(22)))—Publisher FASB—URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>~~

[+ Details](#)

Name:us-gaap_NetIncomeLoss **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

Number of shares issued which are neither cancelled nor held in the treasury.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_SharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number of new stock issued during the period.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

[+ Details](#)

Name:us-gaap:StockIssuedDuringPeriodSharesNewIssues **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItem **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItem **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation**Namespace Prefix:**us-gaap**Data Type:**xbri:sharesItemType**Balance Type:**na**Period Type:**duration

[- Definition](#)

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap:StockIssuedDuringPeriodValueNewIssues**Namespace Prefix:**us-gaap**Data Type:**xbri:monetaryItemType**Balance Type:**credit**Period Type:**duration

[- Definition](#)

Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOffForfeitures**Namespace Prefix:**us-gaap**Data Type:**xbri:monetaryItemType**Balance Type:**credit**Period Type:**duration

[-Definition](#)

Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)) Publisher FASB URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph \(d\)\(1\)](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (d)(1)) Publisher FASB URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+ Details](#)

Name:us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation**Namespace Prefix:**us-gaap**Data Type:**xbri:monetaryItemType**Balance Type:**credit**Period Type:**duration

[-Definition](#)

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic 952-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10> Publisher FASB URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12> Publisher FASB URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)) Publisher FASB URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)) Publisher FASB URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)) Publisher FASB URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2>

[+ Details](#)

Name:us-gaap:StockholdersEquity **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant XML 17-R6.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Statements of Cash Flows (Unaudited) – USD (\$) 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023

Cash Flows From Operating Activities Net loss \$(9,121,410) \$(8,716,589) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation 48182 Non-cash lease expense for right-of-use assets 64,700 60,552 Stock-based compensation 474,466 803,521 Warrants issued to purchase 158,007 shares of common stock in connection with a consulting agreement 1,310,875 **Net changes in operating assets and liabilities:** Prepaid expenses and other (1,020,375) 1836,344 Operating lease liability (61,776) (57,929) Accounts payable 400,093 18,751 Due (from) to related parties (39) 5,740 Accrued expenses 266,539 (200,825) Net-cash used in operating activities (8,997,321) (5,939,478) **Cash Flows From Investing Activities** Purchase of property and equipment (3,244) (2,776) Net-cash used in investing activities (3,244) (2,776) **Cash Flows From Financing Activities** Net proceeds from common stock issued 7,213,721 6,352,077 Shares withheld to pay taxes on stock-based compensation (15,590) Settlement of stock award (8,561) (52,746) Payment of finance lease obligation (3,738) Net cash provided by (used in) financing activities 7,185,832 6,299,331 Net Increase (Decrease) in Cash (1,814,733) 357,077 Cash and Cash Equivalents – Beginning of Period 4,706,197 6,503,595 Cash and Cash Equivalents – End of Period 2,891,464 6,860,672 **Non-Cash Financing Activities** Issuance of common stock in satisfaction of a due to licensor in connection with a licensing agreement 189,000 Right-of-use asset obtained in exchange for financing lease liability 11,804 Financing lease liability (11,804) Net

[– Definition](#)

Financing lease liability:

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_FinancingLeaseLiability **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[– Definition](#)

Due (from) to related parties:

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_IncreaseDecreaseInDueFromToRelatedParties **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[– Definition](#)

Non-cash lease liability net:

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_NonCashLeaseLiabilityNet **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[– References](#)

No definition available.

[+ Details](#)

Name:PCSA_OperatingAndFinanceLeaseExpense **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[– Definition](#)

Payments for settlement of stock awards:

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_PaymentsForSettlementOfStockAwards **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[– Definition](#)

Stock issued in satisfaction of due to licensor in connection with licensing agreement:

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_StockIssuedInSatisfactionOfDueToLicensorInConnectionWithLicensingAgreement **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[– References](#)

No definition available.

[+ Details](#)

Name:us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[– Definition](#)

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482913/230-10-50-8> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-24-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-24> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-4-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-4>

[+ Details](#)

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations **Namespace Prefix:**us-gaap **Data Type:** [xbrli:monetaryItemType](#) **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-24-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-SubTopic-230-Topic-830-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147477401/830-230-45-1>

[+ Details](#)

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect **Namespace Prefix:**us-gaap **Data Type:** [xbrli:monetaryItemType](#) **Balance Type:**debit **Period Type:**duration

[- Definition](#)

The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(b\)-SubTopic-10-Topic-230-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(b)-SubTopic-10-Topic-230-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482099/360-10-50-1>

[+ Details](#)

Name:us-gaap_Depreciation **Namespace Prefix:**us-gaap **Data Type:**[xbrli:monetaryItemType](#) **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of cash outflow for principal payment on finance lease.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(g\)\(1\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(g)(1)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147478964/842-20-50-4>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-5-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-5-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479041/842-20-45-5>

[+ Details](#)

Name:us-gaap_FinanceLeasePrincipalPayments **Namespace Prefix:**us-gaap **Data Type:**[xbrli:monetaryItemType](#) **Balance Type:**credit **Period Type:**duration

[- Definition](#)

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28>

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInAccountsPayable **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28)

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInAccruedLiabilities **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInOperatingCapitalAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Amount of increase (decrease) in obligation for operating lease.

[+ References](#)

Reference 1: [http://www.xbri.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbri.org/2009/role/commonPracticeRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbri.org/2009/role/commonPracticeRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(g\)\(1\)-SubTopic-20-Topic-842-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbri.org/2009/role/commonPracticeRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(g)(1)-SubTopic-20-Topic-842-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4)

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInOperatingLeaseLiability **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of increase (decrease) in prepaid expenses, and assets classified as other.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28)

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-\(b\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Subparagraph-(b)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-28)

[+ Details](#)

Name:us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 24_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInFinancingActivities **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[-References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 24_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-24

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInInvestingActivities **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[-References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 28_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 24_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 25_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInOperatingActivities **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**na **Period Type:**duration

[-References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 9_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(g\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (g)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph \(g\)\(3\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph (g)(3)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph \(SX 210.5-03\(20\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph (SX 210.5-03(20))_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.4-08(g)(1)(ii))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(b\)\(2\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (b)(2)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 8_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

~~<https://asc.fashb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic_250_SubTopic_10_Name_Accounting_Standards_Codification_Section_50-Paragraph_11_Subparagraph_\(a\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic_250_SubTopic_10_Name_Accounting_Standards_Codification_Section_50-Paragraph_11_Subparagraph_(a)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic_250_SubTopic_10_Name_Accounting_Standards_Codification_Section_50-Paragraph_11_Subparagraph_\(b\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic_250_SubTopic_10_Name_Accounting_Standards_Codification_Section_50-Paragraph_11_Subparagraph_(b)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147483443/250-10-50-11)Reference 16: http://www.xbrl.org/2003/role/disclosureRef_Topic_250_SubTopic_10_Name_Accounting_Standards_Codification_Section_50-Paragraph_4_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef_Topic_946_SubTopic_830_Name_Accounting_Standards_Codification_Section_55-Paragraph_10_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef_Topic_946_SubTopic_220_Name_Accounting_Standards_Codification_Section_45-Paragraph_7_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147479105/946-220-45-7Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic_944_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1_Subparagraph_\(SX_210.7-04\(18\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic_944_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1_Subparagraph_(SX_210.7-04(18))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef_Topic_946_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1_Subparagraph_\(SX_210.6-07\(9\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic_946_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1_Subparagraph_(SX_210.6-07(9))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef_Topic_946_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_3_Subparagraph_\(SX_210.6-09\(1\)\(d\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef_Topic_946_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_3_Subparagraph_(SX_210.6-09(1)(d))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_\(SX_210.13-01\(a\)\(4\)\(i\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_(SX_210.13-01(a)(4)(i))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_\(SX_210.13-01\(a\)\(4\)\(iii\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_(SX_210.13-01(a)(4)(iii))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_\(SX_210.13-01\(a\)\(4\)\(iii\)\(A\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_(SX_210.13-01(a)(4)(iii)(A))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_\(SX_210.13-01\(a\)\(4\)\(iv\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_(SX_210.13-01(a)(4)(iv))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_\(SX_210.13-01\(a\)\(5\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1A_Subparagraph_(SX_210.13-01(a)(5))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_\(SX_210.13-02\(a\)\(4\)\(i\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_(SX_210.13-02(a)(4)(i))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_\(SX_210.13-02\(a\)\(4\)\(iii\)\(A\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_(SX_210.13-02(a)(4)(iii)(A))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_\(SX_210.13-02\(a\)\(4\)\(iii\)\(B\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_(SX_210.13-02(a)(4)(iii)(B))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_\(SX_210.13-02\(a\)\(4\)\(iv\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_(SX_210.13-02(a)(4)(iv))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_\(SX_210.13-02\(a\)\(5\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic_470_SubTopic_10_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1B_Subparagraph_(SX_210.13-02(a)(5))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef_Topic_260_SubTopic_10_Name_Accounting_Standards_Codification_Section_45-Paragraph_60B_Subparagraph_\(a\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef_Topic_260_SubTopic_10_Name_Accounting_Standards_Codification_Section_45-Paragraph_60B_Subparagraph_(a)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147482689/260-10-45-60B)Reference 33: http://www.xbrl.org/2003/role/disclosureRef_Topic_205_SubTopic_20_Name_Accounting_Standards_Codification_Section_50-Paragraph_7_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147483499/205-20-50-7Reference 34: http://fashb.org/us-gaap/role/ref/legacyRef_Topic_230_SubTopic_10_Name_Accounting_Standards_Codification_Section_45-Paragraph_28_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147482740/230-10-45-28Reference 35: [http://www.xbrl.org/2003/role/disclosureRef_Topic_220_SubTopic_10_Name_Accounting_Standards_Codification_Section_45-Paragraph_1A_Subparagraph_\(a\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic_220_SubTopic_10_Name_Accounting_Standards_Codification_Section_45-Paragraph_1A_Subparagraph_(a)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef_Topic_220_SubTopic_10_Name_Accounting_Standards_Codification_Section_45-Paragraph_1B_Subparagraph_\(a\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic_220_SubTopic_10_Name_Accounting_Standards_Codification_Section_45-Paragraph_1B_Subparagraph_(a)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://fashb.org/us-gaap/role/ref/legacyRef_Topic_942_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1_Subparagraph_\(SX_210.9-04\(22\)\)_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147478524/942-220-S99-1](http://fashb.org/us-gaap/role/ref/legacyRef_Topic_942_SubTopic_220_Name_Accounting_Standards_Codification_Section_S99-Paragraph_1_Subparagraph_(SX_210.9-04(22))_Publisher_FASB_URI_https://asc.fashb.org/1943274/2147478524/942-220-S99-1)~~

[+ Details](#)

Name:us-gaap-NetIncomeLoss **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap-NoncashInvestingAndFinancingItemsAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-15-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-15-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482740/230-10-45-15>

[+ Details](#)

Name:us-gaap-PaymentsRelatedToTaxWithholdingForShareBasedCompensation **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-13-Subparagraph-\(c\)-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-13-Subparagraph-(c)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482740/230-10-45-13>

[+ Details](#)

Name:us-gaap-PaymentsToAcquirePropertyPlantAndEquipment **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

The cash inflow from the additional capital contribution to the entity.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482740/230-10-45-14>

[+ Details](#)

Name:us-gaap-ProceedsFromIssuanceOfCommonStock **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of increase in right-of-use asset obtained in exchange for finance lease liability.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-55-Paragraph-53-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(g\)-\(2\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(g)-(2)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147478964/842-20-50-4>

[+ Details](#)
Name:us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of noncash expense for share-based payment arrangement.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

[+ Details](#)
Name:us-gaap_ShareBasedCompensation **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration XML 18 R7.htm IDEA: XBRL DOCUMENT
Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) Sep. 30, 2023
shares Consulting Agreement [Member] | Spartan Capital Securites LLC [Member] Collaborative
Arrangement and Arrangement Other than Collaborative [Line Items] Warrants to purchase shares 158,007

[- Definition](#)

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3>

[+ Details](#)
Name:us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1)

[+ Details](#)
Name:us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Details](#)
Name:us-gaap_TypeOfArrangementAxis=PCSA-ConsultingAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)
Name:dei_LegalEntityAxis=PCSA-SpartanCapitalSecuritesLLCMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** XML 19 R8.htm IDEA: XBRL DOCUMENT
Pay vs Performance Disclosure - USD (\$) 3 Months Ended 9 Months Ended
Sep. 30, 2024
Jun. 30, 2024
Mar. 31, 2024
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2024
Sep. 30, 2023

Pay vs Performance Disclosure [Table] Net Income (Loss) \$ (3,384,703) \$ (3,010,326) \$ (2,726,381) \$ (2,081,951) \$ (2,612,565) \$ (4,022,073) \$ (9,121,410) \$ (8,716,589)

[- References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 402-Subsection v-Paragraph 1>

[+ Details](#)
Name:ced_PvpTable **Namespace Prefix:**ced **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ Details](#)
Name:us-gAAP-NetIncomeLoss **Namespace Prefix:**us-gAAP **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration XML 20 R0.htm IDEA XBRL DOCUMENT
Insider Trading Arrangements 3 Months Ended
Sep 30 2024
Insider Trading Arrangements (Line Items): [Rule 10b5-1 Arrangement Adopted](#)false [Non-Rule 10b5-1 Arrangement Adopted](#)false [Rule 10b5-1 Arrangement Terminated](#)false [Non-Rule 10b5-1 Arrangement Terminated](#)false
[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher-SEC-Name-Regulation-S-K-Number-229-Section-408-Subsection-a

[+ Details](#)
Name:ecd-InsiderTradingArrLineItems **Namespace Prefix:**ecd **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration
[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher-SEC-Name-Regulation-S-K-Number-229-Section-408-Subsection-a-Paragraph-1

[+ Details](#)
Name:ecd-NonRule10b51ArrAdoptedFlag **Namespace Prefix:**ecd **Data Type:**xbri:booleanItemType **Balance Type:**na **Period Type:**duration
[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher-SEC-Name-Regulation-S-K-Number-229-Section-408-Subsection-a-Paragraph-1

[+ Details](#)
Name:ecd-NonRule10b51ArrTrmtdFlag **Namespace Prefix:**ecd **Data Type:**xbri:booleanItemType **Balance Type:**na **Period Type:**duration
[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef_Publisher-SEC-Name-Regulation-S-K-Number-229-Section-408-Subsection-a-Paragraph-1

[+ Details](#)
Name:ecd-Rule10b51ArrAdoptedFlag **Namespace Prefix:**ecd **Data Type:**xbri:booleanItemType **Balance Type:**na **Period Type:**duration
[- References](#)

[+ Details](#)

Name:~~eed_Rule10b51ArrTrmntdFlag~~**Namespace Prefix:**~~eed~~**Data Type:**~~xbri:boolean~~**Item Type****Balance Type:**~~na~~**Period Type:**~~duration~~**XML 21 R10.htm IDEA: XBRL DOCUMENT**

Organization and Summary of Significant Accounting Policies9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract] Organization and Summary of Significant Accounting Policies

Note 1 – Organization and Summary of Significant Accounting Policies

Organization

We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next Generation Chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety/efficacy profiles when compared to their currently marketed counterparts.

On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended, with the Secretary of State of Delaware that effected a of our common stock, par value \$ per share (the “Reverse Stock Split”). Pursuant to the Certificate of Amendment, our issued common stock decreased from shares to shares and our outstanding common stock decreased from to . The Reverse Stock Split did not affect our authorized common stock of shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial statements give retroactive effect to the Reverse Stock Split.1 for 20 reverse stock split0.000124,706,4741,291,00024,606,4741,286,000100,000,000

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

Liquidity

Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGC drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of \$ million at September 30, 2024. During the nine months ended September 30, 2024, we generated a net loss of \$ million and used \$ million in net cash for operating activities. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.84.59.19.0

We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold shares of our common stock, pre-funded warrants to purchase up to shares of our common stock, and warrants for the purchase of up to shares of our common stock for net proceeds of \$ million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for shares of our common stock 476,0001,079,5551,555,5556,31,079,555

In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the “Registration Statement”), including a base prospectus relating to the offering of up to \$ in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings, and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the “Sales Agreement”) between us and A.G.P./Alliance Global Partners (the “Sales Agent”), through which we may issue and sell in a registered “at the market offering” shares of our common stock having an aggregate offering price of up to \$ million (subject to adjustment) from time to time through or to our Sales Agent (the “ATM Offering”). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement. On July 31, 2024, we received \$ in net proceeds from the sale of shares of common stock under the ATM Offering.50,000,0002,4931,000374,190

We do not have sufficient cash on hand or available to fund our operations for the next twelve months:

At September 30, 2024, we had cash and cash equivalents totaling \$ million. Based on our current business plans, we will need to obtain additional funding from the sale of equity and/or debt securities, complete a strategic transaction or other funding transactions in order to continue our Phase 2 trial of NGC-Cap and conduct future preclinical studies and clinical trials for other drugs in our portfolio. In 2024, we started our Phase 2 trial of NGC-Cap in breast cancer, and on October 2, 2024, we dosed the first patient in that trial. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations.2.9

We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed.

Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.

Use of Estimates

In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management’s experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

Income Taxes

We account for income taxes in accordance with ASC Topic 740. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At September 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more-likely-than-not that such benefits will not be realized. The valuation allowance is reviewed quarterly and will be maintained until sufficient positive evidence exists to support its reversal.*Income Taxes;*

Under ASC 740-270, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses.*Income Taxes – Interim Reporting*

Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to specified limits. Total cash held by our banks at September 30, 2024, exceeded FDIC limits.

Recent Accounting Pronouncements

From time to time, the Financial Accounting Standards Board (“FASB”) or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update (“ASU”). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

References

No definition available.

[+ Details](#)

Name:~~us-gaap_AccountingPoliciesAbstract~~**Namespace Prefix:**~~us-gaap~~**Data Type:**~~xbri:string~~**Item Type****Balance Type:**~~na~~**Period Type:**~~duration~~

Definition

The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.

References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef_Topic-235-Name-Accounting-Standards-Codification_Publisher-FASB_URI-https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef_Topic-275-Name-Accounting-Standards-Codification_Publisher-FASB_URI-https://asc.fasb.org/275/tableOfContent

[+ Details](#)

Name:us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock **Namespace Prefix:**us-gaap **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration XML 22 R11.htm IDEA: XBRL DOCUMENT **Stockholders' Equity 9 Months Ended**
Sep. 30, 2024

Equity [Abstract] **Stockholders' Equity**
Note 2 – Stockholders' Equity

-
Preferred Stock

-
There were issued or outstanding shares of preferred stock at either September 30, 2024 or December 31, 2023.
No

-
Common Stock

-
During the nine months ended September 30, 2024, we sold shares of common stock, pre-funded warrants to purchase up to shares of common stock in lieu of shares of common stock (the "Pre-Funded Warrants"), and warrants to purchase up to shares of our common stock (the "Common Warrants") in a public offering (the "Offering"). The Common Warrants have an exercise price of \$, are immediately exercisable and expire on . The shares of common stock were offered at a combined public offering price of \$ per share and accompanying Common Warrant and \$ per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of \$ and were exercised in full simultaneously with the closing of the Offering in exchange for shares of our common stock. Gross proceeds in connection with the Offering were \$ million. We received \$ million in net proceeds from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement agent warrants to purchase shares of common stock, exercisable at \$ per share that expire on 476.0001.079.5551.555.5554.50January 30, 20294.504.49990.00011.079.5557.06.362.2225.625February 1, 2027

-
During the nine months ended September 30, 2024, we also received approximately \$931,000 in net proceeds from the sale of 374,190 shares of common stock under the ATM Offering on July 31, 2024. During the nine months ended September 30, 2024, we also issued (i) 5,000 shares of common stock to Elion Oncology, Inc. ("Elion") in satisfaction of the third milestone event under the license agreement, (ii) 30,000 shares of common stock to a consultant in accordance with their consulting agreement, and (iii) 16,199 shares of common stock to certain employees and consultants, net of 7,154 shares of common stock withheld for income taxes owed upon distribution of the shares.

-
[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_EquityAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The entire disclosure for equity.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef_Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef_Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(e\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(e)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 505-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)

+ Details

Name:us-gaap:StockholdersEquityNoteDisclosureTextBlock Namespace Prefix:us-gaap Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML:23_R12.htm

IDEA:XBRL DOCUMENT

Stock-based Compensation9 Months Ended

Sep-30-2024

Share-Based Payment Arrangement [Abstract] Stock-based Compensation

Note 3 - Stock-based Compensation

On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of shares of our common stock. At September 30, 2024, we have shares available for future grants 800,000353,641

Stock Compensation Expense

We recorded stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 as follows:

2024 2023 2024 2023

Three Months Ended September 30,

Nine Months Ended September 30,

	2024	2023	2024	2023
Research and development	\$ 54,018	\$ 76,626	\$ 130,722	\$ 286,152
General and administrative	\$ 100,173	\$ 66,268	\$ 343,744	\$ 517,369
Total	\$ 154,191	\$ 142,894	\$ 474,466	\$ 803,521

Stock Options

Stock options to purchase shares of common stock with a weighted-average exercise price of \$ expired during the nine months ended September 30, 2024. At September 30, 2024, we had outstanding and exercisable options for the purchase of shares with a weighted average exercise price of \$ and a weighted average remaining contractual life of years. At September 30, 2024, we did not have any unrecognized stock-based compensation expense related to our granted stock options.4,245336,002,747409,093,0

Restricted Stock Awards

During the nine months ended September 30, 2024, we vested Restricted Stock Awards ("RSAs") with a weighted average grant-date fair value of \$ per share. We had RSAs outstanding at September 30, 2024 1,2509,26n9

Restricted Stock Units

Activity with respect to our Restricted Stock Units ("RSUs") during the nine months ended September 30, 2024 was as follows:

		Number of shares	Weighted-average grant-date fair value-per share
Outstanding at January 1, 2024		222,722	\$ 45.82
Granted		192,026	1.63
Forfeited		(13,750)	70.47
Issued		(16,199)	109.35
Outstanding at September 30, 2024		384,799	20.21
Vested and unissued		144,450	44.89
Unvested at September 30, 2024		240,349	5.38

On June 28, 2024, we granted RSUs for the future issuance of shares of common stock to our employees which vest accordingly. RSUs for the future issuance of shares of common stock vest on January 1, 2025. RSUs for the future issuance of shares of common stock vest over a three-year period upon meeting service requirements. RSUs for the future issuance of shares of common stock vested upon grant due to regaining Nasdaq compliance, and RSUs for the future issuance of shares of common stock vest upon dosing the first patient in our Phase 2 study in NGC-Cap.39,20214,96918,1733,0303,030

On July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer ("CFO"). In addition to cash compensation, the Compensation Committee awarded RSUs for the future issuance of shares of common stock to Mr. Skibsted, which vest accordingly: vest on July 16, 2025; vest upon reaching a market capitalization (i.e. total value of Processa's outstanding shares of stock at the then current market price) of at least \$ million; and vest upon receipt of cumulative financing(s) of at least \$ million.28,00014,0007,000307,00015

On September 3, 2024, RSUs for the future issuance of shares of common stock were granted to our independent directors and vest on the earlier of June 28, 2025 or the next annual shareholder meeting.124,824

At September 30, 2024, unrecognized stock-based compensation expense of approximately \$ for RSUs is expected to be fully recognized over a weighted average period of years. The unrecognized expense excludes approximately \$ of expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time.613,0000,9432,000

Holders of our vested RSUs will be issued shares of our common stock upon meeting the distribution restrictions contained in their Restricted Stock Unit Award Agreement. The distribution restrictions are different (longer) than the vesting schedule, imposing an additional restriction on the holder. Unlike RSAs, while certain employees may hold fully vested RSUs, the individual does not hold any shares or have any rights of a shareholder until the distribution restrictions are met. Upon distribution to the employee, each RSU converts into one share of our common stock. The RSUs contain dividend equivalent rights.

Warrants

During the nine months ended September 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase shares of common stock as part of the Offering (see Note 2). Warrants to purchase shares of our common stock expired unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of shares of our common stock in exchange for a payment of \$ 1,617,7777,50015,00010,000

At September 30, 2024, we had outstanding warrants for the purchase of shares of our common stock with a weighted average exercise price of \$ and a weighted average remaining contractual life of years. All the outstanding warrants are exercisable as of September 30, 2024. We did not have any unrecognized stock-based compensation expense related to our granted warrants at September 30, 2024 1,775,7845,954.0

- Definition

The entire disclosure for share-based payment arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (a)(1)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 718_Name Accounting Standards Codification_Publisher FASB_URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (h)(2)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (h)(2)(i)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (l)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Name:us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock **Namespace Prefix:**us-gaap **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration

~~No definition available.~~

Namespace Prefix:us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

Net Loss per
Sep. 30, 2024

Note 4 - Net Loss per Share of Common Stock

Basic net loss per share is computed by dividing our net loss available to common shareholders by the weighted average number of shares of common stock outstanding (which excludes unvested RSAs and includes vested RSUs) during the period. Diluted loss per share is computed by dividing our net loss available to common shareholders by the diluted weighted average number of shares of common stock (which includes the potentially dilutive effect of stock options, unvested RSAs, unvested RSUs and warrants) during the period. Since we experienced a net loss for all periods presented, basic and diluted net loss per share are the same. As such, diluted loss per share for the three and nine months ended September 30, 2024 and 2023 excludes the impact of potentially dilutive common shares since those shares would have an anti-dilutive effect on net loss per share.

	2024	-	2023	2024	2023
--	------	---	------	-----------------	-----------------

~~Three Months Ended September 30~~

	2024	2023	2024	2023
...	...	...	...	...

Net loss available to common stockholders	\$	(3,384,703)	\$	(2,081,951)	\$	(9,121,410)	\$	(8,716,589)
---	----	-------------	----	-------------	----	-------------	----	-------------

1,350,166	2,509,941	1,279,296	(1.05)	\$(1.94)	\$(3.15)	\$(6.61)
-	-	-	-	-	-	-

Basic and diluted net loss per share \$

		September 30,		September 30,	
		2024	2023	2024	2023
-	-	-	-	-	-

1,151,425

~~Weighted~~

<u>number</u>	
of yeast	

RSUs
basic and

157.969	125.933	142.294	127.873		3.275.998	1.350.188	2.909.941	1.279.298
--------------------	--------------------	--------------------	--------------------	-------	-----------	-----------	-----------	-----------

Weighted average number of common shares basic and diluted

stock since those shares would have had an anti-dilutive effect on net loss per share during the periods then ended. 2,816,666269,950

~~No definition available.~~

Name:us-gaap-EarningsPerShareAbstract **Namespace Prefix:**us-gaap **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

~~The entire disclosure for earnings per share.~~

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Publisher FASB_URI https://asc.fasb.org/260-tableOfContents/260-3-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-3

+ Details

Name:us-gaap_EarningsPerShareTextBlock**Namespace Prefix:**us-gaap**Data Type:**dtr-types:textBlockItemType**Balance Type:**na**Period Type:**duration XML 25 R14.htm IDEA: XBRL DOCUMENT

Leases **9 Months Ended**

Sep. 30, 2024

Leases **Leases**

Note 5 -- Leases

We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of % in determining the present value of the lease payments based on the information available at the lease commencement date. 8

Lease costs included in our condensed consolidated statements of operations totaled approximately \$ and \$ for the three months ending September 30, 2024 and 2023, respectively, and approximately \$ and \$ for the nine months ended September 30, 2024 and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as follows at September 30, 2024: 23,00024,00068,00073,000

Remaining lease term (years) for our facility lease		=	=	1.0
Remaining lease term (years) for our equipment lease		=	=	
1-4	8.0%			
Weighted average discount rate for our facility and equipment leases				

Annual lease liabilities for the operating lease were as follows at September 30, 2024:

2024	=	=	
2025	=	=	
Total lease payments	=	=	23,347
Less: Interest	=	=	70,040
Present value of lease liabilities	=	=	93,387
Less: current maturities	=	=	(4,610)
Non-current lease liability	=	=	88,777
	=	=	(88,777)
	=	=	\$

Annual lease liabilities for the financing lease were as follows at September 30, 2024:

2024	=	=	
2025	=	=	
2026	=	=	
Total lease payments	=	=	1,616
Less: Interest	=	=	6,820
Present value of lease liabilities	=	=	488
Less: current maturities	=	=	8,924
Non-current lease liability	=	=	(857)
	=	=	8,067
	=	=	(5,899)
	=	=	\$
	=	=	2,168

- References

No definition available.

+ Details

Name:PCSA_DisclosureLeasesAbstract**Namespace Prefix:**PCSA**Data Type:**xbri:stringItemType**Balance Type:**na**Period Type:**duration

- Definition

Lessee Operating And Financing Leases [Text Block]

+ References

No definition available.

+ Details

Name:PCSA_LesseeOperatingAndFinancingLeasesTextBlock**Namespace Prefix:**PCSA**Data Type:**dtr-types:textBlockItemType**Balance Type:**na**Period Type:**duration XML 26 R15.htm IDEA: XBRL DOCUMENT

Related Party Transactions **9 Months Ended**

Sep. 30, 2024

Related Party Transactions [Abstract] **Related Party Transactions**

Note 6 -- Related Party Transactions

CorLyst, LLC ("CorLyst") reimburses us for shared costs related to payroll, health insurance and rent based on actual costs incurred, which are recognized as a reduction of our general and administrative operating expenses being reimbursed in our condensed consolidated statement of operations. We recorded approximately \$ and \$ of reimbursements during the three months ended September 30, 2024 and 2023, respectively, and approximately \$ and \$ for the nine months ended September 30, 2024 and 2023, respectively, amounts were due from CorLyst at September 30, 2024 or 2023. Our President of Research and Development is the CEO of CorLyst, and CorLyst is a shareholder. 33,00026,00083,00090,000Ne

- References

No definition available.

+ Details

Name:us-gaap_RelatedPartyTransactionsAbstract**Namespace Prefix:**us-gaap**Data Type:**xbri:stringItemType**Balance Type:**na**Period Type:**duration

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://ase.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://ase.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://ase.fasb.org/1943274/2147480990/946-20-50-5

~~Paragraph 3 - Publisher FASB - URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1~~

[+ Details](#)

Name:us-gaap-RelatedPartyTransactionsDisclosureTextBlock**Namespace Prefix:**us-gaap**Data Type:**dtr-types:textBlockItemType**Balance Type:**na**Period Type:**duration XML 27-R16.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies9 Months Ended

Sep. 30, 2024

Commitments and Contingencies Disclosure [Abstract][Commitments and Contingencies](#)

Note 7 – Commitments and Contingencies

Purchase Obligations

We enter into contracts in the normal course of business with contract research organizations (“CROs”) and subcontractors to further develop our products. The contracts are cancelable, with varying provisions regarding termination. If we terminated a cancelable contract with a specific vendor, we would only be obligated for products or services that we received at the effective date of the termination and any applicable cancellation fees. At September 30, 2024, we are contractually committed to pay up to \$ million of future services under these cancelable contracts with the CROs. Our actual contractual obligations will also vary depending on the progress and results of the remaining clinical trials. 13.0

[– References](#)

No definition available.

[+ Details](#)

Name:us-gaap-CommitmentsAndContingenciesDisclosureAbstract**Namespace Prefix:**us-gaap**Data Type:**xbrl:stringItemType**Balance Type:**na**Period Type:**duration

[– Definition](#)

The entire disclosure for commitments and contingencies.

[+ References](#)

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-405-SubTopic-30-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/405-30/tableOfContent>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-440-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-440-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-450-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/450/tableOfContent>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-954-SubTopic-440-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-954-SubTopic-440-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478522/954-440-50-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-440-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-440-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482648/440-10-50-4)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-440-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/440/tableOfContent>

[+ Details](#)

Name:us-gaap-CommitmentsAndContingenciesDisclosureTextBlock**Namespace Prefix:**us-gaap**Data Type:**dtr-types:textBlockItemType**Balance Type:**na**Period Type:**duration XML 28-R17.htm IDEA: XBRL DOCUMENT

Organization and Summary of Significant Accounting Policies (Policies)9 Months Ended

Sep. 30, 2024

Accounting Policies [Abstract][Organization](#)

[Organization](#)

We are a clinical-stage biopharmaceutical company focused on incorporating our Regulatory Science Approach into the development of our Next-Generation Chemotherapy (“NGC”) drugs to improve the safety and efficacy of cancer treatment. Our NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution in the body, while maintaining the well-established existing mechanisms of killing the cancer cells. By modifying the NGC drugs in this manner, we believe our three NGC treatments will provide improved safety-efficacy profiles when compared to their currently marketed counterparts.

On January 22, 2024, we filed a Certificate of Amendment to our Certificate of Incorporation, as amended, with the Secretary of State of Delaware that effected a of our common stock, par value \$ per share (the “Reverse Stock Split”). Pursuant to the Certificate of Amendment, our issued common stock decreased from shares to shares and our outstanding common stock decreased from to . The Reverse Stock Split did not affect our authorized common stock of shares or our common stock par value. All shares of common stock, including common stock underlying warrants, stock options, restricted stock awards and restricted stock units, as well as exercise prices and per share information in these condensed consolidated financial statements give retroactive effect to the Reverse Stock Split. 1 for 20 reverse stock split0.000124,706,4741,291,00024,606,4741,286,000100,000,000

[Basis of Presentation](#)

[Basis of Presentation](#)

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Form 10-Q and Article 8 of Regulation S-X.

Accordingly, they do not include all the information and disclosures required by U.S. GAAP for complete financial statements. All material intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results of operations and cash flows for the periods presented. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year.

- Liquidity

Liquidity

Our condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the continuity of operations, realization of assets and the satisfaction of liabilities and commitments in the ordinary course of business. We have incurred losses since inception, are currently devoting substantially all of our efforts toward research and development of our NGG drug product candidates, including conducting clinical trials and providing general and administrative support for these operations, and have an accumulated deficit of \$ million at September 30, 2024. During the nine months ended September 30, 2024, we generated a net loss of \$ million and used \$ million in net cash for operating activities. To date, none of our drug candidates have been approved for sale, and therefore we have not generated any product revenue and do not expect positive cash flow from operations in the foreseeable future.84.59.19.0

We have financed our operations primarily through public equity issuances, including an offering we closed on January 30, 2024, where we sold shares of our common stock, pre-funded warrants to purchase up to shares of our common stock, and warrants for the purchase of up to shares of our common stock for net proceeds of \$ million, after deducting placement agent fees and offering-related expenses. Simultaneously with the closing of the sale, the pre-funded warrants were exercised in exchange for shares of our common stock 476.0001,079.5551,555.5556,31,079,555

In May 2024, we filed with the SEC a registration statement on Form S-3 (Registration No. 333-279588) (the "Registration Statement"), including a base prospectus relating to the offering of up to \$ in the aggregate of the securities identified in the base prospectus from time to time in one or more offerings, and a prospectus supplement relating to the shares of our common stock that may be issued and sold under a sales agreement dated May 21, 2024 (the "Sales Agreement") between us and A.G.P./Alliance Global Partners (the "Sales Agent"), through which we may issue and sell in a registered "at the market offering" shares of our common stock having an aggregate offering price of up to \$ million (subject to adjustment) from time to time through or to our Sales Agent (the "ATM Offering"). We expect to use net proceeds, if any, from the ATM Offering over time for continued research and development for our portfolio of drug candidates, especially our oncology products, and working capital and general corporate purposes. The shares under the ATM Offering will be sold and issued pursuant to the Registration Statement. On July 31, 2024, we received \$ in net proceeds from the sale of shares of common stock under the ATM Offering.50,000,0002,4931,000374,190

We do not have sufficient cash on hand or available to fund our operations for the next twelve months. At September 30, 2024, we had cash and cash equivalents totaling \$ million. Based on our current business plans, we will need to obtain additional funding from the sale of equity and/or debt securities, complete a strategic transaction or other funding transactions in order to continue our Phase 2 trial of NGG-Gap and conduct future preclinical studies and clinical trials for other drugs in our portfolio. In 2024, we started our Phase 2 trial of NGG-Gap in breast cancer, and on October 2, 2024, we dosed the first patient in that trial. We will continue to be dependent upon equity and/or debt financing until we are able to generate positive cash flows from our operations.2.9

We plan to raise additional funds in the future through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements and other marketing and distribution arrangements, but will only do so if the terms are acceptable to us. If we are unable to obtain adequate financing when needed, we may have to delay, reduce the scope of, or suspend our current or planned future clinical trial plans, or research and development programs. This may also cause us to not meet obligations contained in certain of our license agreements and put these assets at risk. To the extent that we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders' rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures. There can be no assurance that future funding will be available when needed.

Absent additional funding, we believe that our cash and cash equivalents will not be sufficient to fund our operations for a period of one year or more after the date that these condensed consolidated financial statements are available to be issued based on the timing and amount of our projected net loss from continuing operations and cash to be used in operating activities during that period of time. As a result, substantial doubt exists about our ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are available to be issued. The accompanying condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of recorded assets, or the amounts and classification of liabilities that might be different should we be unable to continue as a going concern based on the outcome of these uncertainties described above.

- Use of Estimates

Use of Estimates

In preparing our condensed consolidated financial statements and related disclosures in conformity with U.S. GAAP and pursuant to the rules and regulations of the SEC, we make estimates and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Estimates are used for, but not limited to, preclinical and clinical trial expenses, stock-based compensation, intangible assets, future milestone payments and income taxes. These estimates and assumptions are continuously evaluated and are based on management's experience and knowledge of the relevant facts and circumstances. While we believe the estimates to be reasonable, actual results could differ materially from those estimates and could impact future results of operations and cash flows.

- Income Taxes

Income Taxes

We account for income taxes in accordance with ASC Topic 740. Deferred income taxes are recorded for the expected tax consequences of temporary differences between the basis of assets and liabilities for financial reporting purposes and amounts recognized for income tax purposes. At September 30, 2024 and December 31, 2023, we recorded a valuation allowance equal to the full recorded amount of our net deferred tax assets since it is more likely than not that such benefits will not be realized. The valuation allowance is reviewed quarterly and will be maintained until sufficient positive evidence exists to support its reversal. Income Taxes.

Under ACS 740-270, we are required to project our annual federal and state effective income tax rate and apply it to the year-to-date ordinary operating tax basis loss before income taxes. Based on the projection, no current income tax benefit or expense is expected for 2024 and the foreseeable future since we expect to generate taxable net operating losses. Income Taxes – Interim Reporting

- Concentration of Credit Risk

Concentration of Credit Risk

Financial instruments that potentially subject us to significant concentration of credit risk consist primarily of our cash and cash equivalents. We utilize only well-established banks and financial institutions with high credit ratings. Balances on deposit are insured by the Federal Deposit Insurance Corporation ("FDIC") up to specified limits. Total cash held by our banks at September 30, 2024, exceeded FDIC limits.

- Recent Accounting Pronouncements

Recent Accounting Pronouncements

From time to time, the Financial Accounting Standards Board ("FASB") or other standard setting bodies issue new accounting pronouncements. Updates to the FASB Accounting Standards Codification are communicated through issuance of an Accounting Standards Update ("ASU"). We have implemented all new accounting pronouncements that are in effect and that may impact our condensed consolidated financial statements. We have evaluated recently issued accounting pronouncements and determined that there is no material impact on our condensed consolidated financial position or results of operations.

- Definition

Definition

Business Activities And Organization [Policy Text Block]

+ References

No definition available.

+ Details

Name:PCSA_BusinessActivitiesAndOrganizationPolicyTextBlock Namespace Prefix:PCSA Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Liquidity [Policy Text Block]

+ References

No definition available.

+ Details

Name:PCSA_LiquidityPolicyTextBlock Namespace Prefix:PCSA Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).

+ References

No definition available.

+ Details

Name:us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix:us-gaap Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Disclosure of accounting policy for credit risk.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification Topic 942-SubTopic 825-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1

[+ Details](#)

Name:us-gaap_ConcentrationRiskCreditRisk **Namespace Prefix:**us-gaap **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-20-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-20>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-19-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-19>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482525/740-10-45-25>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-03\(h\)\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-03(h)(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-17-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-17-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-17)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-9>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482525/740-10-45-28>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482765/220-10-50-1>

[+ Details](#)

Name:us-gaap_IncomeTaxPolicyTextBlock **Namespace Prefix:**us-gaap **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or

actual impact:

+ References

No definition available.

+ Details

Name:us-gaap-NewAccountingPronouncementsPolicyPolicyTextBlock**Namespace Prefix:**us-gaap**Data Type:**dtr-types:textBlockItemType**Balance Type:**na**Period Type:**duration

- Definition

Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275-SubTopic 10-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275-SubTopic 10-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 11-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 12-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-8>

+ Details

Name:us-gaap-UseOfEstimates**Namespace Prefix:**us-gaap**Data Type:**dtr-types:textBlockItemType**Balance Type:**na**Period Type:**duration XML 20 R18.htm IDEA- XBRL DOCUMENT

Stock-based Compensation (Tables)9 Months Ended
Sep. 30, 2024

Share-Based Payment Arrangement [Abstract] Schedule of Stock-based Compensation Expense

We recorded stock-based compensation expense for the three and nine months ended September 30, 2024 and 2023 as follows:

	2024	2023	2024	2023
Three Months Ended September 30,				
Nine Months Ended September 30,				

	2024	2023	2024	2023
Research and development	\$ 54,018	\$ 76,626	\$ 130,722	\$ 286,152
General and administrative	\$ 100,173	\$ 66,268	\$ 343,744	\$ 517,369
Total	\$ 154,191	\$ 142,894	\$ 474,466	\$ 803,521

Activity with respect to our Restricted Stock Units ("RSUs") during the nine months ended September 30, 2024 was as follows:

	Number of shares	Weighted-average grant-date fair value per share
Outstanding at January 1, 2024	222,722	\$ 45.82
Granted	192,026	1.63
Forfeited	(13,750)	70.47
Issued	(16,199)	109.35
Outstanding at September 30, 2024	384,799	20.21
Vested and unissued	144,450	44.89
Unvested at September 30, 2024	240,349	\$ 5.38

- References

No definition available.

~~**Name:**us-gaap-DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract **Namespace Prefix:**us-gaap **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration~~

Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited and weighted average grant date fair value.

Reference 1: [http://fashb.org/us-gaap/role/ref/legacyRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)_Publisher FASB_URI https://asc.fashb.org/1943272/4147480429/718-10-50-2](http://fashb.org/us-gaap/role/ref/legacyRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)_Publisher FASB_URI https://asc.fashb.org/1943272/4147480429/718-10-50-2)Reference 2: [http://fashb.org/us-gaap/role/ref/legacyRef_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(d\)_SubTopic 10_Topic 718_Publisher FASB_URI https://asc.fashb.org/1943272/4147480429/718-10-50-2](http://fashb.org/us-gaap/role/ref/legacyRef_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (d)_SubTopic 10_Topic 718_Publisher FASB_URI https://asc.fashb.org/1943272/4147480429/718-10-50-2)Reference 3: [http://fashb.org/us-gaap/role/ref/legacyRef_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(e\)_SubTopic 10_Topic 718_Publisher FASB_URI https://asc.fashb.org/1943272/4147480429/718-10-50-2](http://fashb.org/us-gaap/role/ref/legacyRef_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (e)_SubTopic 10_Topic 718_Publisher FASB_URI https://asc.fashb.org/1943272/4147480429/718-10-50-2)

Name: us_gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock	Namespace Prefix: us_gaap	Data Type: dtr-types:textBlockItemType	Balance Type: na	Period Type: duration
---	----------------------------------	---	-------------------------	------------------------------

Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year:

Reference 1: [http://fash.org/us_gaap/role/ref/legacyRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)_Publisher FASB_URL https://asc.fashb.org/1943274/2147480429/718-10-50-2](http://fash.org/us_gaap/role/ref/legacyRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)_Publisher FASB_URL https://asc.fashb.org/1943274/2147480429/718-10-50-2)

Name:us-gaap-ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock **Namespace Prefix:**us-gaap **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration XML 30 R10-htm IDEA: XBRL DOCUMENT

Net Loss per Share of Common Stock (Tables) 9 Months Ended

Sep. 30, 2024

~~Earnings Per Share [Abstract] Schedule of Net Loss Per Share Basic and Diluted~~

The computation of net loss per share for the three and nine months ended September 30, 2024 and 2023 was as follows:

[illegible]

~~No definition available.~~

Name:us-gaap-EarningsPerShareAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per share computations for income from continuing operations:

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB)
 URI: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap_CommonStockParOrStatedValuePerShare **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX-210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX-210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>

[+ Details](#)

Name:us-gaap_CommonStockSharesAuthorized **Namespace Prefix:**us-gaap **Data Type:**xbrli:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX-210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)

Name:us-gaap_CommonStockSharesIssued **Namespace Prefix:**us-gaap **Data Type:**xbrli:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-SubTopic-10-Topic-505> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX-210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph \(SX-210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph \(SX-210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX-210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph \(SX-210.6-09\(7\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>

[+ Details](#)

Name:us-gaap:CommonStockSharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 28_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 24_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 25_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

[+ Details](#)

Name:us-gaap:NetCashProvidedByUsedInOperatingActivities **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 9_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(g\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (g)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph \(g\)\(3\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph (g)(3)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph \(SX 210.5-03\(20\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph (SX 210.5-03(20))_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 235_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.4-08(g)(1)(iii))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 323_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef_Topic 825_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 28_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(b\)\(2\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (b)(2)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 8_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(b\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (b)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 4_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef_Topic 946_SubTopic 830_Name Accounting Standards Codification_Section 55_Paragraph 10_Publisher FASB_URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification_Section 45_Paragraph 7_Publisher FASB_URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.7-04\(18\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.7-04(18))_Publisher FASB_URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.6-07\(9\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.6-07(9))_Publisher FASB_URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 3_Subparagraph \(SX 210.6-09\(1\)\(d\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 946_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 3_Subparagraph (SX 210.6-09(1)(d))_Publisher FASB_URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(i))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(ii))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iii)(A))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(4)(iv))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph \(SX 210.13-01\(a\)\(5\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1A_Subparagraph (SX 210.13-01(a)(5))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(i))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iii)(A))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iii)(B))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(4)(iv))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph \(SX 210.13-02\(a\)\(5\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef_Topic 470_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1B_Subparagraph (SX 210.13-02(a)(5))_Publisher FASB_URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: http://www.xbrl.org/2003/role/disclosureRef_Topic 205_SubTopic 220_Name Accounting Standards Codification_Section 50_Paragraph 7_Publisher FASB_URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef_Topic 230_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 28_Publisher FASB_URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: [http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 1A_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 1A_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 1A_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 1A_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)

~~10-Name Accounting Standards Codification-Section 4b-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482/99/220-10-4b-1B>Reference 3/4~~
~~[http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-04(22)))-Publisher FASB-URI~~
~~<https://asc.fasb.org/1943274/2147478524/942-220-S99-1>~~

[+ Details](#)

Name:us-gaap_NetIncomeLoss **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

The cash inflow from the additional capital contribution to the entity.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14)

[+ Details](#)

Name:us-gaap_ProceedsFromIssuanceOfCommonStock **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of accumulated undistributed earnings (deficit).

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(30\)\(a\)\(3\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(30)(a)(3))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)\(2\)\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)(2)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(h\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(h)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480990/946-20-50-11>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(23\)\(a\)\(4\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(23)(a)(4))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(17\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(17))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)
Name:us-gaap_RetainedEarningsAccumulatedDeficit **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Number of new stock issued during the period.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-SubTopic10-Topic505-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(28\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(28))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.5-02\(29\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic210-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.5-02(29))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic505-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic505-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-09\(4\)\(b\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-09(4)(b))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6-03\(i\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6-03(i)(1))-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.3-04\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.3-04)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)
Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph4-Subparagraph\(SABTopic4.C\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-4](http://fasb.org/us-gaap/role/ref/legacyRef-Topic505-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph4-Subparagraph(SABTopic4.C)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480008/505-10-S99-4)

[+ Details](#)
Name:us-gaap_StockholdersEquityReverseStockSplit **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Details](#)

Name:us-gaap_SubsidiarySaleOfStockAxis=PCSA_ATMOfferingMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:PCSA_ScenarioAxis=PCSA_RegistrationStatementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)

Name:us_gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)

Name:us_gaap_StatementEquityComponentsAxis=us_gaap_WarrantMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)

Name:us_gaap_TypeOfArrangementAxis=PCSA_SalesAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)

Name:us_gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_AllianceGlobalPartnersMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** **XML 33 R22.htm IDEA:**
XBRL DOCUMENT

Stockholders' Equity (Details Narrative) - USD (\$) 9 Months Ended

Jul. 31, 2024
Jan. 30, 2024
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023

Class of Stock [Line Items] Preferred stock, shares issued 0.0 Preferred stock, shares outstanding 0.0 Proceeds from Issuance of Common Stock \$ 6,300,000 \$ 7,213,721 \$ 6,352,077 Stock withheld for income taxes 7,154 Employees and Consultants [Member] **Class of Stock [Line Items]** Shares issued 16,199 ATM Offering [Member] **Class of Stock [Line Items]** Shares issued 476,000 476,000 Proceeds from Issuance of Common Stock \$ 931,000 \$ 931,000 Purchase Agreement [Member] **Class of Stock [Line Items]** Shares issued 476,000 476,000 Gross proceeds from issuance of common stock \$ 7,000,000 0 Proceeds from Issuance of Common Stock \$ 6,300,000 Purchase Agreement [Member] Placement Agent [Member] **Class of Stock [Line Items]** Class of warrant or right, exercise price of warrants or rights \$ 5.625 Warrant expiration date Feb. 01, 2027 Class of warrant or right, outstanding 62,222 Purchase Agreement [Member] Warrant [Member] **Class of Stock [Line Items]** Class of warrant or right, number of securities called by warrants or rights 1,555,555 1,555,555 Class of warrant or right, exercise price of warrants or rights \$ 4.50 Warrant expiration date Jan. 30, 2029 Purchase Agreement [Member] Pre-Funded Warrants [Member] **Class of Stock [Line Items]** Class of warrant or right, number of securities called by warrants or rights 1,079,555 1,079,555 Class of warrant or right, exercise price of warrants or rights \$ 0.0001 Shares issued, price per share \$ 4.4999 Warrant exercised 1,079,555 1,079,555 License Agreement [Member] Elion Oncology, Inc. [Member] **Class of Stock [Line Items]** Shares issued 5,000 Consulting Agreement [Member] Consultant [Member] **Class of Stock [Line Items]** Shares issued 30,000

[-Definition](#)

Gross proceeds from issuance of common stock.

[+References](#)

No definition available.

[+Details](#)

Name:PCSA_GrossProceedsFromIssuanceOfCommonStock **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[-Definition](#)

Stock issued during period shares stock withheld for income taxes.

[+References](#)

No definition available.

[+Details](#)

Name:PCSA_StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes **Namespace Prefix:**PCSA **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Stock issued during period shares exercised.

[+References](#)

No definition available.

[+Details](#)

Name:PCSA_StockIssuedDuringPeriodSharesWarrantExercised **Namespace Prefix:**PCSA **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[-Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/exampleRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/exampleRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef_Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef_Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(27\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(27)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 13: http://www.xbrl.org/2003/role/disclosureRef_Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(ii\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(ii)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(ii\)\(2\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef_Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(ii)(2)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3)

[+ Details](#)

Name:us-gaap_ClassOfStockLineItems **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Exercise price per share or per unit of warrants or rights outstanding.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-3>

[+ Details](#)

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-3>

[+ Details](#)

Name:us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Number of warrants or rights outstanding.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_ClassOfWarrantOrRightOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(28\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(28))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)

[+ Details](#)

Name:us-gaap-PreferredStockSharesIssued **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

-Definition

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>

+Details

Name:us-gaap-PreferredStockSharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

-Definition

The cash inflow from the additional capital contribution to the entity.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230) Publisher FASB URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14>

+Details

Name:us-gaap-ProceedsFromIssuanceOfCommonStock **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

-Definition

Per share or per unit amount of equity securities issued.

+References

No definition available.

+Details

Name:us-gaap-SharesIssuedPricePerShare **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

-Definition

Number of new stock issued during the period.

+References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505> Publisher FASB URI <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) Publisher FASB URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))) Publisher FASB URI <https://asc.fasb.org/1943274/2147479886/946-10-S99-3>Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)) Publisher FASB URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>

[+ Details](#)

Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

[Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.](#)

[+ References](#)

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(bbb\)\(2\)\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(bbb)(2)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(bbb\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(bbb)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(bbb\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(bbb)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2)

[+ Details](#)

Name:us-gaap_WarrantsAndRightsOutstandingMaturityDate **Namespace Prefix:**us-gaap **Data Type:**xbri:dateItemType **Balance Type:**na **Period Type:**instant

[- Details](#)

Name:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_EmployeesAndConsultantsMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_SubsidiarySaleOfStockAxis=PCSA_ATMOfferingMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_TypeOfArrangementAxis=PCSA_PurchaseAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_SubsidiarySaleOfStockAxis=PCSA_PlacementAgentMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_ClassOfWarrantOrRightAxis=PCSA_PreFundedWarrantMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_TypeOfArrangementAxis=PCSA_LicenseAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_ElionOncologyIncMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=PCSA_ConsultantMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** [XML 34 R23.htm](#) [IDEA:](#) [XBRL DOCUMENT](#)

Schedule of Stock-based Compensation Expense (Details) – USD (\$) 3 Months Ended 9 Months Ended

[Sep. 30, 2024](#)
[Sep. 30, 2023](#)
[Sep. 30, 2024](#)
[Sep. 30, 2023](#)

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] [Total](#)\$ 154,191\$ 142,894\$ 474,466\$ 803,521 [Research and Development Expense \[Member\]](#)
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] [Total](#)\$ 54,01876,626130,722286,152 [General and Administrative Expense \[Member\]](#) **Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]** [Total](#)\$ 100,173\$ 66,268\$ 343,744\$ 517,369

[-Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+References](#)

No definition available.

[+Details](#)

Name:us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems **Namespace Prefix:**us-gaap **Data Type:**xbrl:stringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Amount of noncash expense for share-based payment arrangement.

[+References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Name_Accounting_Standards_Codification_Section_45_Paragraph_28_Subparagraph_\(a\)_SubTopic_10_Topic_230_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef_Name_Accounting_Standards_Codification_Section_45_Paragraph_28_Subparagraph_(a)_SubTopic_10_Topic_230_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147482740/230-10-45-28)

[+Details](#)

Name:us-gaap_ShareBasedCompensation **Namespace Prefix:**us-gaap **Data Type:**xbrl:monetaryItemType **Balance Type:**debit **Period Type:**duration

[-Details](#)

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** [XML 35 R24.htm](#) [IDEA:](#) [XBRL DOCUMENT](#)

Schedule of Restricted Stock Units (“RSUs”) Activity (Details) – Restricted Stock Units (RSUs) [Member] 9 Months Ended

[Sep. 30, 2024](#)
[\\$/ shares](#)
[shares](#)

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] [Number of shares, Beginning balance](#) | [shares](#)222,722 [Weighted-average grant-date fair value per share, Beginning balance](#) | [\\$/ shares](#)\$ 45.82 [Number of shares, granted](#) | [shares](#)192,026 [Weighted-average grant-date fair value per share, granted](#) | [\\$/ shares](#)\$ 1.63 [Number of shares, forfeited](#) | [shares](#)(13,750) [Weighted-average grant-date fair value per share, forfeited](#) | [\\$/ shares](#)\$ 70.47 [Number of shares, issued](#) | [shares](#)(16,199) [Weighted-average grant-date fair value per share, shares issued](#) | [\\$/ shares](#)\$ 109.35 [Number of shares, ending balance](#) | [shares](#)384,799 [Weighted-average grant-date fair value per share, ending balance](#) | [\\$/ shares](#)\$ 20.21 [Number of shares, vested and unissued](#) | [shares](#)144,450 [Weighted-average grant-date fair value per share, vested and unissued](#) | [\\$/ shares](#)\$ 44.89 [Number of shares, unvested](#) | [shares](#)240,349 [Weighted-average grant-date fair value per share, unvested](#) | [\\$/ shares](#)\$ 5.38

[-Definition](#)

Share-based compensation arrangement by share-based payment award equity instruments other than option vested and unvested-outstanding.

[+References](#)

No definition available.

[+Details](#)

Name:PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding **Namespace Prefix:**PCSA **Data Type:**xbrl:sharesItemType **Balance Type:**na **Period Type:**instant

[-Definition](#)

Per share or unit weighted-average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options.

[+References](#)

No definition available.

[+Details](#)

Name:PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue **Namespace Prefix:**PCSA **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

[-Definition](#)

Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period.

[+References](#)

No definition available.

[+Details](#)

Name:PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod **Namespace Prefix:**PCSA **Data Type:**xbrl:sharesItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value.

[+References](#)

No definition available.

[+ Details](#)

Name:PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue **Namespace Prefix:**PCSA **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Share-based compensation arrangement by share-based payment award equity instruments other than options vested and unissued.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued **Namespace Prefix:**PCSA **Data Type:**xbrii:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Share-based compensation arrangement by share-based payment award equity instruments other than options vested and unissued-weighted average grant date fair value.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue **Namespace Prefix:**PCSA **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_\(c\)\(2\)\(iii\)\(03\)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_(c)(2)(iii)(03)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod **Namespace Prefix:**us-gaap **Data Type:**xbrii:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_\(c\)\(2\)\(iii\)\(03\)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_(c)(2)(iii)(03)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_\(c\)\(2\)\(iii\)\(01\)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_(c)(2)(iii)(01)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod **Namespace Prefix:**us-gaap **Data Type:**xbrii:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_\(c\)\(2\)\(iii\)\(01\)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic_718_SubTopic_10_Name_Accounting_Standards_Codification_Section_50_Paragraph_2_Subparagraph_(c)(2)(iii)(01)_Publisher_FASB_URI_https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue **Namespace**

Prefix:us-gaap **Data Type:**dtr-types:perShareItem **Type:**Balance **Type:**na **Period Type:**duration

[- Definition](#)

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(i\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(i)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(ii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(ii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber **Namespace Prefix:**us-gaap **Data Type:**xbrli:sharesItem **Type:**Balance **Type:**na **Period Type:**instant

[- Definition](#)

Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(i\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(i)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(ii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(ii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItem **Type:**Balance **Type:**na **Period Type:**instant

[- Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 35_Paragraph 1D_Publisher FASB_URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 35_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(a\)\(1\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (a)(1)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(a\)\(2\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (a)(2)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(a\)\(3\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (a)(3)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(i\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(i)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(ii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(ii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iv\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iv)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iv\)\(01\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iv)(01)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iv\)\(02\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iv)(02)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iv\)\(03\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iv)(03)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iv\)\(04\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iv)(04)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(i\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(i)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(ii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(ii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(iii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(iii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(iii\)\(01\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(iii)(01)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(iii\)\(02\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(iii)(02)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(iii\)\(03\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(iii)(03)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(d\)\(1\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (d)(1)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(d\)\(2\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (d)(2)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(e\)\(1\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (e)(1)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(e\)\(2\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (e)(2)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(i\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(i)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(ii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(ii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(iii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(iii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(iv\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(iv)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(v\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(v)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** XML 36 R25.htm IDEA: XBRL DOCUMENT

Stock-based Compensation (Details Narrative) – USD (\$) 9 Months Ended

Sep. 03, 2024
Jul. 16, 2024
Jun. 28, 2024
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] **Payments for settlement of stock awards** \$ 8,561 \$ 52,746 **Warrant [Member] | Offering [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Warrants to purchase shares** 1,617,777 **Consulting Agreement [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Warrants, expired** 7,500 **Share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures** 15,000 **Payments for settlement of stock awards** \$ 10,000 **Share-Based Payment Arrangement, Option [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Options, forfeited** 4,245 **Options, forfeited weighted average exercise price** \$ 336.00 **Options exercisable, shares** 2,747 **Options exercisable weighted average exercise price** \$ 409.09 **Exercisable weighted average remaining contractual term** 3 years 10 months 24 days **Restricted Stock [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, vested** 1,250 **Weighted average grant date fair value per share, shares vested** \$ 9.26 **Number of shares, outstanding** 0 **Restricted Stock Units (RSUs) [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, outstanding** 384,799 222,722 **Number of shares, granted** 192,026 **Unrecognized share-based compensation expense** \$ 613,000 **Weighted average period for recognition** 10 months 24 days **Unrecognized share-based compensation expense** \$ 432,000 **Restricted Stock Units (RSUs) [Member] | Employees [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 39,202 **Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 28,000 **Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | July 16, 2025 Vesting [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 14,000 **Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | First Performance Based RSUs [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 7,000 **Market capitalization** \$ 30,000,000 **Restricted Stock Units (RSUs) [Member] | Chief Financial Officer [Member] | Second Performance Based RSUs [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 7,000 **Performance vesting criteria** \$ 15,000,000 **Restricted Stock Units (RSUs) [Member] | Director [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 124,924 **Service Based RSUs [Member] | Employees [Member] | January 1, 2025 Vesting [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 14,969 **Service Based RSUs [Member] | Employees [Member] | 3 Year Vesting [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 18,173 **First Performance Based RSUs [Member] | Employees [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 3,030 **Second Performance Based RSUs [Member] | Employees [Member] | Next Generation Capecitabine - Cap [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Number of shares, granted** 3,930 **Warrant [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Warrants to purchase shares** 1,775,784 **Weighted average exercise price** \$ 5.95 **Weighted average remaining contractual life** 4 years **2019 Plan [Member]** **Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]** **Maximum equity available for issuance** 800,000 **Shares available for future grants** 353,641

[-Definition](#)

Market capitalization.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_MarketCapitalization **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[-Definition](#)

Payments for settlement of stock awards.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_PaymentsForSettlementOfStockAwards **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[-Definition](#)

Performance vesting criteria value

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_PerformanceVestingCriteriaValue **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[-Definition](#)

Share based compensation arrangement by share based payment award equity instruments other than option vested and unvested outstanding.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding **Namespace Prefix:**PCSA **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[-Definition](#)

Unrecognized share-based compensation expense.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_UnrecognizedShareBasedCompensationExpense_**Namespace Prefix:**PCSA_**Data Type:**xbrii:monetaryItemType_**Balance Type:**debit_**Period Type:**duration

[- Definition](#)

Exercise price per share or per unit of warrants or rights outstanding.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 505_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI
<https://asc.fasb.org/1943274/2147481112/505-10-50-3>

[+ Details](#)

Name:us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_**Namespace Prefix:**us-gaap_**Data Type:**dtr:types:perShareItemType_**Balance Type:**na_**Period Type:**instant

[- Definition](#)

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 505_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI
<https://asc.fasb.org/1943274/2147481112/505-10-50-3>

[+ Details](#)

Name:us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_**Namespace Prefix:**us-gaap_**Data Type:**xbrii:sharesItemType_**Balance Type:**na_**Period Type:**instant

[- Definition](#)

Aggregate number of common shares reserved for future issuance.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 210_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.5-02\(29\)\)_Publisher FASB_URI](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 210_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.5-02(29))_Publisher FASB_URI)
<https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)

Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_**Namespace Prefix:**us-gaap_**Data Type:**xbrii:sharesItemType_**Balance Type:**na_**Period Type:**instant

[- Definition](#)

Amount of cost not yet recognized for nonvested award under share-based payment arrangement.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(i\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (i)_Publisher FASB_URI)
<https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+ Details](#)

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_**Namespace Prefix:**us-gaap_**Data Type:**xbrii:monetaryItemType_**Balance Type:**debit_**Period Type:**instant

[- Definition](#)

Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(i\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (i)_Publisher FASB_URI)
<https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+ Details](#)

Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_**Namespace Prefix:**us-gaap_**Data Type:**xbrii:durationItemType_**Balance Type:**na_**Period Type:**duration

[- Definition](#)

The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(2\)\(iii\)\(01\)_Publisher](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(2)(iii)(01)_Publisher)

FASB – URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ **Namespace Prefix:**us-gaap_ **Data Type:** xbrli:sharesItemType **Balance Type:**na **Period Type:**duration

[– Definition](#)

Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 718-SubTopic 10-Subparagraph \(c\)\(1\)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 718-SubTopic 10-Subparagraph (c)(1)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_ **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:durationItemType **Balance Type:**na **Period Type:**duration

[– Definition](#)

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ **Namespace Prefix:**us-gaap_ **Data Type:** xbrli:sharesItemType **Balance Type:**na **Period Type:**duration

[– Definition](#)

The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_ **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[– Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24:

~~[http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(i\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(i)_Publisher FASB_URI)~~
~~<https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25>~~: ~~[http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(ii\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(ii)_Publisher FASB_URI)~~ ~~<https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26>~~: ~~[http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(iii\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(iii)_Publisher FASB_URI)~~ ~~<https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27>~~: ~~[http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(iv\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(iv)_Publisher FASB_URI)~~ ~~<https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28>~~: ~~[http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(f\)\(2\)\(v\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (f)(2)(v)_Publisher FASB_URI)~~ ~~<https://asc.fasb.org/1943274/2147480429/718-10-50-2>~~

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

[Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.](#)

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(04\) -Publisher FASB](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB)
-URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

[Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.](#)

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef_Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(03\) -Publisher FASB](http://fasb.org/us-gaap/role/ref/legacyRef_Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB)
-URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

[The difference between the maximum number of shares \(or other type of equity\) authorized for issuance under the plan \(including the effects of amendments and adjustments\), and the sum of: 1\) the number of shares \(or other type of equity\) already issued upon exercise of options or other equity-based awards under the plan; and 2\) shares \(or other type of equity\) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.](#)

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

[The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.](#)

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber **Namespace Prefix:**us-gaap **Data Type:**xbrli:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iii\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iii)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iv\)\(03\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iv)(03)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod **Namespace Prefix:**us-gaap **Data Type:**xbrli:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph \(c\)\(1\)\(iv\)\(03\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 718_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 2_Subparagraph (c)(1)(iv)(03)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef_Name Accounting Standards Codification_Topic 718_SubTopic 10_Section 50_Paragraph 2_Publisher FASB_URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

[+ Details](#)

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 **Namespace Prefix:**us-gaap **Data Type:**xbrli:durationItemType **Balance Type:**na **Period Type:**duration

[- Details](#)

Name:us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_SubsidiarySaleOfStockAxis=PCSA_OfferingMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_TypeOfArrangementAxis=PCSA_ConsultingAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[+ Details](#)

Name:us-gaap_EarningsPerShareBasic **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 2_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph \(d\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph (d)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)

[+ Details](#)

Name:us-gaap_EarningsPerShareBasicLineItems **Namespace Prefix:**us-gaap **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 55_Paragraph 52_Publisher FASB_URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(g\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (g)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph \(g\)\(3\)_Publisher FASB_URI https://asc.fasb.org/1943274/214748666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 740_SubTopic 323_Name Accounting Standards Codification_Section 65_Paragraph 2_Subparagraph (g)(3)_Publisher FASB_URI https://asc.fasb.org/1943274/214748666/740-323-65-2)Reference 5: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 55_Paragraph 15_Publisher FASB_URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(e\)\(4\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (e)(4)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(f\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 815_SubTopic 40_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (f)_Publisher FASB_URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(b\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (b)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 7_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 7_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 2_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph \(d\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph (d)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 4_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph \(SX 210.5-03\(25\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 2_Subparagraph (SX 210.5-03(25))_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef_Topic 942_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.9-04\(27\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 942_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.9-04(27))_Publisher FASB_URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph \(SX 210.7-04\(23\)\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 944_SubTopic 220_Name Accounting Standards Codification_Section S99_Paragraph 1_Subparagraph (SX 210.7-04(23))_Publisher FASB_URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 7_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-7

[+ Details](#)

Name:us-gAAP_EarningsPerShareDiluted **Namespace Prefix:**us-gAAP **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph \(g\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 805_SubTopic 60_Name Accounting Standards Codification_Section 65_Paragraph 1_Subparagraph (g)_Publisher FASB_URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 2: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 3_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph \(b\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 11_Subparagraph (b)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 5: http://www.xbrl.org/2003/role/disclosureRef_Topic 250_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 4_Publisher FASB_URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: [http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 5_Subparagraph \(SAB Topic 6.B\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5](http://www.xbrl.org/2003/role/disclosureRef_Topic 220_SubTopic 10_Name Accounting Standards Codification_Section S99_Paragraph 5_Subparagraph (SAB Topic 6.B)_Publisher FASB_URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(a\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (a)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 8: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 10_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 11_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 45_Paragraph 60B_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)

[+ Details](#)

Name:us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-16-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-16>

[+ Details](#)

Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-10>

[+ Details](#)

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

[-Details](#)

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember **Namespace Prefix:** **Data Type:** na **Balance Type:** **Period Type:**

[-Details](#)

Name:us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** XML 38 R27.htm IDEA: XBRL DOCUMENT **Net Loss per Share of Common Stock (Details Narrative) – shares** **3 Months Ended** **9 Months Ended**

Sep. 30, 2024

Sep. 30, 2023

Sep. 30, 2024

Sep. 30, 2023

Earnings Per Share [Abstract] **Antidilutive securities excluded from computation of earnings per share, amount** 2,018,880,289.9362,018,880,289.936

[-Definition](#)

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef_Topic 260_SubTopic 10_Name Accounting Standards Codification_Section 50_Paragraph 1_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)

[+Details](#)

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount **Namespace Prefix:**us-gaap **Data Type:**xbrli:sharesItemType **Balance Type:**na **Period Type:** duration

[-References](#)

No definition available.

[+Details](#)

Name:us-gaap_EarningsPerShareAbstract **Namespace Prefix:**us-gaap **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration XML 39 R28.htm IDEA: XBRL DOCUMENT **Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)** Sep. 30, 2024**Property, Plant and Equipment [Line Items]** **Weighted average discount rate for our facility and equipment leases** 8.00% **Facility Lease [Member]** **Property, Plant and Equipment [Line Items]** **Remaining lease term (years)** 1 year **Equipment [Member]** **Property, Plant and Equipment [Line Items]** **Remaining lease term (years)** 1 year 4 months 24 days

[-Definition](#)

Operating and financing lease weighted average discount rate.

[+References](#)

No definition available.

[+Details](#)

Name:PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate **Namespace Prefix:**PCSA **Data Type:**dtr-types:percentItemType **Balance Type:**na **Period Type:**instant

[-Definition](#)

Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 7A_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 7A_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph \(a\)\(1\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph (a)(1)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-3)

[+Details](#)

Name:us-gaap_LesseeFinanceLeaseRemainingLeaseTerm **Namespace Prefix:**us-gaap **Data Type:**xbrli:durationItemType **Balance Type:**na **Period Type:**instant

[-Definition](#)

Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 7A_Subparagraph \(c\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 7A_Subparagraph (c)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph \(a\)\(1\)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 3_Subparagraph (a)(1)_Publisher FASB_URI https://asc.fasb.org/1943274/2147478964/842-20-50-3)

[+Details](#)

Name:us-gaap-LesseeOperatingLeaseRemainingLeaseTerm **Namespace Prefix:**us-gaap **Data Type:**xbri:durationItemType **Balance Type:**na **Period Type:**instant

-Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147478964/842-20-50-7A>

+Details

Name:us-gaap-PropertyPlantAndEquipmentLineItems **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

-Details

Name:us-gaap-PropertyPlantAndEquipmentByTypeAxis=PCSA-FacilityLeaseMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

-Details

Name:us-gaap-PropertyPlantAndEquipmentByTypeAxis=us-gaap-EquipmentMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** XML 40 R29.htm IDEA: XBRL DOCUMENT

Schedule of Annual Lease Liabilities for all Operating Leases (Details) Sep-30-2024

USD (\$) **Leases-2024**\$ 23,347**2025**70,040**Total lease payments**93,387**Less: Interest**(4,610)**Present value of lease liabilities**88,777**Less: current maturities**(88,777)**Non-current lease liability**

-References

No definition available.

+Details

Name:PCSA-DisclosureLeasesAbstract **Namespace Prefix:**PCSA **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

+Details

Name:us-gaap-LesseeOperatingLeaseLiabilityPaymentsDue **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

+Details

Name:us-gaap-LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.

+References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

+Details

Name:us-gaap-LesseeOperatingLeaseLiabilityPaymentsRemainderOffiscalYear **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

+Details

Name:us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Present value of lessee's discounted obligation for lease payments from operating lease.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

+Details

Name:us-gaap_OperatingLeaseLiability **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

+Details

Name:us-gaap_OperatingLeaseLiabilityCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

+Details

Name:us-gaap_OperatingLeaseLiabilityNoncurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant XML 41-R30.htm IDEA: XBRL DOCUMENT

Schedule of Annual Lease Liabilities for all Financing Leases (Details) Sep-30-2024
USD (\$) **Leases 2024**\$ 1,616**2025**6,820**2026**488**Total lease payments**8,924**Less: Interest**(857)**Present value of lease liabilities**8,067**Less: current maturities**(5,899)**Non-current lease liability**\$ 2,168

-References

No definition available.

+Details

Name:PCSA_DisclosureLeasesAbstract **Namespace Prefix:**PCSA **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

-Definition

Present value of lessee's discounted obligation for lease payments from finance lease.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-6>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

+Details

Name:us-gaap_FinanceLeaseLiability **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

[+ Details](#)

Name:us-gaap_FinanceLeaseLiabilityCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 45_Paragraph 1_Subparagraph \(b\)_Publisher FASB_URI](http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 45_Paragraph 1_Subparagraph (b)_Publisher FASB_URI)
<https://asc.fasb.org/1943274/2147479041/842-20-45-1>

[+ Details](#)

Name:us-gaap_FinanceLeaseLiabilityNoncurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of lessee's undiscounted obligation for lease payments for finance lease.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

[+ Details](#)

Name:us-gaap_FinanceLeaseLiabilityPaymentsDue **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

[+ Details](#)

Name:us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

[+ Details](#)

Name:us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.

[+ References](#)

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

[+ Details](#)

Name:us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef_Topic 842_SubTopic 20_Name Accounting Standards Codification_Section 50_Paragraph 6_Publisher FASB_URI
<https://asc.fasb.org/1943274/2147478964/842-20-50-6>

[+ Details](#)

Name:us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant XML 42 R31.htm IDEA: XBRL DOCUMENT

Leases (Details Narrative) - USD (\$) 3 Months Ended 9 Months Ended

Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023

Leases **Operating and financing lease borrowing rate**8.00% 8.00% **Lease cost**\$ 23,000\$ 24,000\$ 68,000\$ 73,000

[- References](#)

No definition available.

[+ Details](#)

Name:PCSA_DisclosureLeasesAbstract **Namespace Prefix:**PCSA **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Operating and financing lease weighted average discount rate.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_OperatingAndFinancingLeaseWeightedAverageDiscountRate **Namespace Prefix:**PCSA **Data Type:**dtr-types:percentItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Amount of lease cost recognized by lessee for lease contract.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-55-Paragraph-53-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147478964/842-20-50-4>

[+ Details](#)

Name:us-gaap_LeaseCost **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration XML 43 R32.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - CorLyst, LLC (Member) - USD (\$) 3 Months Ended 9 Months Ended

Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023

Related Party Transaction (Line Items) - Rent and other costs reimbursements received\$ 33,000\$ 26,000\$ 83,000\$ 90,000**Due from related parties**\$ 0\$ 0\$ 0\$ 0

[- Definition](#)

Rent and other costs reimbursements received.

[+ References](#)

No definition available.

[+ Details](#)

Name:PCSA_ProceedsFromRentAndOtherCostsReimbursements **Namespace Prefix:**PCSA **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_OtherReceivablesNetCurrent **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-310-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-13-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147481990/310-10-45-13>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-07\(2\)\(c\)\(2\)\(i\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-07(2)(c)(2)(i))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-07\(2\)\(c\)\(2\)\(ii\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-07(2)(c)(2)(ii))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-07\(2\)\(g\)\(3\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-07(2)(g)(3))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>

"https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
"https://xbrl.fasb.org/srt/2024/elts/srt/2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt/roles/2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt/types/2024.xsd", "https://xbrl.fasb.org/us-
gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles/2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types/2024.xsd",
"https://xbrl.sec.gov/country/2024/country/2024.xsd", "https://xbrl.sec.gov/dei/2024/dei/2024.xsd", "https://xbrl.sec.gov/eed/2024/eed/2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr/2024.xsd",
{ "calculationLink": { "local": { "pca-20240930_cal.xml": 1 }, "definitionLink": { "local": { "pca-20240930_def.xml": 1 }, "labelLink": { "local": { "pca-20240930_lab.xml": 1 }, "presentationLink":
{ "local": { "pca-20240930_pre.xml": 1 } }, "keyStandard": 160, "keyCustom": 33, "axisStandard": 15, "axisCustom": 1, "memberStandard": 14, "memberCustom": 26, "hidden": { "total": 72,
"http://fasb.org/us-gaap/2024": 55, "http://processpharmaceuticals.com/20240930": 13, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 140, "entityCount": 1, "segmentCount": 44,
"elementCount": 419, "unitCount": 5, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 470, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/eed/2024": 4 }, "report": { "R1": { "role":
"http://processpharmaceuticals.com/role/Cover", "longName": "00000001 Document Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "",
"menuCat": "Cover", "order": 1, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": { "span": "b", "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-
30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "b", "span": "p", "body": "html" }, "reportCount": 1, "baseRef": "form10-
q.htm", "first": true, "unique": true } }, "R2": { "role": "http://processpharmaceuticals.com/role/BalanceSheets", "longName": "00000002 Statement Condensed Consolidated Balance Sheets
(Unaudited)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 2,
"firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td":
"tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-
gaap:PrepaidExpenseAndOtherAssetsCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "body", "html" }, "reportCount": 1, "baseRef":
"form10-q.htm", "unique": true } }, "R3": { "role": "http://processpharmaceuticals.com/role/BalanceSheetsParenthetical", "longName": "00000003 Statement Condensed Consolidated
Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement",
"subGroupType": "parenthetical", "menuCat": "Statements", "order": 3, "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CommonStockParOrStatedValuePerShare",
"unitRef": "USDPSHares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "us-gaap:CommonStockParOrStatedValuePerShare", "span": "span", "span": "td", "tr", "table", "body",
"html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:TreasuryStockCommonShares", "unitRef": "Shares",
"xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "span": "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R4": { "role":
"http://processpharmaceuticals.com/role/StatementsOfOperations", "longName": "00000004 Statement Condensed Consolidated Statements of Operations (Unaudited)", "shortName":
"Condensed Consolidated Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 4, "firstAnchor": {
"contextRef": "From2024-07-01to2024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals":
"0", "ancestors": { "td": "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-01to2024-09-30",
"name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "body",
"html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R5": { "role": "http://processpharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity",
"longName": "00000005 Statement Condensed Consolidated Statements of Changes in Stockholders Equity (Unaudited)", "shortName": "Condensed Consolidated Statements of Changes in
Stockholders Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": 5, "firstAnchor": { "contextRef": "AsOf2022-12-31-us-
gaap:CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "body", "html" },
"reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-01-01to2023-03-31-us-gaap:CommonStockMember", "name": "us-
gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "body", "html" }, "reportCount":
1, "baseRef": "form10-q.htm", "unique": true } }, "R6": { "role": "http://processpharmaceuticals.com/role/StatementsOfCashFlows", "longName": "00000006 Statement Condensed
Consolidated Statements of Cash Flows (Unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement",
"subGroupType": "", "menuCat": "Statements", "order": 6, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false",
"lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-
01to2024-09-30", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "body", "html" }, "reportCount": 1, "baseRef":
"form10-q.htm", "unique": true } }, "R7": { "role": "http://processpharmaceuticals.com/role/StatementsOfCashFlowsParenthetical", "longName": "00000007 Statement Condensed
Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical)", "isDefault": "false",
"groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": 7, "firstAnchor": { "contextRef": "AsOf2023-09-
30-custom:ConsultingAgreementMember-custom:SpartanCapitalSecuritiesLLCMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef":
"Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "td", "tr", "table", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "AsOf2023-09-30-custom:ConsultingAgreementMember-custom:SpartanCapitalSecuritiesLLCMember", "name": "us-
gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "td", "tr", "table",
"body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R8": { "role": "http://xbrl.sec.gov/eed/role/PvpDisclosure", "longName": "995410 Disclosure Pay
vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 8, "firstAnchor": {
"contextRef": "From2024-07-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table", "body", "html" },
"reportCount": 1, "baseRef": "form10-q.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/eed/role/InsiderTradingArrangements", "longName": "995445 Disclosure
Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 9,
"firstAnchor": { "contextRef": "From2024-07-01to2024-09-30", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span":
"span", "p", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-07-01to2024-09-30", "name":
"ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "span", "p", "body", "html" }, "reportCount": 1, "baseRef":
"form10-q.htm", "first": true, "unique": true } }, "R10": { "role": "http://processpharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "longName": "995613
Disclosure Organization and Summary of Significant Accounting Policies", "shortName": "Organization and Summary of Significant Accounting Policies", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": 10, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-
gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef":
"form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role":
"http://processpharmaceuticals.com/role/StockholdersEquity", "longName": "995614 Disclosure Stockholders'2019 Equity", "shortName": "Stockholders'2019 Equity", "isDefault": "false",
"groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 11, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-
gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-
q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role":
"http://processpharmaceuticals.com/role/Stock-basedCompensation", "longName": "995615 Disclosure Stock-based Compensation", "shortName": "Stock-based Compensation", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 12, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1,
"baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-
gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1,
"baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://processpharmaceuticals.com/role/NetLossPerShareOfCommonStock", "longName": "995616 Disclosure Net
Loss per Share of Common Stock", "shortName": "Net Loss per Share of Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 13,
"firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": {
"body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-
gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true,
"unique": true } }, "R14": { "role": "http://processpharmaceuticals.com/role/Leases", "longName": "995617 Disclosure Leases", "shortName": "Leases", "isDefault": "false", "groupType":
"disclosure", "subGroupType": "", "menuCat": "Notes", "order": 14, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name":
"PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-
q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role":
"http://processpharmaceuticals.com/role/RelatedPartyTransactions", "longName": "995618 Disclosure Related Party Transactions", "shortName": "Related Party Transactions", "isDefault":
"false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 15, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-
gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-
q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil":
"false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role":
"http://processpharmaceuticals.com/role/CommitmentsAndContingencies", "longName": "995619 Disclosure Commitments and Contingencies", "shortName": "Commitments and
Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": 16, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name":
"us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef":
"form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role":
"http://processpharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "longName": "995620 Disclosure Organization and Summary of Significant
Accounting Policies (Policies)", "shortName": "Organization and Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType":
"policies", "menuCat": "Policies", "order": 17, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock", "unitRef":
null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-
q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock", "unitRef": null,
"xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm",
"first": true, "unique": true } }, "R18": { "role": "http://processpharmaceuticals.com/role/Stock-basedCompensationTables", "longName": "995621 Disclosure Stock-based Compensation
(Tables)", "shortName": "Stock-based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": 18, "firstAnchor": {
"contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": { "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true },
"uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",
"decimals": null, "ancestors": { "us-gaap:EarningsPerShareTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null,
"ancestors": { "us-gaap:EarningsPerShareTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role":
"http://processpharmaceuticals.com/role/LeasesTables", "longName": "995623 Disclosure Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure",
"subGroupType": "tables", "menuCat": "Tables", "order": 20, "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name":
"PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingAndFinancingLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals":
null, "ancestors": { "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": {
"contextRef": "From2024-01-01to2024-09-30", "name": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingAndFinancingLeasesTableTextBlock",
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-
q.htm", "first": true, "unique": true } }, "R21": { "role": "http://processpharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "longName":
"995624 Disclosure Organization and Summary of Significant Accounting Policies (Details Narrative)", "shortName": "Organization and Summary of Significant Accounting Policies (Details
Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": 21, "firstAnchor": { "contextRef": "From2024-01-22to2024-01-22", "name":
"us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "span", "p":
"PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first":
true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-22to2024-01-22", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US",

"decimals": null, "ancestors": { "span": "p", "PCSA:BusinessActivitiesAndOrganizationPolicyTextBlock": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative", "longName": "995625 - Disclosure - Stockholdersu2019 Equity (Details Narrative)", "shortName": "Stockholdersu2019 Equity (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "span": "span", "span": "span", "p": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockSharesIssued", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "span": "span", "span": "span", "p": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R23": { "role": "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails", "longName": "995626 - Disclosure - Schedule of Stock-based Compensation Expense (Details)", "shortName": "Schedule of Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpenseMember", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R24": { "role": "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRSUsActivityDetails", "longName": "995627 - Disclosure - Schedule of Restricted Stock Units (u201cRSUsu201d) Activity (Details)", "shortName": "Schedule of Restricted Stock Units (u201cRSUsu201d) Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2023-12-31", "us-gaap:RestrictedStockUnitsRSUMember", "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "AsOf2023-12-31", "us-gaap:RestrictedStockUnitsRSUMember", "name": "PCSA:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "td": "tr", "table": "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R25": { "role": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "longName": "995628 - Disclosure - Stock-based Compensation (Details Narrative)", "shortName": "Stock-based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "PCSA:PaymentsForSettlementOfStockAwards", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "us-gaap:WarrantMember-custom-OfferingMember", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "p": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R26": { "role": "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails", "longName": "995629 - Disclosure - Schedule of Net Loss Per Share Basic and Diluted (Details)", "shortName": "Schedule of Net Loss Per Share Basic and Diluted (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative", "longName": "995630 - Disclosure - Net Loss per Share of Common Stock (Details Narrative)", "shortName": "Net Loss per Share of Common Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "span": "span", "p": "us-gaap:EarningsPerShareTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "span": "span", "p": "us-gaap:EarningsPerShareTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R28": { "role": "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails", "longName": "995631 - Disclosure - Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)", "shortName": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "p": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "custom-FacilityLeaseMember", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "td", "tr", "table": "PCSA:ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R29": { "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails", "longName": "995632 - Disclosure - Schedule of Annual Lease Liabilities for all Operating Leases (Details)", "shortName": "Schedule of Annual Lease Liabilities for all Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R30": { "role": "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllFinancingLeasesDetails", "longName": "995633 - Disclosure - Schedule of Annual Lease Liabilities for all Financing Leases (Details)", "shortName": "Schedule of Annual Lease Liabilities for all Financing Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R31": { "role": "http://processapharmaceuticals.com/role/LeasesDetailsNarrative", "longName": "995634 - Disclosure - Leases (Details Narrative)", "shortName": "Leases (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "PCSA:OperatingAndFinancingLeaseWeightedAverageDiscountRate", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": { "span": "span", "p": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "name": "us-gaap:LeaseCost", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "td": "tr", "table": "PCSA:LesseeOperatingAndFinancingLeasesTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "unique": true } }, "R32": { "role": "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative", "longName": "995635 - Disclosure - Related Party Transactions (Details Narrative)", "shortName": "Related Party Transactions (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "From2024-07-012024-09-30", "custom-CorLyStLLCMember", "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "span", "p": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "From2024-07-012024-09-30", "custom-CorLyStLLCMember", "name": "PCSA:ProceedsFromRentAndOtherCostsReimbursements", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": { "span": "span", "p": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R33": { "role": "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative", "longName": "995636 - Disclosure - Commitments and Contingencies (Details Narrative)", "shortName": "Commitments and Contingencies (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "AsOf2024-09-30", "custom-CROsMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "span": "span", "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "custom-CROsMember", "name": "us-gaap:PurchaseObligation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": { "span": "span", "p": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body": "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "tag": { "PCSA-ATMOfferingMember": { "xbrltype": "domainItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ATMOfferingMember", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": "lang": { "en-us": { "role": { "label": "ATM Offering [Member]", "documentation": "ATM Offering [Member]" } } }, "auth-ref": { "r513": "r514", "r515": "r557", "r577" } }, "eod-AdjToCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/eod/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount" } } }, "auth-ref": { "r469" } }, "eod-AdjToCompAxis": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "AdjToCompAxis", "presentation": { "http://xbrl.sec.gov/eod/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]" } } }, "auth-ref": { "r469" } }, "eod-AdjToNonPeeNeeCompFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "AdjToNonPeeNeeCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/eod/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth-ref": { "r469" } }, "eod-AdjToPeeCompFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/eod/2024", "localname": "AdjToPeeCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/eod/role/PvpDisclosure": "lang": { "en-us": { "role": { "label": "Adjustment to PEO Compensation, Footnote" } } }, "auth-ref": { "r469" } }, "us-gaap-AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "order": "debit", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth-ref": { "PCSA-AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards": { "xbrltype": "monetaryItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname":

"AdjustmentsToAdditionalPaidInCapitalSettlementOfStockAwards": {"crdr": "debit", "presentation": {"http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Settlement of stock award", "documentation": "Adjustments to additional paid in capital settlement of stock awards" } } }, "auth_ref": {"us-gaap-AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": {"http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": {"lang": {"en-us": {"role": {"label": "Warrant granted in connection with a consulting agreement", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants, includes allocation of proceeds of debt securities issued with detachable stock purchase warrants" } } }, "auth_ref": {"r5": {"r17": "r63" } } }, "us-gaap-AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {"http://processapharmaceuticals.com/role/StatementsOfCashFlows": {"lang": {"en-us": {"role": {"label": "Adjustments to reconcile net loss to net cash used in operating activities" } } }, "auth_ref": {"ecd-AggtErrCompAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": {"r434": "r445", "r455", "r480" } } }, "ecd-AggtErrCompNotYetDeterminedTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"lang": {"en-us": {"role": {"label": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": {"r437": "r448", "r458", "r483" } } }, "ecd-AllAdjToCompMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "All Executive Categories Member", "documentation": "All Executive Categories Member", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "All Individuals Member", "documentation": "All Individuals Member", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {"lang": {"en-us": {"role": {"label": "PCSA Alliance Global Partners Member", "documentation": "PCSA Alliance Global Partners Member", "presentation": {"http://processapharmaceuticals.com/20240930", "localname": "Alliance Global Partners Member", "presentation": {"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Alliance Global Partners [Member]", "documentation": "Alliance Global Partners [Member]" } } }, "auth_ref": {"dei-AmendmentDescription": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": {"http://processapharmaceuticals.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": {"dei-AmendmentFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": {"http://processapharmaceuticals.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": {"dei-AnnualInformationForm": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": {"http://processapharmaceuticals.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": {"r441": {"us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": {"http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Antidilutive securities excluded from computation of earnings per share, amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": {"r129": {"us-gaap-AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": {"http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails": {"lang": {"en-us": {"role": {"label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": {"us-gaap-AntidilutiveSecuritiesNameDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": {"http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails": {"lang": {"en-us": {"role": {"documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": {"r11": {"us-gaap-ArrangementsAndNonarrangementTransactionsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": {"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": {"http://processapharmaceuticals.com/role/StatementsOfCashFlowsParentetical": {"http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": {"http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": {"lang": {"en-us": {"role": {"documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": {"r234": {"us-gaap-Assets": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"lang": {"en-us": {"role": {"totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": {"r70": "r75", "r86", "r103", "r133", "r136", "r138", "r139", "r141", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r235", "r237", "r253", "r283", "r338", "r391", "r392", "r403", "r415", "r527", "r528", "r566" } } }, "us-gaap-AssetsAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"lang": {"en-us": {"role": {"label": "ASSETS" } } }, "auth_ref": {"us-gaap-AssetsCurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"parentTag": "us-gaap-Assets", "weight": 1.0, "order": 1.0 } }, "presentation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"lang": {"en-us": {"role": {"totalLabel": "Total Current Assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": {"r83": "r90", "r103", "r141", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r235", "r237", "r253", "r403", "r527", "r528", "r566" } } }, "us-gaap-AssetsCurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"lang": {"en-us": {"role": {"label": "Current Assets" } } }, "auth_ref": {"us-gaap-AssetsNoncurrentAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"lang": {"en-us": {"role": {"label": "Other Assets" } } }, "auth_ref": {"us-gaap-AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "crdr": "debit", "calculation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"parentTag": "us-gaap-Assets", "weight": 1.0, "order": 3.0 } }, "presentation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"lang": {"en-us": {"role": {"totalLabel": "Total Other Assets", "label": "Assets, Noncurrent, Other than Noncurrent Investments and Property, Plant and Equipment", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets, excluding property, plant, and equipment and other property and investments, that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Charges and Other Assets." } } }, "auth_ref": {"dei-AuditedAnnualFinancialStatements": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": {"http://processapharmaceuticals.com/role/Cover": {"lang": {"en-us": {"role": {"label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": {"r441": {"ecd-AwardExrcPrice": {"xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Exercise Price" } } }, "auth_ref": {"r491": {"ecd-AwardGrantDateFairValue": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Fair Value as of Grant Date" } } }, "auth_ref": {"r492": {"ecd-AwardTmgDisclneltms": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDisclneltms", "auth_ref": {"r487": {"ecd-AwardTmgHowMnpiCnsdrdTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Award Timing, How MNPI Considered" } } }, "auth_ref": {"r487": {"ecd-AwardTmgMethodTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Award Timing Method" } } }, "auth_ref": {"r487": {"ecd-AwardTmgMnpiCnsdrdFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Award Timing MNPI Considered" } } }, "auth_ref": {"r487": {"ecd-AwardTmgMnpiDisclTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDisclTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Award Timing MNPI Disclosure" } } }, "auth_ref": {"r487": {"ecd-AwardTmgPredtrmndFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Award Timing Predetermined" } } }, "auth_ref": {"r487": {"us-gaap-AwardTypeAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": {"http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": {"http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": {"r188": "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213" } } }, "ecd-AwardUndrlygSecuritiesAmt": {"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Underlying Securities" } } }, "auth_ref": {"r490": {"ecd-AwardsCloseToMnpiDisclndName": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclndName", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"verboseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": {"r489": {"ecd-AwardsCloseToMnpiDisclTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclTable", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": {"r488": {"ecd-AwardsCloseToMnpiDisclTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDisclTableTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {"lang": {"en-us": {"role": {"label": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": {"r488": {"us-gaap-BasisOfAccountingPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyTextBlock", "presentation": {"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies": {"lang": {"en-us": {"role": {"label": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": {"PCSA-BusinessActivitiesAndOrganizationPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "BusinessActivitiesAndOrganizationPolicyTextBlock", "presentation": {"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies": {"lang": {"en-us": {"role": {"label": "Organization", "documentation": "Business Activities And Organization [Policy Text Block]" } } }, "auth_ref": {"us-gaap-BusinessDescriptionAndAccountingPoliciesTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": {"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies": {"lang": {"en-us": {"role": {"label": "Organization and Summary of Significant Accounting Policies", "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": {"r54": "r55" } } }, "PCSA-CROsMember": {"xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "CROsMember", "presentation": {"http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative": {"lang": {"en-us": {"role": {"label": "CROs [Member]", "documentation": "CROs [Member]" } } }, "auth_ref": {"us-gaap-CashAndCashEquivalentsAtCarryingValue": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": {"http://processapharmaceuticals.com/role/BalanceSheets": {"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": {"lang": {"en-us": {"role": {"label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": {"r9": "r85", "r387" } } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": {"http://processapharmaceuticals.com/role/StatementsOfCashFlows": {"lang": {"en-us": {"role": {"periodStartLabel": "Cash and Cash Equivalents u2013 Beginning of Period", "periodEndLabel": "Cash and Cash Equivalents u2013 End of Period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": {"r9": "r51", "r101" } } }, "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-

gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net Increase (Decrease) in Cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage, including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r0", "r51" } }, "eecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote" } } }, "auth_ref": { "r467" } }, "srct_ChiefFinancialOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefFinancialOfficerMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "auth_ref": { "r522" } }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": { "r1" }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r87", "r88", "r89", "r135", "r164", "r165", "r166", "r168", "r171", "r176", "r178", "r306", "r307", "r308", "r309", "r394", "r504", "r510" } }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": { "r26" } }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Warrant or Right Exercise Price Of Warrants Or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": { "r179" } }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Warrants to purchase shares", "verboseLabel": "Class of warrant or right, exercise price of warrants or rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": { "r179" } }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of warrant or right, outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": { "r1" }, "eecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount" } } }, "auth_ref": { "r468" } }, "eecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Company Selected Measure Name" } } }, "auth_ref": { "r468" } }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": { "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical": { "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r234" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r39", "r71", "r285", "r325" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "r1" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://processapharmaceuticals.com/role/CommitmentsAndContingencies": { "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r58", "r148", "r149", "r383", "r524", "r526" } }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Maximum equity available for issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r42" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r405", "r406", "r407", "r409", "r410", "r411", "r412", "r513", "r512", "r575", "r577" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r42" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r42", "r326" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r42" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://processapharmaceuticals.com/role/BalanceSheetsParenthetical": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r5", "r42", "r326", "r344", "r577", "r578" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Common stock, par value \$0.0001, 100,000,000 shares authorized, 3,271,944 issued and 3,266,944 outstanding as September 30, 2024, and 1,291,000 issued and 1,286,000 outstanding at December 31, 2023", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r42", "r286", "r403" } }, "eecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": { "r473" } }, "eecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": { "r472" } }, "eecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": { "r474" } }, "eecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": { "r471" } }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Concentration of Credit Risk", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": { "r32", "r78" } }, "PCSA_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ConsultantMember", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Consultant [Member]", "documentation": "Consultant [Member]" } } }, "auth_ref": { "r1" }, "PCSA_ConsultingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ConsultingAgreementMember", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParenthetical": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Consulting Agreement [Member]", "documentation": "Consulting Agreement [Member]" } } }, "auth_ref": { "r1" }, "PCSA_CorLystLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "CorLystLLCMember", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "CorLyst, LLC [Member]", "documentation": "CorLyst, LLC [Member]" } } }, "auth_ref": { "r1" }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": { "r1" }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": { "r1" }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format -MM-DD." } } }, "auth_ref": { "r1" }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": { "r3", "r16" } }, "srct_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": { "r522", "r576" } }, "PCSA_DisclosureLeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "DisclosureLeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases", "documentation": "Schedule Of Annual Lease Liabilities For All Operating Leases", "verboseLabel": "Schedule Of Annual Lease Liabilities For All Financing Leases" } } }, "auth_ref": { "r1" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensation": { "lang": { "en-us": { "role": { "label": "Stock-based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": { "r184", "r187", "r214", "r215", "r217", "r396" } }, "us-

gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "PCSA_DisclosureOfOrganizationAndSummaryOfSignificantAccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "PCSA_DisclosureOfOrganizationAndSummaryOfSignificantAccountingPoliciesAbstract", "auth_ref": [], "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other.' } } }, "auth_ref": { "r429" } }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": { "r427", "r429", "r441" } }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [], "dei_DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [], "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date, for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [], "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [], "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r429" } }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": { "r416" } }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": { "r429" } }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": { "r429" } }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r462" } }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other.'" } } }, "auth_ref": [], "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": { "r419" } }, "PCSA_DueToLicensor": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "DueToLicensor", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets" }, "lang": { "en-us": { "role": { "label": "Due to licensor", "documentation": "Due to licensor." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [], "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" }, "lang": { "en-us": { "role": { "label": "Net Loss per Common Share - Basic", "documentation": "Basic net loss per share." } } }, "auth_ref": { "r97", "r109", "r110", "r111", "r112", "r113", "r114", "r119", "r122", "r126", "r127", "r128", "r132", "r230", "r233", "r247", "r248", "r281", "r293", "r388" } }, "us-gaap_EarningsPerShareBasicLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasicLineItems", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" }, "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r122", "r123", "r126" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" }, "lang": { "en-us": { "role": { "label": "Net Loss per Common Share - Diluted", "documentation": "Diluted net loss per share." } } }, "auth_ref": { "r97", "r109", "r110", "r111", "r112", "r113", "r114", "r119", "r122", "r126", "r127", "r128", "r132", "r230", "r233", "r247", "r248", "r281", "r293", "r388" } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStock" }, "lang": { "en-us": { "role": { "label": "Net Loss per Share of Common Stock", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r118", "r120", "r130", "r131" } }, "PCSA_ElionOncologyIncMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ElionOncologyIncMember", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Elion Oncology, Inc. [Member]", "documentation": "Elion Oncology, Inc. [Member]" } } }, "auth_ref": [], "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails" }, "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [], "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Unrecognized share based compensation expense", "documentation": "Amount of cost not yet recognized for nonvested award under share based payment arrangement." } } }, "auth_ref": { "r216" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PhYnMndTnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r216" } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Option [Member]", "documentation": "Share based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [], "PCSA_EmployeesAndConsultantsMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "EmployeesAndConsultantsMember", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Employees and Consultants [Member]", "documentation": "Employees and Consultants [Member]" } } }, "auth_ref": [], "PCSA_EmployeesMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "EmployeesMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" }, "lang": { "en-us": { "role": { "label": "Employees [Member]", "documentation": "Employees [Member]" } } }, "auth_ref": [], "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [], "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [], "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [], "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [], "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha 2 country code" } } }, "auth_ref": [], "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [], "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [], "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": { "r422" } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10 digit SEC issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r418" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [], "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [], "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Domain", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [], "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r418" } }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": { "r503" } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://processapharmaceuticals.com/role/Cover" }, "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters." } } }, "auth_ref": [] }

"License Agreement [Member]" } } } , "auth ref": [] , "PCSA LiquidityPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "LiquidityPolicyTextBlock", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Liquidity", "documentation": "Liquidity [Policy Text Block]" } } } , "auth ref": [] , "dei LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": { "http://processapharmaceuticals.com/role/Cover" } , "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } } , "auth ref": [] , "PCSA MarketCapitalization": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "MarketCapitalization", "crdr": "debit", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Market capitalization", "documentation": "Market capitalization." } } } , "auth ref": [] , "srt MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } } , "auth ref": { "r150", "r151", "r152", "r153", "r183", "r218", "r249", "r279", "r294", "r296", "r303", "r316", "r317", "r376", "r377", "r378", "r379", "r380", "r384", "r385", "r393", "r394", "r395", "r398", "r399", "r400", "r401", "r404", "r529", "r568", "r569", "r570", "r571", "r572", "r573" } } , "PCSA MaximumValueToBeSold": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "MaximumValueToBeSold", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Maximum value to be sold" } } } , "auth ref": [] , "PCSA MaximumValueToBeSoldAtMarketOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "MaximumValueToBeSoldAtMarketOffering", "crdr": "debit", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Maximum value to be sold at the market offering", "documentation": "Maximum value to be sold at the market offering." } } } , "auth ref": [] , "ecd MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Measure [Axis]" } } } , "auth ref": { "r468" } } , "ecd MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Name" } } } , "auth ref": { "r468" } } , "ecd MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } , "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value" } } } , "auth ref": { "r487" } } , "ecd MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement" } } } , "auth ref": { "r495" } } , "ecd NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Named Executive Officers Footnote" } } } , "auth ref": { "r469" } } , "us gaap NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long term credit." } } } , "auth ref": { "r100" } } , "us-gaap NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities" } } } , "auth ref": [] } , "us-gaap NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } } , "auth ref": { "r100" } } , "us-gaap NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities" } } } , "auth ref": [] } , "us-gaap NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "parentTag": "us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } } , "auth ref": { "r51", "r52", "r53" } } , "us-gaap NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities" } } } , "auth ref": [] } , "us-gaap NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } , "http://processapharmaceuticals.com/role/StatementsOfOperations" } , "parentTag": null, "weight": null, "order": null, "root": true } } , "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" , "http://processapharmaceuticals.com/role/StatementsOfCashFlows" , "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity" , "http://processapharmaceuticals.com/role/StatementsOfOperations" } , "auth ref": { "r48", "r53", "r73", "r82", "r91", "r92", "r96", "r103", "r107", "r109", "r110", "r111", "r112", "r113", "r116", "r117", "r124", "r141", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r230", "r233", "r248", "r253", "r291", "r346", "r366", "r367", "r413", "r527" } } , "us-gaap NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails" } , "lang": { "en-us": { "role": { "label": "Net loss available to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } } , "auth ref": { "r98", "r109", "r110", "r111", "r112", "r119", "r120", "r125", "r128", "r233" } } , "us-gaap NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } } , "auth ref": [] , "PCSA NextGenerationCapcitabineCAPMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "NextGenerationCapcitabineCAPMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Next Generation Capcitabine Cap [Member]", "documentation": "Next Generation Capcitabine Cap [Member]" } } } , "auth ref": [] , "dei NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": { "http://processapharmaceuticals.com/role/Cover" } , "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } } , "auth ref": [] , "PCSA NonCashLeaseLiabilityNet": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "NonCashLeaseLiabilityNet", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "label": "Net", "documentation": "Non cash lease liability net." } } } , "auth ref": [] , "ecd NonGAAPMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGAAPMeasureDescriptionTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description" } } } , "auth ref": { "r468" } } , "ecd NonPeeNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgCompActuallyPaidAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "documentation": "Non-PEO NEO Average Total Comp Amt" } } } , "auth ref": { "r466" } } , "ecd NonPeeNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeeNeoAvgTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" } , "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount" } } } , "auth ref": { "r465" } } , "ecd NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted" } } } , "auth ref": { "r495" } } , "ecd NonRule10b51ArrTrmtdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmtdFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" } , "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated" } } } , "auth ref": { "r495" } } , "us-gaap NoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashInvestingAndFinancingItemsAbstract", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "label": "Non-Cash Financing Activities" } } } , "auth ref": [] , "PCSA OfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OfferingMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Offering [Member]", "documentation": "Offering [Member]" } } } , "auth ref": [] , "PCSA OperatingAndFinanceLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OperatingAndFinanceLeaseExpense", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "parentTag": "us-gaap-NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows" } , "lang": { "en-us": { "role": { "label": "Non cash lease expense for right of use assets" } } } , "auth ref": [] , "PCSA OperatingAndFinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OperatingAndFinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets" } , "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets" } , "lang": { "en-us": { "role": { "label": "Current maturities of lease liabilities", "documentation": "Operating and finance lease liability current." } } } , "auth ref": [] , "PCSA OperatingAndFinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OperatingAndFinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets" } , "parentTag": "us-gaap-Liabilities", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets" } , "lang": { "en-us": { "role": { "label": "Non current lease liabilities", "documentation": "Operating and finance lease liability noncurrent." } } } , "auth ref": [] , "PCSA OperatingAndFinancingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OperatingAndFinancingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets" } , "parentTag": "us-gaap-AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets" } , "lang": { "en-us": { "role": { "label": "Lease right-of-use assets, net of accumulated amortization", "documentation": "Amount of lessee's right of use underlying asset under operating and finance leases." } } } , "auth ref": [] , "PCSA OperatingAndFinancingLeaseWeightedAverageDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OperatingAndFinancingLeaseWeightedAverageDiscountRate", "presentation": { "http://processapharmaceuticals.com/role/LeasesDetailsNarrative" } , "lang": { "en-us": { "role": { "label": "Weighted average discount rate for our facility and equipment leases", "documentation": "Operating and financing lease weighted average discount rate." } } } , "auth ref": [] , "us-gaap OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfOperations" } , "lang": { "en-us": { "role": { "label": "Operating Expenses" } } } , "auth ref": [] , "us-gaap OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations" } , "parentTag": "us-gaap-NetIncomeLoss", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://processapharmaceuticals.com/role/StatementsOfOperations" } , "lang": { "en-us": { "role": { "totalLabel": "Operating Loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } } , "auth ref": { "r74", "r390", "r517", "r518", "r519", "r520", "r521" } } , "us-gaap OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" } , "lang": { "en-us": { "role": { "label": "Present value of lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } } , "auth ref": { "r262" } } , "us-gaap OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" } , "lang": { "en-us": { "role": { "negatedLabel": "Less: current maturities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } } , "auth ref": { "r262" } } , "us-gaap OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfAnnualLeaseLiabilitiesForAllOperatingLeasesDetails" } , "lang": { "en-us": { "role": { "label": "Non current lease liability",

"documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, {"auth_ref": "r262" } } }, {"PCSA OrganizationLineItems": { "xbrltype": "stringItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OrganizationLineItems", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "OrganizationLineItems [Line Items]" } } } }, {"auth_ref": { "PCSA OrganizationTable": { "xbrltype": "stringItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "OrganizationTable", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "OrganizationTable [Table]" } } } }, {"auth_ref": { "us-gaap-OtherIncomeAndExpensesAbstract": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncomeAndExpensesAbstract", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Other Income (Expense)" } } } }, {"auth_ref": { "us-gaap-OtherLiabilitiesCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Due to related parties", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } } }, {"auth_ref": { "r35", "r403" } } }, {"ecd-OtherPerfMeasureAmt": { "xbrltype": "decimalItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount" } } } }, {"auth_ref": { "r468" } } }, {"us-gaap-OtherReceivablesNetCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Due from related parties", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } } }, {"auth_ref": { "dei-OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17 or Item 18 specified when the basis of accounting is neither US GAAP nor IFRS." } } } }, {"auth_ref": { "r429" } } }, {"ecd-OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount" } } } }, {"auth_ref": { "r436", "r447", "r457", "r482" } } }, {"ecd-OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Compensation Amount" } } } }, {"auth_ref": { "r439", "r450", "r460", "r485" } } }, {"ecd-OutstandingRecoveryIndName": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "verboseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } } }, {"auth_ref": { "r439", "r450", "r460", "r485" } } }, {"ecd-PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "auth_ref": { "r464" } } }, {"PCSA-PaymentsForSettlementOfStockAwards": { "xbrltype": "monetaryItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "PaymentsForSettlementOfStockAwards", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "negatedLabel": "Settlement of stock award", "label": "Payments for settlement of stock awards", "documentation": "Payments for settlement of stock awards." } } } }, {"auth_ref": { "us-gaap-PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to pay taxes on stock-based compensation", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } } }, {"auth_ref": { "r99" } } }, {"us-gaap-PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } } }, {"auth_ref": { "r50" } } }, {"ecd-PeerGroupIssuesFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuesFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote" } } } }, {"auth_ref": { "r467" } } }, {"ecd-PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount" } } } }, {"auth_ref": { "r467" } } }, {"ecd-PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount" } } } }, {"auth_ref": { "r466" } } }, {"ecd-PeoName": { "xbrltype": "normalizedStringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "PEO Name" } } } }, {"auth_ref": { "r469" } } }, {"ecd-PeoTotalCompAmt": { "xbrltype": "monetaryItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount" } } } }, {"auth_ref": { "r465" } } }, {"PCSA-PerformanceVestingCriteriaValue": { "xbrltype": "monetaryItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "PerformanceVestingCriteriaValue", "crdr": "debit", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Performance vesting criteria", "documentation": "Performance vesting criteria" } } } }, {"auth_ref": { "PCSA-PlacementAgentMember": { "xbrltype": "domainItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "PlacementAgentMember", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Placement Agent [Member]", "documentation": "Placement Agent [Member]" } } } }, {"auth_ref": { "us-gaap-PlanNameAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } } }, {"auth_ref": { "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" } } }, {"us-gaap-PlanNameDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } } }, {"auth_ref": { "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555" } } }, {"ecd-PnsnBnfItsAdjFnTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnfItsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote" } } } }, {"auth_ref": { "r466" } } }, {"dei-PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13c-4(c) under the Exchange Act." } } } }, {"auth_ref": { "r423" } } }, {"dei-PreCommencementTenderOffer": { "xbrltype": "booleanItem", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } } }, {"auth_ref": { "r425" } } }, {"PCSA-PreFundedWarrantMember": { "xbrltype": "domainItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "PreFundedWarrantMember", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants [Member]", "documentation": "Pre-Funded Warrant [Member]" } } } }, {"auth_ref": { "us-gaap-PreferredStockSharesIssued": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } } }, {"auth_ref": { "r41", "r164" } } }, {"us-gaap-PreferredStockSharesOutstanding": { "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } } }, {"auth_ref": { "r41", "r326", "r344", "r577", "r578" } } }, {"us-gaap-PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Prepaid expenses and other", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } } }, {"auth_ref": { "r507" } } }, {"us-gaap-ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap-NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Net proceeds from common stock issued, verboseLabel": "Net proceeds from sale of common stock", "terseLabel": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } } }, {"auth_ref": { "r1" } } }, {"PCSA-ProceedsFromRentAndOtherCostsReimbursements": { "xbrltype": "monetaryItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ProceedsFromRentAndOtherCostsReimbursements", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Rent and other costs reimbursements received", "documentation": "Rent and other costs reimbursements received." } } } }, {"auth_ref": { "us-gaap-PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails": { "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } } }, {"auth_ref": { "r4", "r268" } } }, {"us-gaap-PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } }, {"auth_ref": { "r268" } } }, {"us-gaap-PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Property and Equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment and furniture and fixtures." } } } }, {"auth_ref": { "r4", "r268", "r282", "r290", "r403" } } }, {"us-gaap-PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails": { "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } } }, {"auth_ref": { "r57", "r268" } } }, {"PCSA-PurchaseAgreementMember": { "xbrltype": "domainItem", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "PurchaseAgreementMember", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Purchase Agreement [Member]", "documentation": "Purchase agreement [Member]" } } } }, {"auth_ref": { "us-gaap-PurchaseObligation": { "xbrltype": "monetaryItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PurchaseObligation", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Purchase obligation", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier." } } } }, {"auth_ref": { "ecd-PvpTable": { "xbrltype": "stringItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]" } } } }, {"auth_ref": { "r464" } } }, {"ecd-PvpTableTextBlock": { "xbrltype": "textBlockItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure, Table" } } } }, {"auth_ref": { "r464" } } }, {"srt-RangeAxis": { "xbrltype": "stringItem", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } } }, {"auth_ref": { "r150", "r151", "r152", "r153", "r181", "r183", "r210", "r211", "r212", "r218", "r240", "r277", "r278", "r279", "r294", "r296", "r303", "r316", "r317", "r376", "r377", "r378", "r379", "r380", "r384", "r385", "r393", "r394", "r395", "r398", "r399", "r400", "r401", "r404", "r407", "r525", "r529", "r559", "r569", "r570", "r571", "r572", "r573" } } }, {"srt-RangeMember": { "xbrltype": "domainItem", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": {

"http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "auth_ref": { "r150": "r151", "r152": "r153", "r181": "r183", "r210": "r211", "r212": "r218", "r240": "r277", "r278": "r279", "r294": "r296", "r303": "r316", "r317": "r376", "r377": "r378", "r379": "r380", "r384": "r385", "r393": "r394", "r395": "r398", "r399": "r400", "r401": "r404", "r407": "r525", "r529": "r559", "r560": "r570", "r571": "r572", "r573" } }, "ced_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "auth_ref": { "r431": "r442", "r452": "r477" } }, "PCSA_RegistrationStatementMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "RegistrationStatementMember", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Registration Statement [Member]" } } }, "auth_ref": { } }, "us-gaap-RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": { "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r140": "r182", "r274": "r275", "r284": "r289", "r319", "r320", "r321", "r322", "r323", "r343", "r345", "r375", "r565" } }, "us-gaap-RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": { "r274": "r275", "r565" } }, "us-gaap-RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "auth_ref": { } }, "us-gaap-RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r140": "r349", "r350", "r353" } }, "us-gaap-RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": { } }, "us-gaap-RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": { "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": { "r140": "r182", "r274": "r275", "r284": "r289", "r319", "r320", "r321", "r322", "r323", "r343", "r345", "r375", "r565" } }, "us-gaap-RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactions": { "lang": { "en-us": { "role": { "label": "Related Party Transactions", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) parent company and its subsidiaries, (b) subsidiaries of a common parent, (c) and entity and its principal owners, and (d) affiliates." } } }, "auth_ref": { "r271": "r272", "r273": "r275", "r276": "r311", "r312", "r313", "r351", "r352", "r353", "r372", "r374" } }, "us-gaap-ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "ord": "debit", "calculation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "parentTag": "us-gaap-OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://processapharmaceuticals.com/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": { "r56" } }, "us-gaap-ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfStockBasedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported costs for research and development expense have been included." } } }, "auth_ref": { } }, "ced_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": { "r432", "r443", "r453", "r478" } }, "ced_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement Determination Date" } } }, "auth_ref": { "r433", "r444", "r454", "r479" } }, "ced_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Restatement does not require Recovery" } } }, "auth_ref": { "r440", "r451", "r461", "r486" } }, "us-gaap-RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": { "r1" } }, "us-gaap-RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": { } }, "us-gaap-RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "ord": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap-StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r44", "r63", "r287", "r301", "r302", "r310", "r327", "r403" } }, "us-gaap-RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": { "r81", "r104", "r105", "r106", "r108", "r113", "r115", "r117", "r142", "r143", "r144", "r225", "r226", "r227", "r228", "r229", "r231", "r232", "r233", "r239", "r241", "r242", "r244", "r246", "r260", "r261", "r298", "r300", "r314", "r577" } }, "us-gaap-RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "ord": "debit", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Right of use asset obtained in exchange for financing lease liability", "documentation": "Amount of increase in right of use asset obtained in exchange for finance lease liability." } } }, "auth_ref": { "r266", "r402" } }, "ced_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": { "r495" } }, "ced_Rule10b51ArrTrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmndFlag", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": { "r495" } }, "us-gaap-SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": { } }, "PCSA_SalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "SalesAgreementMember", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Sales Agreement [Member]", "documentation": "Sales Agreement [Member]" } } }, "auth_ref": { } }, "PCSA_ScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ScenarioAxis", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "verboseLabel": "ScenarioAxis [Axis]" } } }, "auth_ref": { } }, "PCSA_ScenarioDomain": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ScenarioDomain", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table", "presentation": { "http://processapharmaceuticals.com/role/CommitmentsAndContingenciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParentetical": { "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue generating activity or operations." } } }, "auth_ref": { "r234" } }, "us-gaap-ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": { "http://processapharmaceuticals.com/role/NetLossPerShareOfCommonStockTables": { "lang": { "en-us": { "role": { "label": "Schedule of Net Loss Per Share Basic and Diluted", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per share computations for income from continuing operations." } } }, "auth_ref": { "r516" } }, "us-gaap-ScheduleOfEarningsPerShareBasicByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTable", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails": { "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about basic earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": { "r10", "r12", "r122", "r123", "r126" } }, "us-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails": { "lang": { "en-us": { "role": { "label": "Share Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": { "r29" } }, "us-gaap-ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOperatingAndFinancingLeasesDetails": { "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r4", "r268" } }, "us-gaap-ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": { "http://processapharmaceuticals.com/role/RelatedPartyTransactionsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": { "r30", "r31", "r349", "r350", "r353" } }, "us-gaap-ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationTables": { "lang": { "en-us": { "role": { "label": "Schedule of Stock-based Compensation Expense", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": { "r6", "r7", "r68" } }, "us-gaap-ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r185", "r186", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213" } }, "us-gaap-ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationTables": { "lang": { "en-us": { "role": { "label": "Schedule of Restricted Stock Units (u201cRSUsu201d) Activity", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { "r65" } }, "us-gaap-ScheduleOfStockByClassTable": { "xbrltype": "stringItemType",

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": { "r18": "r18", "r19": "r20", "r21": "r22", "r23": "r59", "r61": "r62", "r63": "r87", "r88": "r89", "r135": "r164", "r165": "r166", "r168", "r171", "r176", "r178", "r306", "r307", "r308", "r309", "r394", "r504", "r510" } }, "PCSA_ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingandFinancingLeasesTableTextBlock", "presentation": { "http://processapharmaceuticals.com/role/LeasesTables": { "lang": { "en-us": { "role": { "label": "Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases", "documentation": "Schedule Of Weighted Average Remaining Lease Terms And Discount Rate For Our Operating and Financing Leases [Table Text Block]" } } }, "auth_ref": { "PCSA_SecondPerformanceBasedRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "SecondPerformanceBasedRSUMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Second Performance Based RSUs [Member]", "documentation": "Second Performance Based RSUs [Member]" } } }, "auth_ref": { "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r417": "r417", "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": { "r421": "r421", "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "order": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsNoncurrentOtherThanNoncurrentInvestmentsAndPropertyPlantAndEquipment", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Security deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": { "r506": "r506", "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r420": "r420", "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": { "r426": "r426", "PCSA_ServiceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ServiceBasedRestrictedStockUnitsMember", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Service Based RSUs [Member]", "documentation": "Service Based RSUs [Member]" } } }, "auth_ref": { "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "order": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfStock-basedCompensationExpenseDetails": "http://processapharmaceuticals.com/role/StatementsOfCashFlows", "lang": { "en-us": { "role": { "verboselabel": "Stock-based compensation", "label": "Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r2": "r2", "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "periodStartLabel": "Number of shares, Beginning balance", "periodEndLabel": "Number of shares, ending balance", "label": "Number of shares, outstanding", "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than option vested and unvested outstanding." } } }, "auth_ref": { "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value per share, Beginning balance", "periodEndLabel": "Weighted average grant date fair value per share, ending balance", "documentation": "Per share or unit weighted average fair value of vested and nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue" } } }, "auth_ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": { "r204": "r204", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value per share, forfeited", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r204": "r204", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Number of shares, granted", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r202": "r202", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value per share, granted", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r202": "r202", "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "negatedLabel": "Number of shares, issued", "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period." } } }, "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriod" } } }, "auth_ref": { "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value per share, shares issued", "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options issued in period weighted average grant date fair value." } } }, "auth_ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "periodEndLabel": "Number of shares, unvested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r199": "r199", "r200": "r200", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "periodEndLabel": "Weighted average grant date fair value per share, unvested", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r199": "r199", "r200": "r200", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Weighted average remaining contractual life", "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r69": "r69", "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissued", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Number of shares, vested and unissued", "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options vested and unissued." } } }, "auth_ref": { "PCSA_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndUnissuedWeightedAverageGrantDateFairValue", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value per share, vested and unissued", "documentation": "Share-based compensation arrangement by share-based payment award equity instruments other than options vested and unissued weighted average grant date fair value." } } }, "auth_ref": { "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Number of shares, vested", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r203": "r203", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Weighted average grant date fair value per share, shares vested", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r203": "r203", "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsusActivityDetails": "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative", "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r185": "r185", "r186": "r188", "r189": "r189",

"r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213" }}, "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Warrants, expired", "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed." } } }, "auth-ref": { "r67" } }, "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Share-based compensation arrangement by share-based payment award, non-option equity instruments, forfeitures", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth-ref": { "r66" } }, "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Shares available for future grants", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth-ref": { "r27" } } }, "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Options exercisable, shares", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth-ref": { "r193" } } }, "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Options exercisable-weighted average exercise price", "documentation": "The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth-ref": { "r193" } } }, "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Options, forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth-ref": { "r197" } } }, "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardTypeAndPlanNameDomain", "presentation": { "http://processapharmaceuticals.com/role/ScheduleOfRestrictedStockUnitsRsumActivityDetails": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth-ref": { "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213" } } }, "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Options, forfeited weighted average exercise price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth-ref": { "r197" } } }, "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm", "presentation": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Exercisable weighted average remaining contractual term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth-ref": { "r27" } } }, "us-gaap:SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssuedPricePerShare", "presentation": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Shares issued, price per share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth-ref": { "r1" } }, "PCSA:SharesIssuedInConnectionWithLicenseAgreementShares": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "SharesIssuedInConnectionWithLicenseAgreementShares", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Shares issued in connection with license agreement, shares", "documentation": "Number of shares issued in connection with license agreement." } } }, "auth-ref": { "r1" } }, "PCSA:SharesIssuedInConnectionWithLicenseAgreementValue": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "SharesIssuedInConnectionWithLicenseAgreementValue", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Shares issued in connection with license agreement", "documentation": "Value of shares issued in connection with license agreement." } } }, "auth-ref": { "r1" } }, "us-gaap:SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth-ref": { "r1" } }, "us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "negatedLabel": "Shares withheld to pay income taxes on stock-based compensation, shares", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth-ref": { "r1" } }, "dei:SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": { "http://processapharmaceuticals.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth-ref": { "r424" } }, "PCSA:SpartanCapitalSecuritiesLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "SpartanCapitalSecuritiesLLCMember", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlowsParentetical": { "lang": { "en-us": { "role": { "label": "Spartan Capital Securities LLC [Member]", "documentation": "Spartan Capital Securities LLC [Member]" } } }, "auth-ref": { "r1" } }, "us-gaap:StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/ScheduleOfNetLossPerShareBasicAndDilutedDetails": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "http://processapharmaceuticals.com/role/Stock-basedCompensationDetailsNarrative": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth-ref": { "r5", "r42", "r45", "r46", "r81", "r94", "r95", "r96", "r104", "r105", "r106", "r108", "r113", "r115", "r117", "r134", "r142", "r143", "r144", "r180", "r225", "r226", "r227", "r228", "r229", "r231", "r232", "r233", "r239", "r240", "r241", "r242", "r243", "r244", "r246", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r270", "r292", "r298", "r299", "r300", "r314", "r368" } } }, "us-gaap:StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth-ref": { "r104", "r105", "r106", "r134", "r261", "r280", "r304", "r315", "r318", "r319", "r320", "r321", "r322", "r323", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r345", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r408" } } }, "us-gaap:StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth-ref": { "r1" } }, "us-gaap:StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth-ref": { "r1" } }, "us-gaap:StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth-ref": { "r1" } }, "us-gaap:StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth-ref": { "r104", "r105", "r106", "r134", "r140", "r261", "r280", "r304", "r315", "r318", "r319", "r320", "r321", "r322", "r323", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r339", "r340", "r341", "r342", "r343", "r345", "r347", "r348", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r368", "r408" } } }, "dei:StkPreOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "StkPreOrTsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method" } } }, "auth-ref": { "r435", "r446", "r456", "r481" } }, "PCSA:StockIssuedInSatisfactionOfDueToLicensorInConnectionWithLicensingAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "StockIssuedInSatisfactionOfDueToLicensorInConnectionWithLicensingAgreement", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Issuance of common stock in satisfaction of a due to licensor in connection with a licensing agreement", "documentation": "Stock issued in satisfaction of due to licensor in connection with licensing agreement." } } }, "auth-ref": { "r1" } }, "us-gaap:StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://processapharmaceuticals.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "http://processapharmaceuticals.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Shares issued in connection with capital raise, net of transaction costs, shares", "verboseLabel": "Shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth-ref": { "r5", "r41", "r42", "r63", "r381" } }, "us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock-based compensation, net of forfeitures, shares", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth-ref": { "r5", "r41", "r42", "r63" } } }, "us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock-based compensation, shares", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth-ref": { "r5", "r41", "r42", "r63" } }, "PCSA:StockIssuedDuringPeriodSharesStockWithheldForIncomeTaxes": { "xbrltype": "sharesItemType", "nsuri": "http://processapharmaceuticals.com/20240930", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOffForfeitures", "crdr": "credit", "presentation": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "label": "Stock-based compensation", "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth-ref": { "r28", "r41", "r42", "r63" } }, "us-gaap:StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "parentTag": "us-gaap:LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://processapharmaceuticals.com/role/BalanceSheets": { "http://processapharmaceuticals.com/role/StatementsOfChangesInStockholdersEquity": { "lang": { "en-us": { "role": { "deficitLabel": "Total Stockholders' 2019 Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth-ref": { "r42", "r45", "r46", "r56", "r328", "r344",

I&NVNCO0Z5<IKf:NMCI@U(IZ1)@XT.S5FZ<KL\$IA MXL5YX(OUYA 76OWLZQ8:FEL,SLW#1FR+9UZ4HU@=-@~Y X5R "B\$X"JT"J6 ME1A~0OHFOJ)VA(IA5NL"RU7HN5-FB@DV, (T\$XPD)-=1/LKfH0(1<35tH!_MS,%G%9TA0V>DGRNVY3(ASUG5H11K1JRP+P+15NRN)(9FQZ X2 BCE@<# MOV~21 NOS/ J~P~_..RCGPJF.LT.FT5DH1A1ZJ OE98N1SG<P5(ML&.)&U 1V8X)V1A1KXG7T N6\$J<J MJD1EYWG611.E8HK= B(02DPJ0<G3@1=-+ A2 .6%9AO<=) WUYU= 52%GC+1 MG<V1<7EDJB1%HL\$F .HA6Y%RN.11FHOSWA217/I#\$\$H 3OH1S7T#!>YS%6 M%69..X1L JX95#(0)M1GL<=J MJD1EYWG611>V .Y HO"PIJ>JH0RF2BHHE M:HOP42&E1U<=8LXC=L 114Z5BX9AWN0 .P<PD7IM1I29L 5@=-XL>.>F= MG5U2=DIZYQV..UWMV>2 +3K=-/C 9FJD.P5BZIK7M2CJLW+<N<J*#>A4G7C MEKU"TOI< 9LLN1J321N1H4IUXZBZ,43&N;N= F<~<~YXVH.N=1J6=4<1 MGAT<FJG(ATP%1XXCI 20.ZLZ= 3N"325OJ=M- W7JJSR8M1KJ=M4J+GZ.M.DW12>>U/UH+<+&HOGIXA<~FJ4QEPH\$JHK75N1J9S@JMB =-MT3J1L 2CJV#>=5@<~(O&F&J&E87JY1CXPXV5&NP"FE JC- B:BHB6~XW?X M..71H=-2A\$%<^P2FX@C<+C-L4.F@4?L1K4G&X7LC&O&#&HUR4.OI/TNMG#D-MHU)K4FG?G!_!jN>+YTRP<v\$P\$S(3- S!6*24*ZKU.C19J-Z:GCZ/RB6? M/O=1\$G6CIC#IRJZL9PE+<JH0I8F6G\$>F0I.5U(I)A.TRZSD 7+V7PK<^M P102P.6@-LHJ=6= ASFGIP<6%\$ H+E@>=O+3(N-1Mf5MA M3<^XU>J>? J!AIGCDP<~(00C7) H%NIT.YM1)8XZJVTY"WS7=7M>=GN M18 M25MHHERU<+M+(%\$8H<7J6IPGDUH1QO.F07.ZV04X7GXR<6HJ/X>5Z.C7= M)YXVR>MDXON9WB1"56>I\$J>~OG8?L.FLZ<M1JM#Q? G@T5K6C8@G.IX>2>.0E&A.O17<^M 25U=MOJDD>1J)1D3ZUR6.FQ123X+SDN%G@CGB.R.N#G.V%79<~2N1J9K23.B8N#R.M.99B(DX1&IV6 <-<C19)~IW#5L@V1B?O! <<=WHU4D<135<1.&PAU\$ M&L+M(MT!M<E#J.HH.V" RY3O=J#U.2&8 IP>1YDC6I0<0AOO/O/<O&AYH&G&N79+ M#5(1<~UY/W7T"J.A!>29F9XU<@<S1B1@/U"~#0.9ID.9BROZ \$H)DYS. M1DP716>?2R)R41JA62120XQ~>ABVR3C5%G(K(8=>=RPI.A9CH&U(YD7 M%V\$S.WA!>UXB?>~1J.VW>Y*P.B.HC"1IEBKPS<DK8D6DQ%Y200Y%JWM@ MJJ2XES.Q&S.0R.T1=1OZK>2.CQC&T1<I9L1F3P<#6 A6<KXJL4<M@<7X1L8R<B/RD0.ZD6G7H=1L"2CfCS29.>@<Q66T1"56*W9.MPHI8FCHYT<@>.6MD?21UO M.PW1RH'BJOA< PI#Y&T.MWH>K!~I"~L.G58U7D.(4.L=J(MA2~UADCS MSZ7.8E=1BB17%&IUB&W%BDOLAY+FD&4BG&VR=2.E2.MH.F4VVJ<ZS6J_#1*BV.R!K4ZLBE<&1E*2 (-#2N2.2.B.E?E?Z\$A1B2N5V1JL1.62QO1<1 M4 Q40RHR2JF.EYGB 4+11+G 36&2+>?KZ?Ff%G3H0M1L"V05D.4TPOJBDCC%PFK@M?#_MDP<K2D1H4+SN 7+6=>QJS4X.08E!920#_M!B!X5~C"IE .S+=!\$UJHJTY?ZV@!OM.\$!JZ.S!H\$MSWACTB9<=M1621\$M9AOGJOVN<10632@)3009X3J113 MUTE"=><L16\$6K/R>#050VS"E&&SV@4B(D+14&8O.&?2TRPHV>JYOB03 ML8K@JHMRH? E\$SWRH9Q0%FLI@JH/EDC&_&PO@<@.J%JH77V<DRZJ<R M!>AII<SL<KJ\$VC 2W6W1.JONQOT1N7UH5W133GVUHU Q3Y.M 150VW9W1W@ZOO>?7O0 4K.IF!>=2>.7OJ@<1VC7%CN%N1@>~WWGSCF@<Z MSXJ.126&23@>Q%PZMO!O@/AH\$S= KW?2#?2W<5K= U&ST~!H\$;OFUOTX M.2RX>D<KM U2V70ZP9K!0#LN<%=>V18&1.UL"ID6&4PKOFUHU!6G.MI M@<QGUGU&E<FZ@<F92A 9&B?>_#ZG 7.PK!>8~J9876AGI<NZCJ<U45@E\$! M=R&SLU>AE&G&5XCLB?>XWN>S2_>YIE 4~O2W.G.TXNFJXQ9T6+BA*MH!F6J6%M6W2 MXKH&W%Q164F2Q<U>~L71JH14\$11001<(*?7EE@<XU+14~*7M M*~9T@<S.BTQ+FA+>=G6.B.UOCL1"V"MU4JN15TUDD?>76B6N PMPMUJ\$5DJPWE. L1VME5_~%1A:TMMAU<~<~.LY%<~#4U6<EZYRX.NXX#30C.DZ>=%FF<9E.C3B+JX%7AL@P3Y+=144.6M\$<B\$V"1HY#5@<(RO&>8O@W1LZ"<~M.\$2K!..R\$<RH3J5V"11J%@PTC2 M<H740 6C<MD1\$!/"~H1VTBUZ<6ZPZ.6+0LEP<K!C152@PEMR<7<3D M9XNN0GOS&R5C?V2JNJC2@9JZ 4@1 313TF 43&#%M1C.C60 <~>A>J M+NVBKV9W(OTADYOBVIVYH~RWO2HJF6+N&C+H.159!-=YFV!PLR5T1Y<JH\$5\$5A&S?ODQO1A4 M&L+V W1YOHF 2>1GEO#5 21J1JH1(9V!>=1A48N\$<ZLF&N1!\$<#FM! M+MTGL@/PMK6N#QO>~<@<F7P>4Y&BFAEE>=2.6GHE!2RE@MP84&M M&Q<0233EFA L1F.(D>48CE@OC\$Y1.SRC<@<J.N82 &*!L.9KNP5 BSZW MMC63F)9J2L9LJN1JH!6M% (H<E5T!ONYAQGOH\$>..ZXJYU@G<~\$Y<F (M DGBCTE?Z!\$%<V@J\$KHT<YX5R&53X1/J!<N.C.M90~OH=AH<G&V3I8M3<7&51O<55<1#H1~OW1EYRWXOXM2FAOURU!MX E1UV04T5@<#H1R BCW"1ISOV.P#8D?Y8Y7D.E.P&C<#..#WYX 21IR5G.E.M 7(IEF 31N1917APU/SOCP(E.#0W1J1#R.JZL+LYY#1\$526<C"JW1~<^2 M/BU~9H1MZ\$&0<0.3~1JLH<H<Z55 .G+ E1J?11\$4SY5!P4K1D4I!CA3 M>J>PMN910N<NKK+OQC(E<

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lI.M^=>OVI6=PA6M^VTY^WMH1=MO38V1A8H73JMDPOR<^8R8H&L4I4M>5.5OLPP.M@%(MUB/-.X &P^%>16KH7W5LWT78.0ZZ8D^JAAc%OY6H.O7HZ %W4IMZ.JR.M%2A+OJH^T2?IP2?CH.XDS<5&9D.0YCW9I.A9=0L.*C3L6>=>R.EZJ+I+^723 M+Dl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c&NKTJF^Y0Z\$ M9LSJST^7I^/HFHW+U01=>W2<T.Y.I.RM5&P^IWC7TKU?72XI25&=0.E%IMWN<=>M40^/G3<?>=>KEKHEI^ZANGBMTICJ3N.QOEWI.U>I>=>4\$^D\$V.E.2\$G6YVJ2.M\$=SQ5I5M9L4O.AXG9^<329A^E8I.15^<F.%2%52I2A3 MUBP4\$S^G<I#%>^<3DP9CB0^RG#.#124.Y^Q1WI%\$TDHYER.44IQ(Z3JA6.ZMR.WDJRD^5U+<FJR^ER.74VMFEJL6JV17.RM19Q&KR=K18.OJ^I^TU%\$KIOIH.MNRD%=>LW63M>#>AV^5Z.5>H^K4N14I7RSNK&B&B-GS018VJ^UBB8WJ6X1A.MV%GCG^C.TY\$P1^RXF@F&X1L.C5\$X^JIV(4^76+>+<IOP+I^ID32>=>9Y.M.H\$>Z6K3C^>64HPSIR^5RAFE8H^/4^L^I^Y3ISPR5K1O>=>? XW<=>S.IY8.MG.VRO5WORC2+1.LXW.SKXVJ6X8JA.EVQO33A.W19P.V.65Z&6^U73 MNF.M^<I^FIDEMJ.RV^YUIC9Y90LNVLOJL.C6Y7^*83*3N^=>6IQVWF1DOY3 M==>MOF2R3DC\$C\$PM7A+I.XMK^%K7ZA@D61.ID@<S^N^..4220.QO3?>1175MKU17R?>M<+7&C^<I@<KFD^63ZRC?I^&R&KSRKER<=>L^YNB15^/S^M2W1JCG2FE^<4L.M4@IF.38S1.CDG24?>T^EBIKC1^I^7A^C^M+WG+P^5LX1^4I^Z>S<=>O^#R1 MRVAUP+3.9M5555&X+3#BPQCS5./6J^IXD<=>E&9Z\$<NF5Y^60E^Y^<KIPGW.M@<=>LOTESMFV^=>GLHRBPV>089#>ZHL72PDA8A?2M8YKDP&V^3E+^TTOZH^M54T=>A1=3 2P1+<=<O^C^M^M9&S&8>L^O^L^2VUJ5>GU(OQ^P^FJZD^IH^>J5+R+1 M8YA^R^L+<?>R^3<=>@HI/Z.2S)7O.^#I2^ZC\$G%)PL@=>=>EUKFY4.CUI>=>K&625^1UPGX.ITJNXI8&K&6&74.LDI.YJ2^Hc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c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c&NKTJF^Y0Z\$ M9LSJST^7I^/HFHW+U01=>W2<T.Y.I.RM5&P^IWC7TKU?72XI25&=0.E%IMWN<=>M40^/G3<?>=>KEKHEI^

90#P8G*9DD=>@!+<+<+ MMD=A!_MB*WEC&+M+2R G.60(AB1-BWSIW+^A^*LLDDZ2B*%TGD\$DJ1T0^M.MBNS.P5WX*0\$ M(=U04(G3%GAVF+%\$I0*2I8&+|HJBF(Q?F+P+P+I C EU80#80%L^P) M&2\$2DL<=>HAST+|HCWIE1W>JZGZYN=>JY<O^N.GVWSZ?>_BO&#(H/29/KTA M^O)OIL0%BR>*1+>DM@>_XN2@+1PQF56B>|1H+22.N6>2+N\$&.%1Y0. M#Z1J#162MU764R&+M=1C)OHHV.4V1T^VK<| @e@&+ M1J>R=6#Z?Q 3/2C^Z E&SSCKZ 10BLDB3Y.YPH0I#X\$480%1QF=IAC M=8.R0/>1L.OVVV.CY3V61#>GRXUL>|A%AB5H0^Y P\$1|PGLEFPM6M9.C77 M4Z27.W2XACS.UW+>|N&DX 29\$8#%2R1P2I>?>#6RK &(\$2'0H/LFOE4>|D M=02M8(ANYK#VE\$=Q\$A#E\$2 M(\$S.H810>+14H\$5LE<+>|11AB1#L91M+Z<=> M\$5 %>L20Y0#XW1+|Q2+?+7B1JND1IWM2/D9|<+>A#E=VU\$KEBOH(Q&B\$&MM\$SY NED#3G@WQOBW51<3>33PXFZ1B9M&59.41(K#A#Y&AAYE1|2|22I3Z1R^O M#2Y&7ABP1H2>+S+47 **H+E>=>#..922&8^Q>8>18#8R01HOF>?>Z9\$5P.M2.FELG(1+1A#ETHYX3.DGS.F5U\$Q(C#FO)S|S|T.D"0B20QW51#>BRF3<M88M#M@>@P#>#>=H)@Y=+419R^+R^O M#29T46B#(SEKMB#XU1Y#4Q MWS51UUV1=M(WVF\$M &B1I7^X1_09#A0<""F%90AP%+QR&R1%OCAP<+TMO\$5EF.18\$&PF MRLI.73UUV\$W1^FANUHHHHH|OPLU1&EQ2V1&541#7PB_C9GA&>_X9J|/#A^*_MU^X&6/O&+1+H&G IC8GP1P^N14P.RB=I7Z^A.OIOF\$5M^G1 M.R.T^C=+S1+9ILK1V^HKOIEA1^XL282 MT1^Z^W? P2Y1J#8#0 WBD5V_K+1+H8^YHO1+> %&G>+>44VU%M1LH18H.1V03.O&G<+>|H&L\$1Z^Z<=>_THKH#E1J.UZH.93TO.GDD1796* M2I#3N/5%UB1TG C OPD9=>_6UR^IAP#E#1^C1C#M5.N.ACGHM20H8J#>|(MCMGBH.EHLMIN8BV/E8#12^XGC1_10 DXT0Y0%>V5-P&S08HQ7_4CT&IN;Y M=Z=RO(B=57)14I>Z>T^K?>V1>TIV=EOKSAQOIMZ16TY@&8A R1QG#1@<+<6<? M0\$5<^27I?&T\$91_13% RF6D1G0#1.G#P0VZ#Q1<?26XF45<~%H.BYNO%>OX M.6T\$SHYK<| IRH1..V18YC87+ZXK9Y>Q.FHRY1AQS0.% ET3#1.L.CIDLV3+5T2&2+1LBD#31JA7R^Y+|H^ M66<+>X6Z.5G<1W5VPEZ.SR+1<47C\$1\$V&U=A5\$FCHM(I10:~%2XGHS1@P^ MHHV+FX.@YIWH MNH^R<+6>2X3.HIHFH.Z02V16\$2UT2I^Z&6.. F93JRI&O^1L#L0^R001 M#C.TU.W1.OVFBJH1D1B+35R.HI^EAC3I;#=\$72\$Z5R(MW.8F%1=5X4ID6_1YK_MBY&K? +NVM=70/QX@S(5>F11XU^1AQ2\$86#K.M2.3_0BDX24E1JLHOSX^C=RD8QW.JCZD^JLGD4^&#M5+D1C.K="591>E8ZIG.O^M2^P4D8.TV.86^96.16\$! M2:MCVQX87Y8.4A.0M^THJB^L^C@S+Y/T#UB14O1#61QJOP#X13>U2 M_UE_Y<(-E&S18?>@T7RWE08C.H?C\$CLCIR&H55&HRCG%+DD#>...<=\$2B7 MB6#5N3/#>#M6M1&1K1B1K SLROHOA1XEBIYO M3W67>=28C(I=11HW7IEI@KY/T72RIT@>S;S7H1^+T+Z? 7 \$K/I7B_K<M@|W1LB00B^>_14P.DP1W(ILK1^GU4+6#13Z0(R* <Q\$B5B&6&8L.NT6 M+>1&2WD2=02\$SE^@1.KNC8&Y4Y0TL^L.LOX#<L5?3Y0NY_1\$O&11YDR2<C M.D1L.U2\$>_C/RGNW+NTB#1 2&T(C1Z1H=IS5AXC=32C(BN2I>|>@BBDWIKI/ M2Y6G21Z^BX&T^T1L6>+TVN.2.ETP#R7JHER6A<KOFFL1KQ.OJM1V74SYA MPD40L@<P.ITJTVJ1V4I@/AV18864F..31BQ9VY16C%>2=&6A7+1L.3.M_2R>4E10>_STJEB1K1FQ^1P.\$1\$16Y@&8B>_WAI>X>M>MO=EJTB8C_BGNQO5.OHID X^<G\$QX3& 6J8U7H43YNA C=S_OWD#VV^C MWD<21(T^I^T^I^F&A& 13^YVBNAT29E.7^IYVVCV1J0&1Z3&5&L D40LB M5WBL14JRIK.8A3.0T1A91^6J1\$>_90RGA1^F&08_@<Y/OFLQ^>I2^A^P^VQ.C#6.75XWIR&4&201_>O A=M=>S\$M513HSPGCG0C4>_A9%1<+>R&STY#>#B M.H3^6ZIOFU11Y4A9C_S# MOG-1>6<+>3WPB9U0C<6\$Z45M.G.#N#>P^F^OZ^@<@|E@F M#2N>#>I2^1^PY<C#K(C)_1IDZUIITP.6^1_ZWO@H1\$>S;M>+>14#>S^# ME@K^PN<3>Y>+>S^U<+>V^A^ZNA?> 2YV1&+>#VJABX_#E=DPAB%#P4S3.3_W5_2A1>T#1>5IPWGA<OIG.M\$T.LIS/F1>UGC+AR.P>#1Z>@L0<4L2VZ.P.G1#>@X3=D2U1G8XXON1A72<M! I#N^BOMEQZC40U^X9KM000&B;+J#R=>+W0\$5#IBDWO&K<^U1@CNS5.98 M&395JFX.FR<?>WOHUR_1VRU1U1O_1I911.RX&.F5RCF 6<51Y&6 M5<+>f<+>9SDY2IND9^ \$X1DIGN&ZODR_X1<@P>K6_>Y.MN1(>+>V>VVO@>_W.544T1W1+<?>R?91?>@M^C K8IX8XK^G^LJIG.C1O1+>M9\$P1RZTOY<61GD PGR^A6BOBYB M^C_>WN1+>#>1833/I4<+2%& 22.16A0H&A^&Y^%12<+>BOB07P0%#AR^L M4WV_>|S1<8C.P4S3@<W\$SN1M^P.TV7V1BV9V143<+>?>PX29JFO>?>E KOPQ2K1<M0X0Q1_0.#K1_>UN\$G 19^PON1A M0=>+>W1X0\$M5^M9&6+148P+>IAGI97B1H&E<@>OD6@<O=11A0FO1L03 X.M_#>S1C.N.0QYD1C.H0^B@BOXA2T1C1@<+>1>?>5X5KQ E88@<2_V.M\$P.P<1S\$ G&7?>D^M\$>SH7+>G1=A.OOXVKA9M\$B1ACJL.N^1)>1KN(0=M>A.O016^711NOIJA&#R0F+D94T_1I7^*G@QXOP#H42X1L^12^2.57=M3L M#8K.RDPZT51H^1Z&S^P2<

[illegible]

[illegible]

(1+4+U+WLOI<+>C%)%8-MN9UN.KWO8KFK=M=8:6>U\$W4ALCF7Z5E.#AJTYWV24%BK2+0:|K7I&D-MR#6CKKPDOA*+|SHNM.6#L%?<+1F0HJ/<E.513J.AW>?P&Q<=<U3^K7:5@D48F*GKJ/I.MI(30:0H)=.JR.PGIFP<QZSK%Q.PCFCF=U>RZIR/HGF/SV<=>#7.M.G'R-0Z8X&Q8-M>K.VIZ/<_SKL?GIB7%>GDAY(HRB2)U%U%-G\$M&L.I-M.YS@OX4HEOGHEV2M^AAH58NOQDP-2-7-74-\$Z%1GE>6IUK.)%HZ2>KUKK.MK(&-IKO)HFS-DUHH*M^UX^X%>TOIT<-782Q(OJRMHTS<+>0U1^*#>8A.V.MWPBVS1VLGXF08I.YB6+6A(5:3)5IBH&S\$4(A/EWP=5X1:6T(<+>YV.MR.M-1C3R4+FBXM>K.Z2ZNGP34.0HYZ&-&L2M.:&X7#-36ZX(-78.CKY(OZFZ32R+&L.E.:\$ON>.:QV/V"/ME.M?>OD.U=V2D8%O-PWT+/(H.5=4H+>T"GE.2BZ.RG=/(O+&^5^>)MRBJ9.8X0):?%)R+U49JA.LUY(S5I/ED:TF76BQ>I?E4I+H16B6ID55I)<=>R80P17I.MW?>D.V7DFUCRDLR&CHKD.N-1G?V@DOV3/34C^OX(X=SW4E)IF4+>+1.HP\$M.EOP>8(D+>+7AQX?P.F7FOECMFHXZ-?%O\$&3M.20X.IUKI=EK(<=<ZW3IV05/C=15>)&FENOSWNC<=>ZISMIL/P4NU4L(+C.MZT5L&KVU.V795/<+>WJ:=FZ+BBK^QZ=>X1.6N5:IGIT.VM-LZD-T.7\$-6.MU/DH7.F08N6.@2F4MSDHH>(ALB-IMQZ3IG9\$4AD3*8L.7U=UX-14Q3P24I^AMK\$06.7U=T.555.M0U/Q\$>+14H=BU+>NWTFFIK2^<+>SVG.-WMOD:..RCLXQVLEIYK670I:05<=>MIUKI=OM+?2.MZRZ4I33^CND4L.9QC/I^7Z.M0.1^O1.2:..L44%+A^Y8CW7I^G^>FIEH+|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|C89FD.5<=<7P*8XSAJ5^M.ZB/L2ZHT^*&JUCO58:..8P+>H.MTRW60/=>%L/5(4I?_JMAQKM-D.M?>R2#5(SILWY5^E1C\$6I27#DMDZN="PS#0Q.MW9&6P^61-0.0%?Q.W.5%2KMT?>QGR4I.YT0@>?%QMDH8(E@+I)UNAF^M5\$P.MISH0>WDB1+3K%Y.29RKL.BFX.F.T\$M.F4+5^B1U(6^N4^<+>TU.0Y.O.M(TTIF7JMR<7?/7?44%JX9\$[3+^<+>2+1?V.WH2^UO\$4F?>.G08HG.MKW-IHTL?+>|+|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|8GL0Q.TB1B^<+>B^Y.R.(G240+P^<=<B=<=<AR53N.YUGO%<=<MKY3B.KI3VIT\$<=<4KHX^<=<0X^<=<15LOCDS64:(S1=>G^M16VX?C1^#U<+>(7271G%5F6-K+WMUSJ&=MKAI>M>I<=<6W@LX/@.GIXDYOLYF^>?>N=34\$N^K.N2^<=<E)O^<TBU^HIOXIX.U.MOVLID6CD(FI^X^?HIS0@.XMBK-(C4?%&+PG7+0^<T^%<+>IM8..0.A&K7.10:12U^F<+>E1EG

M3GP:Q:R//WY=F85VW.FZ(0SQ67%FS.SQ"WZSJ#.#YH.AMY:/FHO53TFJ.M35BA>M+V%.-90/H/3/KS:F?MDY^JHW(29)QOYN/(ZRS:EP.J"/HLE
M6G5VJ2LH+FIW#M#SYQ3558=-WO)EL2BU)HJZMU24SG<NNW#JH8.J+.%?4N7.M%6MHLARQ<4.#THVWNOQM85SHHHWXPLOY58%ZYU/L#ME=KL:3ZCZ>.+J
M8=>RWVD60.OXO.VV.F.7IEXIOL71HW-78./BCIYVZHKI=I00.OUW/O%O.LF.M+V:G1?OE.4YSD^Y=>O34LNI^IGTW4IWRWRWF.4>IYVBI/AST8HXV^T
MGE/KUBH93OM.V.7W3SZY4.HOM^JONT5FUXJ3.I?O7<IW<3JP.M2MKL^NI.YJHJ^INC2^90G?2U/LU^I=MG<UK<6%PZ#W5MSS.GG3/M7E/HJO/
EQ=>N\$XJB3/ZL.FVZ&HMD)BEOG/60CXO-1LF+NNWHDXY^U^5-MMB=-3HRYP>.%?%FDB^07IMOPI/BJV6^KE:J3I75-MRE.7YV?>
1A^)=S1=WA5P^U^U10+I.V%<#X=UBE.ZNN^YVM70RQ0?N/MV39^INV67>G+BCAE59W6E+8-6U^QJR.BUNL94U3C+>SPG2?JA<.&M.S/E:MWHI
Y&G<=>Z2A7?>DA.Z>PSIE-2044-6.M#1DU9-2044/(R3KA(0\$A97.^Y?<6/L.30I02P.8%<LH>6Q8IM0-3I\$PI25LKK.H.MBEA=>+JH9+I+I
<>G8QC/F/CIZ=7H>+I<6&H8RB19U<CJ-49=7OI^U^M.LZ?D^7ZMU3I2I-06A7^M#5%233ME^XOXV^+X^GFR&7H^S^SLCWYAQ6.MC:G19<I^I^QBZ&
I-3A7ZV>^Y8XK1^&N^W<C^G%>P4I4I^V%&NBW^U^M>#BELM1B^2QKJ9^IY&ARXV^5\$U^K1BCXHU2IG<@SJGS^FXAHW^YQ^9IA^I&T2I.MOIZU.T^X(SW/L^<^>2YD^U/VZ
3)JICR^692WW2/5I>/GWM?GIC(O-9.M7@ISCAUD^A47I^U^C+U^7DX&9^U^3XZ.CMN^W-V.%-V13WBOM.GIDD=>^?Y^MWE:E(6F&5&%>+59VY^.\$%N^JBE(%>5L^>2IQ8?
R100X)4TFL00^#P&I05Y^ZM^M052MKL.JHD#<@T^O^X^QML6+13PEE^A)H^<EK225V9^2H^EZV7I39ECR1^MK0?Z@WI>=<R^NM+P%EXH0.2575H.S^U5=RI>I90^I^=
7H/KQ3L1^TQ.M=H74B^59\$=>ERISP^T51^I^>@FN#JOZN49+I^A^G#0L97^<K6C^<C5E66G^MU<=SS<@>4V/I^06G9^LSA8=8=&GQ>97^>MB.N.O35<X^P^T^H8BVL5Z<M^7
U^#7B+I5Z.Z>OF<S>S9IR?D=956N^J^U^0L1M^6DDP?Y=U^R9IB.RHH^2^A^U^Z>I^H2^M^L^M(B)=6^7HJK+I^I^SIX=RX#LA^C39I+G&I5.IF<@XK0^UO^>9^W9&R^I^O^M
TW^YJL2I+I^L^W^O^C&S?QIC.OI.GM^#>AII^P^H&GEC7I^C^>D4J^<S^Y^MAIH^G^4BY^=EQIMK<-1^Z1ZIMTR^>8C(\$P.S+^87YXZX.U4I4I7=I^Q^H^M0I9HP
K&4&VJ25^UZL/98>=>W2T&JP.FMN/9.X.W:3SIDV7.7Y\$-LRPH/O.M55V-.8+I^QHOE-0I+7^YD,8E,Q0K1GQYAJL-/4CD<=<89#N^I^6<=<%3LP+<=<03EQZ1G0,,\$FFE?
I.VF66320P(\$A.SRG.CMWRXT^MZF1^ST^AY^>.&DRK8VYK^L>79.61\$?EOC1^IOT<=<^RRD@>^F7I^R\$.Y=>4M^4M^?2^)&I0+XOZ^N7\$1^ENKDIY^\$*(4G.B9XT=IS7HC35M-/H
HBB.YA.S^M78J34Z^I.G10^H^440T^0I^MK8^IYLM^54ND^#^F7UW1^#^/4K/I^P^M7^M4C>V8GV^R7SK^ZL3>=,^TTOFN-1A18T^#23>20EQE1^
MLJ.I^>A2L^91J^@90^?^72.X^UICOD(Z-<K&E^DUO^O^>BP7R3R?2Y3^M90E^I23^IPXQZ^WN^Y7IAD&F6IX24WPA5Z>=>^QCB3W4Z^>^O^#A^F0^WP
MA.BOH^ATK#>#81EAPYB9I0IG^@H84TF^F9:R9QYEA8(P925,25I>#5S5^OLKJ^Y&SG7^I7A-W6:M6^V3^KDGM6)BEM-I^OJIDJG.WUZ^C^Q(49IPU^94^*9K
/P+&#Z9J9K<4\$7^M.H7U6O)5Z_BD=7AN1366M(R0JR^IH9P08.T^0N32.Z^#)/JP<^9Z5XIBI^B^/MI2@BEP^?69%ERCL%>LITVMEI1OJDILOOS2A1UD4.V4\$F+H0U^XFRKJ7Z+
M2D.POF=>RPA^KA#^JF<#>2C^XJ1S^Z.WEY^4=5MA5.M+INT.Z^25I4^OO^>AS6NOS?J^G^&L^N^P^Y^WT@Y94I<3\$>L6^YANCIP^MN>=>GIGF3P5^&819856S6IX^SL7X^UUT(K
MG^F+JP^<0DFQ08+>J^IAB^>7+BB+I&V^QY5O.UM.Z^F^IET^=UEXW\$5#3^&M1G^O^I^83GN=1^UM^K^XG66%5%<9%I0B^36H^I^@R<C^>5%>Tl@.H&45I&5I&V^I^DF3NFCO
MU4&=I^L^D^B5L^I^G1SGK^>7&KKR<@ZD95I>Z^H^KJIA^<G^I-U3^#<100OK^K4^P^I^F7FL9)UZJ^F^I^Y^CZ^IOXKD^%9.6020^X<=<8^YEW^I^C1VH7I>D^E^NI^MZJ
*K1&88M^JLVL^LKL1<I>7UN4IY&C^I^NOJ^NOV2I^H6^MX^K^K4^XKDT^1^L\$>=>SB4.P.9I&6#8\$>@-S+FA6V^NA^/G^H#E^Z8H8B5Z^M#>ZV9PS.2\$

[illegible]

[illegible]

[illegible]

PreferredStockSharesIssuedIfIdDoC20231231ZmOgXWww4jIjTitle="Preferred stock, shares issued">no
issued or outstanding
shares of preferred stock at either September 30, 2024 or December 31, 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white;"></p><i>Common Stock</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in;">During the nine months ended September 30, 2024, we sold 476,000 shares of common stock, pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock (the "Pre-Funded Warrants"), and warrants to purchase up to 1,555,555 shares of our common stock (the "Common Warrants") in a public offering (the "Offering"). The Common Warrants have an exercise price of \$4.50</p><p>are immediately exercisable and expire on January 30, 2029. The shares of common stock were offered at a combined public offering price of \$4.50 per share and accompanying Common Warrant and \$4.4999 per Pre-Funded Warrant and accompanying Common Warrant. The Pre-Funded Warrants had an exercise price of \$0.0001 and were exercised in full simultaneously with the closing of the Offering in exchange for 1,079,555 shares of our common stock. Gross proceeds in connection with the Offering were \$7.0 million. We received \$6.3 million in net proceeds from the Offering, after deducting the fees of the placement agent and other offering-related expenses. We also issued to the placement agent warrants to purchase 62,222 shares of common stock, exercisable at \$5.625 per share that expire on February 1, 2027</p><p></p><p style="font: 10pt Times New Roman, Times, Serif; font-size: 10pt;">During the nine months ended September 30, 2024, we also received approximately 931,000</p></p><p style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">in net proceeds from the sale of 374,190</p></p><p style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">shares of common stock under the ATM Offering on July 31, 2024. During the nine months ended September 30, 2024, we also issued (i) 5,000</p></p><p style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">shares of common stock to Ellion Oncology, Inc. ("Ellion") in satisfaction of the third milestone event under the license agreement; (ii) 30,000</p></p><p style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">shares of common stock to a consultant in accordance with their consulting agreement; and (iii) 16,199</p></p><p style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">shares of common stock to certain employees and consultants, net of 7,154</p></p><p style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">shares of common stock withheld for income taxes owed upon distribution of the shares.</p></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify;"></p><p style="font: 10pt Times New Roman, Times, Serif; font-size: 10pt;"></p><p></p></p><p style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 11pt; text-align: justify; text-indent: -11pt;"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in;"></p><p style="font: 10pt Times New Roman, Times, Serif; font-size: 10pt;"></p><p>On June 19, 2019, our stockholders approved, and we adopted, the Processa Pharmaceuticals Inc. 2019 Omnibus Equity Incentive Plan (the "2019 Plan"). The 2019 Plan allows us, under the direction of our Board of Directors or a committee thereof, to make grants of stock options, restricted and unrestricted stock and other stock-based awards to employees, including our executive officers, consultants and directors. On June 28, 2024, our shareholders approved an increase of shares available under the 2019 Plan, which now provides for the aggregate issuance of 800,000 shares of our common stock. At

[illegible]

~~ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_pid_c20240628_20240628_us-gaap-AwardTypeAxis_custom-ServiceBasedRestrictedStockUnitsMember_srt-TitleOfIndividualAxis_custom-EmployeesMember-us-gaap-VestingAxis_custom-ThreeYearVestingMember_z52SRb0ha3a2" title="Number of shares, granted">18,173~~ shares of common stock vest over a three-year period upon meeting service requirements; RSUs for the future issuance of 3,030 shares of common stock vested upon grant due to regaining Nasdaq compliance, and RSUs for the future issuance of 3,030 shares of common stock vest upon dosing the first patient in our Phase 2 study in NGC-Cap.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On July 16, 2024, Russell Skibsted was appointed as our Chief Financial Officer ("CFO"). In addition to cash compensation, the Compensation Committee awarded RSUs for the future issuance of 28,000 shares of common stock to Mr. Skibsted, which vest accordingly.14,000 vest on July 16, 2025.30 million; and 7,000 vest upon receipt of cumulative financing(s) of at least \$30 million; and 7,000 vest upon receipt of cumulative financing(s) of at least \$15 million.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">On September 3, 2024, RSUs for the future issuance of 124,824 shares of common stock were granted to our independent directors and vest on the earlier of June 28, 2025 or the next annual shareholder meeting.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">At September 30, 2024, unrecognized stock-based compensation expense of approximately \$613,000 for RSUs is expected to be fully recognized over a weighted average period of 0.9 years. The unrecognized expense excludes approximately \$432,000 of expense related to certain grants of RSUs with performance milestones that are not probable of occurring at this time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">During the nine months ended September 30, 2024, we did not grant any warrants to purchase shares of our common stock other than warrants to purchase 1,617,777 shares of common stock as part of the Offering (see Note 2). Warrants to purchase 7,500 shares of our common stock expired unexercised. We also repurchased a warrant issued to a consultant in 2023 for the purchase of 15,000 shares of our common stock in exchange for a payment of \$10,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">At September 30, 2024, we had outstanding warrants for the purchase of 1,775,784 shares of our common stock with a weighted average exercise price of \$5.95 and a weighted average remaining contractual life of 4.0 years. All the outstanding warrants are exercisable as of September 30, 2024. We did not have any unrecognized stock-based compensation expense related to our granted warrants at September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt

bottom: 1pt; text-align: left;"><td></tr><tr id="xdx_405_eus-gaap--ShareBasedCompensation_zcOrDhnlbrke" style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left;"><td style="border-bottom: Black 2.5pt double; text-align: right;">154,191</td><td style="padding-bottom: 2.5pt; text-align: left;"><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: right;">142,894</td><td style="padding-bottom: 2.5pt; text-align: left;"><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left;"><td style="border-bottom: Black 2.5pt double; text-align: right;">474,466</td><td style="padding-bottom: 2.5pt; text-align: left;"><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left;"><td style="padding-bottom: 2.5pt; text-align: right;">803,521</td><td style="padding-bottom: 2.5pt; text-align: left;"><td></tr></table>
540187662613072286152100173662683437445173691541911428944744668035214245336.002747409.09P3Y10M24D12509.260<p id="xdx_89F_eus-gaap--ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_zcFY5C6npUP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.25in">Activity with respect to our Restricted Stock Units ("RSUs") during the nine months ended September 30, 2024 was as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0">Schedule of Restricted Stock Units ("RSUs") Activity</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"><tr style="vertical-align: bottom;"><td style="text-align: center;"><td style="padding-bottom: 1pt"><td style="border-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 60%">Outstanding at January 1, 2024</td><td style="width: 2%"><td style="width: 1%; text-align: left;"><td><td id="xdx_983_ecustom--</td></tr></table>
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstanding_iS_c20240101_20240930_us-gaap-AwardTypeAxis_us-gaap--RestrictedStockUnitsRSUMember_zjnMxibElEik" style="width: 16%; text-align: right" title="Number of shares, Beginning balance">222,722</td><td style="width: 1%; text-align: left;"><td style="width: 2%"><td style="width: 1%; text-align: left;"><td style="width: 1%; text-align: left;"><td id="xdx_989_ecustom--</td></tr></table>
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionOutstandingWeightedAverageGrantDateFairValue_iS_pid_c20240101_20240930_us-gaap-AwardTypeAxis_us-gaap--RestrictedStockUnitsRSUMember_z7QI8JGzHank" style="width: 16%; text-align: right" title="Weighted-average grant-date fair value per share, Beginning balance">45.82</td><td style="width: 1%; text-align: left;"><td style="width: 1%; text-align: left;"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Number of
shares</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align: center;">Weighted-average
grant-date fair
value per share</td><td style="padding-bottom: 1pt"><td style="padding-bottom: 1pt"><td style="vertical-align: bottom; background-color: White"><td>Granted</td><td style="padding-bottom: 1pt; text-align: left;"><td style="padding-bottom: 1pt"><td colspan="2" style="border-bottom: 1pt; text-align

[illegible]

[illegible]

AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis--us-gaap--RestrictedStockUnitsRSUMember_zlsyeCCGgoTL9" title="Weighted average number of vested RSUs--basic">142,294</td><td style="padding-bottom: 1pt; text-align: left"></td><td style="padding-bottom: 1pt"></td><td style="border-bottom: Black 1pt solid; text-align: left"></td><td style="border-bottom: Black 1pt solid; text-align: right">127,873</td><td style="padding-bottom: 1pt; text-align: left"></td></tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left; padding-bottom: 2.5pt">Weighted-average number of common shares-basic and diluted</td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">3,275,998</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">1,350,188</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">2,909,941</td><td style="padding-bottom: 2.5pt; text-align: left"></td><td style="padding-bottom: 2.5pt"></td><td style="border-bottom: Black 2.5pt double; text-align: left"></td><td style="border-bottom: Black 2.5pt double; text-align: right">1,279,298</td><td style="padding-bottom: 2.5pt; text-align: left"></td></tr></table>-3384703-2081951-9121410-871658932759983275998135018813501882909941290994112792981279298-1.03-1.03-1.54-1.54-3.13-3.13-6.81-6.813118029311802941224255122425527676472767647115142511514251579691579691259331259331422294142229412787312787332759983275998135018813501882909941" id="xdx_802_ecustom--LesseeOperatingAndFinancingLeasesTableTextBlock_zVaoO2rCnJl" style="font: 10pt Times New Roman, Times, Serif; margin: Opt Opt 0pt 0; text-align: justify">Note 5--Leases</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt Opt 0pt 0; text-align: justify">10pt">We lease our office space under an operating lease agreement. This lease does not have significant rent escalation, concessions, leasehold improvement incentives, or other build-out clauses. Further, the lease does not contain contingent rent provisions. Our office space lease includes both lease (e.g., fixed payments including rent, taxes, and insurance costs) and non-lease components (e.g., common-area or other maintenance costs), which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. We also lease office equipment under a financing lease. Our leases do not provide an implicit rate and, as such, we have used our incremental borrowing rate of8% in determining the present value of the lease payments based on the information available at the lease commencement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt Opt 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: Opt Opt 0pt 0; text-align: justify; text-indent: 0.25in">10pt">Lease costs included in our condensed consolidated statements of operations totaled approximately \$23,000 and \$24,000 for the three months ending September 30, 2024 and 2023, respectively, and approximately \$68,000 and \$73,000 for the nine months ended September 30, 2024, and 2023, respectively. The weighted average remaining lease terms and discount rate for our leases were as follows at September 30, 2024:</p><p id="xdx_89F_ecustom--ScheduleOfWeightedAverageRemainingLeaseTermsAndDiscountRateForOurOperatingAndFinancingLeasesTableTextBlock_zq5ifQmGweG5" style="font: 10pt Times New Roman, Times, Serif; margin: Opt Opt 0pt 0; text-align: justify; text-indent: 0.25in"></p><table id="xdx_8BF_z3enE10zDmH1" style="display: none"><caption>Schedule of Weighted Average Remaining Lease Terms and Discount Rate for Operating and Financing Leases</caption><tr><th>Stable cellpadding="0">cells="0">0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"</tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 80%; text-align: left">Remaining lease term (years) for our facility lease</td><td style="width: 2%"></td><td style="width: 1%; text-align: left"></td><td style="width: 16%; text-align: right">1.0</td><td style="width: 1%; text-align: left"></td><td style="vertical-align: bottom; background-color: White"><td style="text-align: left">Remaining lease term (years) for our equipment lease</td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right">1.4</td><td style="text-align: left"></td><td style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="text-align: left">Weighted average discount rate for our facility and equipment leases</td><td style="text-align: left"></td><td style="text-align: left"></td><td style="text-align: right">8.0</td><td style="text-align: left"></td></tr></table><p id="xdx_8A5_zGmalQsyggd" style="font: 10pt Times New Roman, Times, Serif; margin: Opt Opt 0pt 0; text-align: justify"></p><table id="xdx_8B7_ztLtmCqlvT" style="display: none"><caption>Schedule of Annual Lease Liabilities for all Operating Leases</caption><tr><th>Stable cellpadding="0">cells="0">0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"</tr><tr style="vertical-align: bottom; background-color: rgb(204,238,255)"><td style="width: 80%; text-align: left">2024</td><td style="width:

[illegible]